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Human growth hormone (hGH) is a peptide hormone that mediates postnatal 
body growth as well as other biological activities such as carbohydrate and fat 
metabolism. Since non-primate GH is inactive in human and the prohibition of GH 
isolation from cadaver donors by the FDA, recombinant hGH produced in 
microorganisms is the predominant way to prepare GH for hormone replacement 
therapy in GH deficiency patients. 
However, direct expression of hGH as intracellular protein in E. coli will carry 
an extra formylmethionine at the N-terminal. In order to produce a mature hormone, 
we decided to express hGH as a novel fusion protein in E. coli BL21 host and then 
enzymatically remove the fusion tag to generate rhGH. The fusion protein was 
constructed by attaching a hexa-histidine tag and a small ubiquitin-like modifier 
(SUMO) at the N-terminal of hGH. The soluble fusion protein was expressed in 2 L 
fermentation bioreactor under optimized conditions. Ninety percent pure fusion 
protein was first purified by immobilized-metal affinity chromatography (IMAC). 
After the cleavage of the fusion tag, mature rhGH was purified by IMAC in the flow 
through fraction. Further purification was done by gel filtration chromatography. The 
gel filtration elution profile and silver stained gel showed that a highly pure and 
iii 
monomeric rhGH can be successfully prepared. The yield was 84 mg/L of 
fermentation culture. Data from N-terminal sequencing and immunoblotting 
suggested that our rhGH is completely identical to hGH sharing the same 
immunoreactivity as a commercial preparation. Subsequent GH receptor binding 
assay confirmed that our rhGH shares a similar biological potency as the commercial 
product. 
A sandwich ELISA was setup for the quantitative determination of rhGH as well 
as to monitor the level of SUMO-hGH during the course of fermentation. Production 
of murine monoclonal antibodies (mAbs) against rhGH by conventional polyethylene 
glycol fusion method was the first step. Two positive hybridoma clones, 23D3 and 
33C5, were generated in two fusion experiments. Both mAbs are determined as IgGi 
subtype with K light chain by isotyping kit. Highly pure mAbs were purified by 
protein G affinity column from the ascites. Immunoblotting results confirmed that 
these mAbs can cross react with the SUMO fusion form of rhGH. A sandwich ELISA 
was setup by using mAb 23D3 as the capturing antibody and rabbit polyclonal 
4« 
anti-serum raised against rhGH as the second antibody. This assay is highly specific 
and the detection limit is 10 ng/ml. The working range of this assay is from 30 to 300 
ng/ml. This sandwich ELISA could be used to directly measure the amount of rhGH 
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Chapter 1 Introduction 
1.1 Growth hormone 
1.1.1 Historical discovery of growth hormone 
The observation of visceral atrophy and weight loss in the animals with 
hypophysectomy provided the first evidence in the linkage between growth and the 
pituitary gland in the early 1900s (1). In 1921, this complicated relationship was 
further clarified by Evans and Long's experiment in using saline extracts of bovine 
anterior pituitary to promote growth in rats (2). This result indicated that the growth 
promoting activity is mediated by a specific growth factor present in the pituitary 
gland. After two decades, growth hormone (GH) was first isolated from bovine 
pituitary gland (3). With innovations in molecular cloning, the complementary DNA 
of GH from human and the other species have been cloned and expressed as 
recombinant GH in bacteria (4. 5). Extensive GH structural, functional and molecular 
signaling studies have been made based on the knowledge in cloning and expression 
of recombinant GH. 
1.1.2 Structural and functional study of GH 
1.1.2.1 Molecular evolution of GH 
GH is a peptide hormone secreted by somatotrophs located in the anterior 
1 
pituitary. Based on the structural features and sequence homology, GH is classified as 
a member of the GH, prolactin and placental lactogen family. Mouse proliferin, 
mouse proliferin-related protein, rat decidual PRL-like protein and somatolactin are 
also found in this family and they are believed to be evolutionarily related protein 
hormones (6, 7, 8, 9, 10). 
Human growth hormone gene is found in the long arm of chromosome 17 with a 
size of 2.6 kb (11). It is a member of the gene cluster associated with the other four 
related genes as illustrated in Fig 1.1. This cluster consists of growth hormone-normal 
gene (GH-N), chorionic somatomammotropin-like gene (CS-L), chorionic 
somatomammotropin-A gene (CS-A), growth hormone-variant gene (GH-V), and 
chorionic somatomammotropin-B gene (CS-B). These five genes are believed to be 
evolved from an ancestral gene since they share greater than 92% identity in their 
coding and flanking regions (11). GH-N is mainly expressed in somatotrophs and a 
small amount of it is expressed in the immune system (B-lymphocytes) while GH-V 
is only expressed in the syncytiotrophoblast of placenta. 
The gene of growth hormone from other species has been cloned and sequenced. 
Comparison of different mammalian GHs, the amino acid sequence between different 
species show a very high similarity, e.g. the pig and dog GHs are identical (Fig 1.2). 
Most of the mature mammalian GHs have 191 amino acid residues except porcine 
2 
0 50 kb 
1 I 
一 GH-N — CS-L — CS-A — GH-V — CS-B — 
—r\— 
region region 
"""•"•••""•"I a b ——————I c 1""""""""""""! d 
— I m^i II ssm III mm iv a m v 
I I 
0 2.6 kb 
Figure 1.1 Schematic illustration of the human GH gene cluster. It is located on 
chromosome 17q23 and spans over 66500 base pairs. It consists of five genes: GH-N, 
CS-L, CS-A, GH-V, and CS-B. hGH gene (GH-N), with approximately 2.6 kb in 
length, consists of five exons (denoted as I to V) and four introns (denoted as a to d). 
This figure was adapted from John J. Kopchick and Jerald M. Andry (12). 
3 
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Figure 1.2 Alignment of mammalian GH amino acid sequence. The full sequence of 
porcine GH is shown and compared with other mammals (• indicated identical amino 
acid, • indicated a gap in the sequence). The numbers marked with a box summarize 
the number of different amino acid from the porcine GH. This figure was adapted 
from O C Wallis et al (13). 
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GH which has 200 amino acid residues. The molecular weight of GHs is in a range of 
21 to 22 kDa. There is about 75 % homology between human and bovine GH (14). 
During the evolution of GH in mammals, a rapid change has been noted in primate 
(for example human) compare with the non-primate mammals (for example pig). 
Such differences lead to the species specificity of GH, in particular GH from 
non-primate source is not active in human (83). 
1.1.2.2 Two dimensional and three dimensional structures of GH 
Mature human GH has a total of 191 amino acid residues with a molecular 
weight of 22.1 kDa. The primary structure of hGH is shown in Fig 1.3. Same as the 
GHS of other mammals, hGH contains no carbohydrate or prosthetic group but two 
disulfide bonds. The four cysteine residues involved in disulfide bonds formation are 
Cys53-Cysl65 and Cysl82-Cysl89 which are conserved within the GH, prolactin 
and placental lactogen family (15). The three dimensional structure of hGH was 
determined by X-ray crystallography in 1992 (16). As Fig 1.4 shows, hGH contains a 
four a-helix bundle in an unusual orientation up-up-down-down topology. Helices 1 
and 4 (at the N- and C-terminal) are slightly longer than the other two helices. A long 
connective loop links up the two parallel helices (helices 1 and 2 from residues 35 to 
71; helices 3 and 4 from residues 129 to 154) while a shorter loop joins helices 2 and 
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I F P T I P L S R L F 
II Q N A M L R A H R L 
21 H Q L A F D T Y E E 
31 F E E A Y I P K E Q 
41 K Y S F L Q A P Q A 
51 S L C F S E S I P T 
61 P S N R E Q A Q Q K 
71 S N L Q L L R I S L 
81 L L I Q S W L E P V 
91 G F L R S V F A N S 
101 L V Y G A S D S D V 
111 Y D L L K D L E E G 
121 I Q T L M G R L E D 
131 G S P R T G Q A F K 
141 Q T Y A K F D A N S 
151 H N D D A L L K N Y 
161 G L L Y C F R K D M 
171 D K V E T F L R I V 
181 Q C R S V E G S C G 
191 F 
Figure 1.3 The 191 amino acid sequence of the mature humane growth hormone. The 
underlined cysteine amino acid residues (Cys53-Cysl65 and Cysl82-Cysl89) form 
t^vo disulfide linkages. 
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國 
Figure 1.4 Ribbon representation of the three dimensional structure of hGH deduced 
from X-ray crystallography. The N-tenninal is denoted by N and the C-terminal 
denoted by C. It consists of a four-helix bundle in up-up-down-down topology. Helix 
1: 9 to 34; Helix 2: 72 to 92; Helix 3: 106 to 128; Helix 4: 155 to 184. The labelled 
amino acids are located in the interface of GH receptor binding site. This figure was 
adapted from de Vos AM et al. (16). 
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3 (residues 93 to 105). Besides the monomeric hGH, dimeric and oligomeric GHs 
(covalently disulfide-linked or non-covalently associated) are identified in both the 
pituitary and plasma (17). 
1.1.2.3 Heterogeneity of GH 
GH is a heterogeneous hormone, it consists of several isoforms. Besides the two 
hormones encoded by the separated genes of GH-N and GH-V, alternative splicing of 
the GH-N mRNA generates a 20 kDa isoform. The 20 kDa GH isoform is identical to 
the 22 kDa GH isoform except the residues from 32 to 46 are deleted. Intensive 
studies have investigated the secretion of GH isoforms (18). The most abundant 
isoform in the circulation is monomeric 22 kDa GH which accounts for 70 to 75 % of 
total GH level. This form is responsible for the action of growth hormone such as 
growth promoting and mediating cellular metabolisms. About 5 to 10 % of total GH 
produced is the 20 kDa isoform. As part of the sequence is deleted from intact GH-N, 
its binding affinity to GH receptor is lower than the intact 22 kDa form and is less 
t* 
biologically active. Isoforms can be generated by different post-translational 
modifications such as deamidation, glycosylation or acylation. Researchers have 
identified GH with post-translational modifications from pituitary extract (18). Table 
1.1 summarizes the GH isoforms found in human. 
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Molecular isoforms Percent of total GH (%) 
Monomers 
22 kDa 70-75 
20 kDa 5-10 
hGH-desamido ([Asp'"]22-kDa) 3 
hGH-desamido ([Glu'^']22-kDa) 5 
N"-acetylated hGH 22 kDa ‘ 5 
hGH,.43 1 
hGH44.i9i 0.2-1 
Dimers (22 and 20 kDa homodimers or 22/20 kDa heterodimers) 10 
Oligomers at higher molecular weight 5 
Oligomers disulphide linked 7 
Oligomers with unknown covalent linkage 2 
Table 1.1 Summary of different GH isoforms found in human. This table is adapted 
from Wood P. (18). 
1.1.2.4 Regulation and secretion pattern of GH 
The regulation of GH secretion is complicated and involves a complex network 
of central and peripheral feedback controls. Some of the major stimuli on GH 
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secretion includes: 1) Physiological conditions like sleep, stress and exercise; 2) 
Reduced energy level such as hypoglycaemia, low plasma fatty acid level, fasting and 
some types of diabetes mellitus patients; 3) Gonadal steroids stimulation in early 
puberty. These stimuli act on the hypothalamus to increase the secretion of growth 
hormone-releasing hormone (GHRH). There are two hypothalamic peptide hormones, 
GHRH and somatostatin, mediating the secretion of GH from the pituitary in the 
hypothalamic-pituitary axis (19). GHRH stimulates the secretion of GH while 
somatostatin inhibits the release of GH from the pituitary. The binding of GHRH to 
GHRH receptors on somatotrophs activates the G-protein coupled receptor resulting 
in the increase of the cellular cAMP level and this in turn triggers the secretion of GH 
from the secretary granules into the blood stream and the circulating GH acts on the 
target organs (20). 
The GH secretion pattern is pulsatile, in a rhythm of pulses in every two to three 
hours (21). The basal GH level between pulses is low (interpulse level is 0.03 ng/ml) 
and the highest secretion peak is at night in young adults (may reach 50-100 ng/ml). 
Women in reproductive age have a higher peak level and basal GH level than men 
due to the higher level of estrogens (gonadal steroids stimulation). Somatopause is a 
natural observation that a decline in GH secretion with increasing age. 
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1.1.2.5 Circulation of GH in blood 
Once GH is secreted into the blood stream, it quickly associates with a high 
affinity growth hormone binding protein (GHBP). The formation of GH-GHBP 
complex protects the GH from degradation and clearance that lengthens its half-life. 
There are two types of GHBPs in the blood, high affinity and low affinity (22). High 
affinity GHBP is found to be the extracellular domain of GH receptor. Human IM-9 
lymphocytes have been used to study the formation of GHBP (23) and it was shown 
that GHBP is generated from the proteolytic cleavage of GH receptor by the zinc 
metalloproteinase TACE (tumor necrosis factor a-converting enzyme). People have 
suggested that up to 60 % of the circulating GH is in the form of GHBP complex (24). 
The binding affinity of GHBP to GH-V is the same as the 22 kDa form while a lower 
binding affinity is found to the 20 kDa form. 
Glomerular filtration and degradation in the proximal tubule cells are responsible 
for the clearance of GH in human (25). The degradation of GH is very efficient, only 
tiny amount of GH (about 0.01 % of serum level) can be found in urine. Monomeric 
forms of GH like the 22 kDa and 20 kDa can be detected in urine but not the other 
isoforms. Dimeric or oligomeric forms may be too large for glomerular filtration. 
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1.1.2.6 Biological activity of GH in human 
The most well known activity of GH is the promotion of postnatal body growth. 
Besides growth promotion, GH also regulates the balance of lipid, carbohydrate and 
nitrogen metabolism as well as electrolyte metabolism (26). GH is found to elicit two 
opposite actions in the human body, the anti-insulin effect and the insulin effect. The 
anti-insulin effect (direct action via GH) includes lipolysis in adipose tissue and 
increase blood glucose level. The lipolytic action promotes the breakdown of stored 
fat resulting in an increase of blood free fatty acid and glycerol level. GH also 
increases the hepatic output of glucose from the breakdown of glycogen. The insulin 
effect (indirect action via IGF-I) includes lipogenesis and increasing both glucose and 
amino acid metabolism. Insulin effect of GH is mediated by insulin-like growth factor 
I (IGF-I). IGF-I is mainly synthesized in the liver and bone and is released upon GH 
stimulation. The ultimate actions of IGF-I includes increasing protein synthesis 
(increase the total muscle mass) and stimulating the bone elongation by acting on the 
cartilage growth plate (27, 28). 
1-2 GH receptor and signal transduction 
( 
GH receptor is a member of the class I cytokine receptor family (29). It consists 
of only one single polypeptide chain with a single extracellular and intracellular 
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domain. GH receptor is widely distributed in the human body. It can be found in the 
liver, muscle, adipose tissue, mammary gland, bone, kidney and embryonic stem cell 
(29, 30). 
The first step of GH signal transduction is the binding of GH to GH receptor and 
the dimerization of two GH receptors. There are two receptor binding sites located on 
the four-helical bundle of GH. As Fig 1.5 shows, the first binding site is formed by 
helices 4 and 1 while the second binding site is formed by helices 1 and 3. GH 
receptor binds to site I first and dimerized by the binding of the second GH receptor 
to site II. Upon the binding of GH to GH receptor, a tyrosine kinase JAK2 becomes 
rapidly phosphorylated and activated (32). The dimerization of the GH receptors 
brings the two JAK2 close together and JAK2 autophosphorylates both JAK2 and the 
intracellular tyrosine residues on the GH receptor. Phosphorylation of GH receptor 
provides the docking site of subsequent signaling molecules (33). Signal transducer 
and activator of transcription 5 (STAT5) then binds to the phosphorylated GH 
receptor and JAK2 activates it by phosphorylation. Two activated STATS s dimerize 
and translocate into the nucleus. It finally activates the gene transcription by 
phosphorylation of the transcription factors (34). Other signaling pathways such as 
MAP kinase pathway and protein kinase C pathway are also reported to be stimulated 
by GH (35, 36). 
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Figure 1.5 Schematic representation of the dimerization of two GH receptors with the 
binding of GH. GH is shown in the middle with four helices labels. The two GH ‘ 
receptors are labeled as GHR 1 and 2. This figure was adapted from Elio F. De Palo 
et al. (31). 
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1.3 GH disorder 
Blood GH level is tightly controlled by the hypothalamic-pituitary axis. Any 
defects in this axis will cause GH imbalance, i.e. GH excess or GH deficiency. 
Hypersecretion of GH, a tonic GH over secretion from the pituitary, is observed 
instead of the normal pulsatile release of GH in pituitary tumor patients. The 
hypersecretion of GH in childhood is called gigantism, while in adulthood is called 
acromegaly. Elongated bones (lengthen in arms and legs) are observed in gigantism 
patients due to over stimulation of GH on the growth plate. Thicken lips, coarse facial 
features and enlarged jaw are always observed in acromegaly patients due to the 
closure of the growth plate in adult. In both diseases, patients will suffer from an 
increased metabolic rate and elevated insulin level as GH elicits anti-insulin effect. 
Prolonged GH over secretion is associated with about two fold higher risk in the 
development of cardiac disease and stroke (37). 
Hyposecretion of GH is a more common GH disorder than hypersecretion of GH. 
GH deficiency can be caused by the damage of the hypothalamus or pituitary gland 
by tumor, infection of or radiation to the brain. Pan-hypopituitary dwarfism is a 
disease due to the deficiency in all types of pituitary hormones. Deficiency of GH 
shows different symptoms in different stages of onset. In childhood, growth failure or 
slow growth rate is the major symptom caused by GH deficiency. In adults, less 
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obvious clinical symptoms are found such as diminishing muscle mass, thin skin, 
osteoporosis. Some psychological symptoms such as social isolation and depressed 
mood are also associated in adult patients. 
1.4 Treatment for GH disorder 
A combination of surgery, radiation therapy, and drugs are used to treat GH over 
secretion. For the treatment of pituitary tumor induced acromegaly or gigantism, 
surgery removal of tumor is regarded as the best treatment for small tumor. If the 
tumor is too large for surgery, combination of radiotherapy as a follow-up treatment 
can significantly reduce GH secretion. Several drugs can also be used to reduce GH 
level. Bromocriptine is one of the dopamine receptor agonist that reduces the 
secretion of GH. Synthetic somatostatin is also injected as a drug to inhibit the GH 
production and secretion. GH receptor antagonist, such as pegvisomant, is a new type 
of GH blocker drug by preventing GH receptor dimerization. Although drugs can 
lower the GH level or diminishing the effect of GH in patients, it requires long term 
treatment as it does not cure the disease. 
Hormone replacement therapy is a treatment for pituitary dwarfism; GH 
deficiency. GH extracted and purified from the pituitary glands of cadaver donors was 
the only source of hGH in the past until recombinant hGH is available in the market. 
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In the old days, liGH was expensive, scarce in supply and may suffer from biological 
contamination as only primate GH is bioactive in human. GH replacement therapy 
involves repeated GH injections over a two to three week interval for a long period of 
time during childhood. Besides replacement in GH deficiency patients, other usage of 
hGH has been investigated and the result is still controversy. In 1990, Rudman D. and 
his research group used hGH to treat body deterioration in a group of old men (from 
61 to 81 years old). Anti-aging effect was claimed as an observation of increasing 
muscle mass and reducing in body fat after six months of daily hGH injections (38). 
Athletes even use hGH to boost-up their athletic performance as the action of the 
hormone can stimulate growth of the skeletal tissue (39). 
1.5 GH assay 
Several types of assay for GH have been developed for analytic and clinical 
diagnostic purposes. It includes bioassays, receptor binding assays and 
immunoassays. 
*4 
Bioassays are the traditional methods to study the action of GH. The most 
classical in vivo assay is based on body growth measurement in hypophysectomized 
rat (removal of the interference caused by endogenous GH). By evaluating the weight 
gain or the length gain in the tibia bone of young rat, the growth promoting effect of 
17 
GH can be measured. However the relative low sensitivity, slow performance and the 
cost of assay make the measurement of GH level in large amount of samples 
impossible. A more sensitive and speedy in vitro bioassay was developed by 
determining the proliferation rate of Nb2 rat lymphoma cell line in GH sample 
containing medium (40). Nonetheless, the need of culture facilities and high cost 
prevents the use of bioassay such as this as a routine basis. 
Receptor binding assay is based on the binding of GH to GH receptors for the 
GH determination. Luciferase reporter assay is one of the receptor binding assays 
widely used. Cells with stable transfected human GH receptor are used as the host for 
the transfection of an experimental vector containing a StatS-binding site followed by 
a luciferase gene. The dimerization of GH receptors activates the signaling pathway 
resulting in luciferase expression. GH levels can be measured by the GH receptor 
activity in terms of luciferase activity. Since it also requires culture facilities, the use 
of receptor binding assay is mainly used in research. 
The development of immunoassays for GH provides a routine measurement for 
diagnostic screening. It is based on the antigen-antibody interaction between the 
epitopes on GH and specific antibodies. Sandwich ELISA is one of the most common 
immunoassays used in the laboratory to determine the GH level in the sample. In 
micro-titer plate, capturing antibodies are coated to capture GH presented in the 
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sample. After washing, radioactive or enzyme labeled detection antibodies are added 
to quantify the formation of an antigen-antibody complex. This complex can be 
measured by the radioactivity or the colour intensity developed by the reaction with 
specific substrate. Immunoassays are highly sensitive and the detection limit of the 
most sensitive assay is about 1-2 ng/ml (41). The high throughput, high sensitive and 
simple experimental equipment requirement make this assay remarkably suitable for 
the screening of GH disorder. However due to the heterogeneity of GH, the result 
generated by highly specific antibodies (even monospecific monoclonal antibody) 
may not be consistent in different laboratories as the affinity towards different GH 
isoforms or even GHBP bound GH is different between each commercially available 
kits. 
1.6 Aims of study 
As bioactive 22 kDa hGH isoform is a simple peptide hormone without any 
post-translation modification, prokaryotic expression system can be employed for 
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rhGH production. In 1979，Goeddel D.V. published the first paper in the direct 
expression of rhGH in E. coli (4). However, direct expression of hGH as intracellular 
protein in E.coli will result in an extra formylmethionine addition at the N-terminal of 
hGH. In order to produce a mature hGH, several expression systems have been 
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studied such as secretory form of hGH by addition of a signaling peptide at the 
N-terminal or enzymatic removal of extra amino acids in the N-terminal by 
introducing a specific protease digestion site (42. 43). 
The aim of this study is to design and optimize a fermentation process for the 
production of rhGH by E. coli. In doing so, we have adopted an enzymatic removal 
approach to generate mature rhGH. A novel fusion expression system by fusing a 
hexa-histidine tag followed by a small ubiquitin-like modifier (SUMO) at the 
N-terminal of hGH gene is constructed to express a SUMO-hGH fusion protein. The 
SUMO fusion can enhance the solubility of rhGH and the His-tag tail can simplify the 
preliminary purification step by using immobilized-metal affinity chromatography. 
After the cleavage of the SUMO tag, the mature hGH is generated. Fermentation 
expression of the SUMO-hGH fusion protein and the downstream process 
development for the isolation of the matured rhGH will be studied. 
It is also our goal to develop an immunoassay to measure the concentration of 
GH during fermentation. A sandwich ELISA using specific murine monoclonal 
antibodies and rabbit polyclonal anti-serum against rhGH will be constructed. The 
sensitivity and cross reactivity of this assay will also be studied in this project. 
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Chapter 2 SUMO-hGH expression vector construction 
2.1 Introduction 
Human growth hormone is essential in the hormonal replacement therapy for 
pituitary dwarfism which is a type of GH deficiency. Since GH from non-primate 
source is inactive in human, GH from cadaver donors became the major source in 
1957 to 1985. The extraction and purification of GH from human pituitaries was 
expensive due to the scarce supply. Moreover, the preparations may suffer from 
biological contaminations which cause diseases such as Creutzfeldt-Jakob disease 
(44). In 1985，synthetic rhGH was approved by the FDA for the treatment of GH 
deficiency. Recombinant hGH produced in microorganisms provides an alternative 
way to prepare a GH with similar biological potency a more economic and safer way. 
hGH (22 kDa isoform) is a relatively simple peptide hormone, which is 
non-glycosaylated and without any prosthetic group (4. 42, 43). A prokaryotic 
expression system, Escherichia coli, was selected in the present study for the 
production of recombinant hGH. The manipulation and expression protocols in E. 
coli are well studied and easy to scale up. E. coli stain BL21 (DE3) was selected 
because it is deficient in both Ion and ompT proteases, such proteases deficiency will 
result in better purification of intact recombinant proteins rather than degraded 
protein fragments. 
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Direct expression of hGH as intracellular protein in E. coli will carry an extra 
formylmethionine at the N-terminal. Although met-hGH shows the equivalent 
bioactivity compare with native hGH (45), researcher reported that met-hGH may be 
involved in the formation of antibody in patients during hormonal replacement 
therapy (46). Secretory of mature hGH (43) and enzymatic removal of extra amino 
acid in N-terminal (47) are methods to solve the problem in direct expression. 
In our study, we aim to design a fermentation framework for the mass production 
of rhGH by E. coli. A novel fusion protein expression system for rhGH production 
has been constructed with a hexa-histidine tag followed by a small ubiquitin-like 
modifier (SUMO) at the N-terminal of hGH. The fusion partner (12 kDa) simplifies 
protein isolation by utilizing two rounds of immobilized metal affinity 
chromatography (IMAC) with increased yield of soluble protein. These features in the 
SUMO-hGH fusion construct not only simplified downstream processes for large 
scale production, but also avoided the refolding problems in handling inclusion 
bodies. After enzymatic digestion, the mature hGH is released from the fusion partner 
and further purified. This chapter describes our study in the construction of the 
SUMO-hGH expression vector and the expression of the soluble protein. 
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2.2 Fusion partner - SUMO 
SUMO belongs to a group of post-translational modifier, ubiquitin-like proteins 
(Ubls). Within a cell, SUMO is covalently attached to specific lysine residues with 
平KXE consensus tetrapeptide motif is any hydrophobic amino acid residue) in the 
target proteins. SUMOylation on cellular protein regulates different biological 
functions, such as signal transduction and translocation between cytosol and nucleus 
(48). The molecular weight of SUMO is about 12 kDa which contains a tightly 
packed globular fold with p-sheets wrapped around an a-helix. 
SUMO fusion structure provides several advantages in the protein expression 
and downstream processing. For protein expression, SUMO fusion tag can enhance 
the expression level of soluble fusion protein in E.coli (49). The solubilizing effect of 
SUMO may be due to chaperoning effects such as providing an outer hydrophilic and 
an inner hydrophobic core structure for the solubilization of the fusion proteins like 
detergent molecules do. Soluble fusion protein overcomes the problem of improper 
folding in the refolding step and minimizes the optimization of conditions in the use 
of different denaturing agents. For fusion tag removal, SUMO protease recognizes the 
three-dimensional structure of the SUMO tag rather than a short cleavage sequence as 
tradition proteases like thrombin and enterokinase. Therefore, the SUMO fusion 
expression system will never encounter the limitation that other recombinant protein 
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cleavage may be encounter due to identical cleavage amino acid sequences presence 
within the target protein. 
2.3 Materials 
2.3.1 Reagents for bacterial culture 
2.3.1.1 Luria-Bertani (LB) broth medium, Miller 
It was prepared by dissolving 25 g LB broth (Sigma-Aldrich, USA) in 1 L 
ddH20. It contains 10 g sodium chloride, 10 g tryptone and 5 g yeast extract. It was 
sterilized by autoclaving for 20 minutes at 121�C. 
2.3.1.2 Kanamycin solution 
The stock solution (5 mg/ml) was prepared by dissolving 5 mg kanamycin 
sulfate (Sigma-Aldrich, USA) into each ml of ddKbO. It was sterilized by filtration 
through a 0.22 , pore size membrane filter (Millipore, USA) and stored in aliquots 
of 1 ml at -20°C. The working concentration was 50 昭/ml. 
2.3.1.3 LB kanamycin (LBK) medium 
LBK was LB medium supplemented with kanamycin at 50 |ig/mL 
2.3.1.4 LB and LBK agar plates 
LB agar was prepared by adding 1.5 % (w/v) of bacto-agar (Sigma-Aldrich, 
USA) to LB medium. It was sterilized by autoclaving and cool to 60�C before 
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pouring into plates. For LBK agar, kanamycin was added at 50 |ig/ml after 
autoclaving. 90 mm disposable Petri dishes contained about 20 ml agar medium were 
allowed to set at room temperature and stored at 4°C. Agar plates were dried in 37°C 
incubator for 2 hours before use. 
2.3.1.5 Isopropyl p-D-thiogalactoside (IPTG) 
The stock solution (1 M) was prepared by dissolving IPTG in ddHiO. It was 
sterilized by filtration through a 0.22 \im pore size membrane filter and stored in 
aliquots of 1 ml at -20°C. 
2.3.1.6 Psi broth Medium 
It was prepared by dissolving 5 g bacto-yeast extract, 20 g bacto-tryptone and 5 
g magnesium chloride into 1 L ddHsO. The pH was adjusted to 7.5 with 1 M KOH. 
2-3.1.7 Tfbl solution 
It was prepared by mixing 30 mM potassium acetate, 100 mM rubidium chloride, 
10 mM calcium chloride, 50 mM manganese chloride and 15 % (v/v) glycerol. The 
PH was adjusted to 5.8 with diluted acetic acid. 
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2.3.1.8 Tfbll solution 
It was prepared by mixing 10 mM MOPS, 75 mM calcium chloride, 10 mM 
rubidium chloride and 15 % (v/v) glycerol. The pH was adjusted to 6.5 with diluted 
NaOH. 
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2.3.2 Reagents for agarose gel electrophoresis 
2.3.2.1 Tris-acetate-EDTA(TAE) buffer 
The 50 X stock solution was prepared by dissolving 242 g ofTris base in 800 ml 
ddH^O. 100 ml of 0.5 M EDTA solution (pH 8.0) and 57.1 ml glacial acetate acid 
were added, the final volume of the stock solution was made up to 1 L with ddH^O. 
2.3.2.2 DNA sample loading buffer 
The 6x loading buffer was prepared by 0.25 % (w/v) bromophenol blue, 0.25 % 
(w/v) xylene cyanol FF and 40 % (w/v) sucrose solution in sterile ddH^O. It was 
stored at 4°C. 
2.3.3 2'-deoxyribonucleoside 5'-triphosphate (dNTP) mix for polymerase chain 
reaction (PGR) 
10 mM stock solution was prepared by mixing 10 of each of the dATP, dTTP, 
dCTP and dGTP (Amersham Bioscience, USA) with 60 of sterile dcfflbO. It was 
<4 
Stored at -20°C. 
2.3.4 Sonication buffer 
It was 50 mM Tris-HCl with the pH adjusted to 8.0 with 1 M HCl. 
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2.3.5 Modified solubilization buffer 
It was 100 mM Tris-Base and 2 M urea with the pH adjusted to 12.5 with I M 
NaOH. 
2.3.6 Reagents for sodium dodecylsulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
2.3.6.1 10 % Sodium dodecylsulphate (SDS) solution 
It was prepared by dissolving 10 g of SDS (Sigma-Aldrich, USA) in a final 
volume of 100 ml ddHiO. It was stored at room temperature. 
2.3.6.2 10 % Ammonium persulphate (APS) solution 
It was prepared by dissolving 1 g (w/v) ammonium persulphate in a final volume 
of 10 ml ddH20. It was stored in aliquots of 1 ml at -20°C. 
2.3.6.3 Acrylamide/Bis-acrylamide, 30 % solution 
It was purchased from Bio-Rad, USA. The concentration is based on the total 
weight of both the acrylamide and bis-acrylamide in the cross-linker ratio 29:1. It was 
stored at 4°C. 
2.3.6.4 Ayvyv'A'-Tetramethylethylenediamme (TEMED) 
It was purchased from Bio-Rad (USA) and stored at 4°C. 
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2.3.6.5 Stacking gel buffer 
It was 0.5 M Tris-HCl dissolved in ddH^O. The pH of this buffer was adjusted to 
pH 6.8 with 1 M HCl and stored at 4°C. 
2.3.6.6 Resolving gel buffer 
It was 1.5 M Tris-HCl dissolved in ddHaO. The pH of this buffer was adjusted to 
pH 8.8 with 1 M HCl and stored at 4°C. 
2.3.6.7 Sample loading buffer 
The 6x loading buffer was prepared with 12.5 % (w/v) SDS, 375 mM Tris-HCl 
(pH 6.8), 60 % (v/v) glycerol, 0 . 0 1 � / � ( w / v ) bromophenol blue and 5 % (v/v) 
(3-mercaptoethanol. It was stored at room temperature. 
2.3.6.8 Tris-glycine electrophoresis buffer 
The 5x stock solution was prepared by dissolving 15.1 g Tris base and 94 g 
glycine in minimal amount of d d H � � . Fifty ml 10 % (w/v) SDS solution was added 
and the final volume was brought to 1 L with ddHbO. The stock solution was diluted 
5 fold before use. 
*4 
2.3.6.9 Coomassie Brilliant Blue staining solution 
It was prepared by dissolving 1 g Coomassie brilliant blue R-250 
(Sigma-Aldrich, USA) in water: methanol: glacial acetic acid (5:5:2 by volume). 
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2.3.6.10 Destaining solution 
It was prepared by mixing 30 % (v/v) methanol, 10 % (v/v) glacial acetic acid in 
1 L ddHiO. 
2.4 Methods 
2.4.1 General techniques in molecular cloning of hGH gene 
2.4.1.1 Preparation of E. coli competent cells 
E. coli strain BL21 (DE3) was used as the host for expression experiments of 
SUMO-hGH fusion protein. E. coli strain DH5a was used as the host for the 
transformation of plasmid vectors for plasmid preparation. Just before the day of 
competent cell preparation, E. coli strain was streaked from frozen stock onto a LB 
agar plate and incubated for 16-18 hours at 37°C. A single colony of E.coli was 
inoculated into 5 ml LB medium and allowed to grow at 37�C with shaking (250 rpm) 
overnight. One percent (0.5 ml) of the overnight culture was inoculated in 50 ml Psi 
broth medium and was grown at 3TC with shaking (250 rpm) until the culture 
reached an OD550 at approximately 0.5. Cells were chilled on ice for 15 minutes and 
were harvested by centriftigation at 5000 rpm for 15 minutes at 4°C. The supernatant 
was removed and the cell pellet was gently resuspended in 20 ml pre-chilled Tfbl 
buffer. Cells were incubated on ice for 15 minutes and were centriftiged again at 5000 
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rpm for 15 minutes at 4°C. Cell pellet was resuspended in 2 ml pre-chilled Tfbll 
buffer. The cell suspension was incubated on ice for 15 minutes. Competent cells 
were aliquoted into 50 each in micro-centrifuge tube and frozen in liquid nitrogen 
immediately. These competent cells were stored at -70°C. 
2.4.1.2 Transformation in E.coli by heat-stock method 
Frozen competent cells were thawn on ice and plasmid or ligation product to be 
transformed was added. It was mixed gently and incubated on ice for 20 minutes. 
Heat-shock transformation was performed by heating the incubation mixture at 42°C 
for 1.5 minutes and immediately cooling the mixture on ice for at least 5 minutes. 
One ml of LB medium was added to the mixture and the competent cells were 
recovered by incubation at 37°C with shaking (250 rpm) for 45 minutes. After the 
recovery step, transformed cells were spread onto LB agar plate containing 
appropriate type of antibiotic (depended on the transformed vector) and incubated at 
37°C for 16-18 hours. Colonies containing plates were wrapped by parafilm and 
stored at 4°C. 
2.4.1.3 Plasmid preparation 
After transformation, colonies from LB agar plate were picked and were grown 
in 5 ml of LB medium containing the appropriate antibiotic at 37°C with shaking (250 
rpm) for 16-18 hours. Cells were harvested by centrifugation at 5000 rpm for 10 
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minutes. The plasmids were purified by using Mini MTM Plasmid DNA Extraction 
System (Viogene-Biotek, Taiwan) according to the instruction manual. Briefly, the 
cell pellet was resuspended in 250 |il of MXl buffer. Two hundreds and fifty jil of 
MX2 buffer was then added and gently mixed by inversion, cell lysate was incubated 
at room temperature for 5 minutes until the lysate became clear. Three hundreds and 
fifty |il of MX3 buffer was added to neutralize the lysate. Supernatant was transferred 
into Mini-M™ column after centrifugation at 13000 rpm-for 10 minutes at room 
temperature. The column was placed onto a collection tube and was centrifuged at 
13000 rpm for 60 seconds. Flow through was discarded. Five hundreds jo-l WF buffer 
was added into the column and was centrifuged for 60 seconds to wash the column. 
The column was washed again with 0.7 ml WS buffer. It was centrifuged for another 
3 minutes to remove residual ethanol. The DNA containing column was placed into a 
new 1.5 ml micro-centrifuge tube and the plasmid DNA was eluted with 50 p.! ddHaO 
by centrifuging at 13000 rpm for 2 minutes. Plasmid DNA was stored at -20°C. 
2.4.1.4 Primer preparation 
Primers were synthesized from Invitrogen, USA. The primers were reconstituted 
to a 100 |iM storage solution with sterile ddHiO. 10 |iM working stock was prepared 
by mixing 10 |j.l storage solution with 90 |il sterile ddHiO. These solutions were 
stored at -20°C. 
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2.4.1.5 Polymerase chain reaction (PCR) 
PGR was performed by mixing 2 |al of DNA template (about 20 ng), 2 i^l of each 
forward and reverse primer (10 pmol), 1 |il of dNTP stock solution (10 pmol), 5 |il of 
1 Ox PCR buffer (Expand High Fidelity buffer with 15 mM magnesium chloride) and 
0.5 III of DNA polymerase (1.75 U, Expand High Fidelity PCR System, Roche, USA). 
The reaction volume was adjusted to 50 }il with sterile ddH20. The PCR was 
preformed in a GeneAmp PCR System 9700 (Applied Biosystems, USA). The 
detailed conditions of PCR were specified in each experiment. 
2.4.1.6 Purification of PCR or restriction digestion product 
DNA sample fragments were purified by using Gel-M™ Gel Extraction System 
(Viogene-Biotek, Taiwan) according to the instruction manual. Briefly, PCR products 
or restriction digestion products were first separated on TAE agarose gel. Gel 
containing target DNA fragment was stained with ethidium bromide and visualized 
by UV trans-illumination. Gel with target DNA fragment was excised using razor 
blade and placed in micro-centrifuge tube. Five hundreds microliter GEX buffer was 
added and was incubated at 60°C for 10 minutes to dissolve the gel. Cooled down gel 
solution was loaded into Gel-M™ column and placed onto a collection tube. Flow 
through was discarded after centriftigation at 14000 rpm for 60 seconds at room 
temperature. Five hundreds microliter WF buffer was added to wash the column by 
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centrifugation. Seven hundreds microliter WS buffer was added to wash the column 
once more time. The column was centrifuged for another 3 minutes to remove 
residual ethanol. The DNA containing column was placed into a new 1.5 ml 
micro-centrifuge tube and the DNA fragment was eluted with 30 |il ddH^O by 
centrifuged at 13000 rpm for 2 minutes. 
2.4.1.7 PCR amplification of the hGH gene 
The hGH gene was well studied and sequenced (4). Based on the amino acid 
sequence, a plasmid vector containing optimized hGH gene for E.coli codon usage 
was synthesized by DNA 2.0, USA. Plasmid vector pJ2:G01458 was used for the 
template for PCR amplification of hGH cDNA (Fig 2.1). The entire sequence of 
pJ2:G01458 can be found in appendix. 
A forward primer incorporated a restriction site for Bsa I (43 bp): 
GC damp recognftfon site hGH gene sequence 
5 ' - C C G G C A C G G G T C T C A A G G T T T T C C A A C T A T T C C A C T G T C C C G T - 3 ' 
Comptementary with 
the pSUMO vector 
A reverse primer incorporated a restriction site for BamH I (38 bp): 
« 
GC clamp recognition site Reverse complement of hGH gene sequence 
5 ' - C C G G C T C G G G A T C C T T A T C A G A A G C C G C A A G A A C C T T C - 3 , 
Reverse complement of 




Entire molecule length: 2794 bp 
EcoRI(27 的 f a t n ^ ⑶ 叫 _ 
BIJNI(26IO)« ； 
hGH 
G01458 « ^ g p P ^ ^ 广\ 
ND^L(2 l&(3)* J F 舊 
at1L1 ‘ � V m ~ -*Kan(R) 
• pJ2:G01458 • 
Af111 (2080) — 2794 bp • 
/ — 
pUC on w 
A|)此I (1535) 4 
Figure 2.1 Schematic representation of hGH gene containing vector pJ2:G01458, 
entire molecule length is 2794 bp (hGH gene: start at 2200, end at 2778). The entire 
sequence of pJ2:G01458 can be found in appendix. 
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PGR amplification was performed as the following conditions: 
Step 1: 94°C 5 minutes 
Step 2: 94�C 1 minute � 
55°C 1 minute > 35 cycles 
68°C 1 minute ) 
Step 3: 68°C 10 minutes 
The PGR product was analyzed by TAE agarose gel electrophoresis (Fig 2.2). A 
DNA band was found with approximate 600 bp which should be the hGH encoding 
sequence amplified with the two inserted restriction sites (611 bp). The PGR product 
was subsequently purified by Gel-M™ Gel Extraction System mentioned in section 
2.4.1.6. 
2.4.1.8 Sub-cloning of Bsa I-hGH-BamH I into pGEM®-T Easy Vector 
The PGR amplified Bsa I-hGH-BamH I gene was purified by G e l - M ™ Gel 
Extraction System. It was sub-cloned into pGEM®-T Easy Vector (Promega, USA) 
for storage and sequencing. The 3 ‘ terminal thymidine overhang of pGEM®-T Easy 
vector (Fig 2.3) enhanced the efficiency of PGR product ligation by preventing 
•4 
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Figure 2.2 Gel electrophoresis showing the PGR amplified hGH gene from 
pJ2:G01458. Lane 1: 1 Kb plus DNA ladder (Invitrogen, USA); Lane 2: hGH gene 
PGR fragment. Electrophoresis was performed using 1 % (w/v) agarose gel. 
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V A S p e l 6 4 
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/ \ N o l l 77 
/ \ Bs tZ I 7 7 
/ \ PstI 8 8 
ori y \ -Sai l 9 0 
‘ \ N d e l 9 7 
\ S a c I 1 0 9 
\ Bs tX I 1 1 8 
\ Ns i l 127 
\ l 141 
\ ‘ S P 6 
T7 Transcription Start 
~ ^ 
5 ' . , . TGTAA TACGA CTCAC TATAG GGCGA ATTGG GCCCG ACGTC GCATG CTCCC GGCCG CCATG 
3 ' . . . ACATT ATGCT GAGTG ATATC CCGCT TAACC CGGGC TGCAG CGTAC GAGGG CCGGC GGTAC 
‘ T7 Promoter ‘ 丨 II II I I I L 
Apal Aatll SphI BstZI Ncol 
GCGGC CGCGG GAATT CGATT3'/ . • ATCAC TAGTG AATTC GCGGC CGCCT GCAGG TCGAC 
CGCCG GCGCC C T T M GCTA \ 鬧 73TTAGTG ATCAC TTAAG CGCCG GCGGA CGTCC AGCTG 
丨 I I ' II I I il 丨丨 I Mot. |1丨 I' ‘ 
•J' •" , , " S a c l l EcoRl Spel EcoRI 二 PstI Sail 
BstZI BstZI SP6 Transcription Start ^ 
CATAT GGGA GAGCT CCCAA CGCGT TGGAT GCATA GCTTG AGTAT TCTAT AGTGT CACCT MAT . . . 3' 
GTATA CCCTC TCGA GGGTT GCGCA ACCTA CGTAT C G M C TCATA A3ATA TCACA GTGGATTTA.. . 5' 
I I I II _ J i ‘ SP6 Promoter ‘ 
Mdel Sad BstXl Nsil 
Figure 2.3 Schematic diagram of the sub-clone vector pGEM®-T Easy and the 
multiple cloning sequences. The 3'-T overhangs were represented in bold. The Bsa 
I-hGH-BamH I PCR product was inserted between the 3’-T overhangs. This figure 
has been adapted from pGEM®-T and pGEM®-TEasy Vector Systems Technical 
Manual, Promega USA. 
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The ligation mixture was prepared according to the instruction manual: 
1 Ox 丁4 Ligation Buffer (NEB, USA) 1 [x\ 
丁4 DNA Ligase (NEB, USA) 2 i^l 
pGEM®-T Easy Vector 0.5 (25 ng) 
PGR product (Bsa I-hGH-BaniH I) 6.5 j^ l 
The total reaction volume was 10 |il. It was incubated overnight at room 
temperature. Five \i\ of ligation product was transformed into DH5a E.coli cells by 
heat shock method as mentioned in section 2.4.1.2. Transformed cells were spread 
onto LB A agar plate and incubated at 37�C for 16-18 hours. The sub-cloned vector 
was purified by miniprep as mentioned in section 2.4.1.3 and was sequenced 
(TechDragon, Hong Kong) to identify positive clones carrying the insert of hGH 
gene. 
2.4.1.9 Cloning of Bsa I-hGH-BamH I into pSUMO Vector 
The positive pGEM®-T Easy Bsa I-hGH-BamH I vector was digested with 
restriction enzymes to extract the target sequence. The digestion reaction was 
separated in two steps, BamH I digestion first and then Bsa I digestion. 
产 step digestion - BamH I digestion: 
pGEM®-T Easy Bsa I-hGH-BamH I vector 20 |il (about 500 ng) 
lOx NE Buffer 3* (NEB, USA) 5 pi 
BamH I (NEB, USA) 2 fil (20000 U/ml) 
Bovine Serum Albumin 5 |il (1 mg/ml) 
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*lx NE Buffer 3 contained 50 mM Tris-HCl, 100 mM NaCl, 10 mM MgCb and 1 
mM dithiothreitol at pH 7.9. 
The digestion mixture was adjusted to 50 |il final volume with sterile ddHsO and 
incubated 5 hours at 37°C. The digestion product was separated by TAE 1 % agarose 
gel electrophoresis. The linearized Bsa I-hGH-BamH I pGEM®-T Easy vector was 
purified by Gel-MTM Gel Extraction System. 
step digestion - Bsa I digestion: 
Linearized pGEM®-T Easy Bsa I-hGH-BamH I vector 30 |il 
1 Ox NE Buffer 3 (NEB, USA) 5 
Bsa I (NEB, USA) 2 nl (10000 U/ml) 
The digestion mixture was adjusted to 50 final volume with sterile ddH20 and 
incubated 16 hours at 50°C. The digestion product was analyzed by TAE agarose gel 
electrophoresis (Fig 2.4). A DNA fragment was found with approximate 600 bp 
which should be the digested Bsa I-hGH-BamH I fragment. It was purified by 
Gel-M™ Gel Extraction System. 
Expression vector pSUMO (T7 Kan) was purchased from LifeSensors (USA) 
(Fig 2.5). Within the vector, the N-terminal of ligation site was already fused with 
hexa-histidine tag followed by SUMO. The ACCT and GATC overhangs of pSUMO 
vector were ligated with Bsa I and BamH I digestion product. The hexa-histidine in 
the N-terminal of fusion protein facilitated the preliminary purification process and 
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1 2 
3000 bp Q Q — — 3 0 1 5 bp 
2000 bp 
650 bp ^ 600 bp 
500 bp 
Figure 2.4 Gel electrophoresis showing the restriction digestion (BamH I and Bsa I) 
of pGEM®-T Easy Bsa I-hGH-BamH I vector. Lane 1: 1 Kb plus DNA ladder 
(Invitrogen, USA); Lane 2: digested pGEM®-T Easy vector (upper band, 3015 bp) 
<4 
and digested hGH fragment (lower band, 600 bp). Electrophoresis was performed 
using 1 % (w/v) agarose gel. 
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Multiple Cloning Site (MCS) 
pSUMO vector is linearized with 6s a I restrict ion enzyme 
NotI 
(小（,丨） S a d Sail Hind 川 EagI Xhol 
GG GATCCGAATTC GAGCTCC GTCGAC AAGCTT GCGGCCGC ACTCGAG CACCA 
CCTCCA GCTTAAG CTCGAGG CAGCTG TTCGAA CGCCGGCG TGAGCTC GTGGT 
/ ’ 
g f |)SlMO 
_ bp 5598 ^ 
T7 Promoter 
Polylmker Map (pSUMO Vector. T7 Kan) 
E n t i r e m o l e c u l e l e n g t h : 5 5 9 8 b p cx Hi-v T-v-j 
M«t Gly H i s Hia Hio H i s His H i s Gly S « r Asp 
I;T.TETAF.;A?ATA,,VR：RR'JTTT.'UVCTRR/UV ；.^ IAF；GA'^ TATA'-.-C ATG G-ST CAT CAC CAT CAT CAT CAC QGG TCG CAC 
<faA<;ATCTTTATTA,i\AACAAATTCyUATT:.*Tn:"CTCTAT;vr:>..；! TAC CCA CTA C.TC. CTA GTA GTA GTQ CCC ACC CTC 
SUMO Fusion Protein ‘ 
Sor Gla Val Aan <3ln Glu Ala Lya Pro Glu Val Lys Pro Glu Val uya Pro Glu Thr His 
TCA CrAA OTC AAT CAA GAA GC.T AAG CCA GAO QVC AAQ CCA GAA GTC AAC CCT GAC ACT CAC ATC 
ACT err CAG TTA CTT CTT CGA TTC GOT CTC CAG TTC CiCiT CTT CA<； TTC OCA CTC TGA GTG TfoS 
Asn I.«u hya val S«r Asp Gly S«r Sot Glu 11办 Ph« Pho Lys lie Lya tys Thr Thr Pro Leu 
AAT TTA AAG OTG TCC GAT GGA TCT TCA GAG ATC TTC TTC AAG ATC AAA SAG ACC ACT CCT TTA 
TTA AAT TTC CAC kGG CTA CCT AGA ACT CTC TAG AAG AAG TTC TAC ITT TTC TGG TOA GtfA AA? 
Arg Arg L«u Mot Glu Ala Pha Ala Lys Arg Gin Gly Lys Glu Met Asp S«r L«u Arg Pha Leu 
AQA AGG CTG GAA GCG TTC GCT AAA AGA CAG GST fAG GAA ATG GAC TCC TTA AOA TTC TTO 
TCT TCC OAC TAC CTT CGC AAG CGA TtT TCT GTC CCA TTC CTT TAC CTG ACQ AAT TCT AAG AAC 
Tyr Asp Cly Il« Arg Il« Cln Ala Anp Gin Ala Pro Glu Asp Lau Asp Mat Olu Asp Asn Asp 
TAC OAC <3<r  ATT AGA ATT CAA GOT CAC； GCC CCT GAA GAT TTG OAC ATG OAT AAC GAT 
A TO CTC CCA TAA TCT TRA G7T CGA CTA CTC CGC CGA CTT CTA AAC CTC TAC CTC CTA TTC CTA 
l i e I I ® a i u A U Hia Arg Glu Gin I l « MCS 
ATT ATT <SAO 007 CAC CGC OAA CAG ATT <3G GATCC;JAArcr«A‘:X”CO?TC;ACAAx;CTraCGCCXX;CA 
TAA TAA CTC CGA GTG GCG CTT CTC TfiA CCTCCA 缺"T、.f;A<;K;CAO(T:;m,.•；AACGCCW饥 
*SUMO Protease cleavage site 
Figure 2.5 Schematic diagram of the expression vector pSUMO and the multiple 
cloning sequences. The AGGT overhang generated by Bsa I digestion complementary 
with the ACCT end of the pSUMO vector and the CTAG overhang generated by 
BamH I complementary with the GATC end. This figure has been adapted from 
polylinker Map (pSUMO Vector, T7 Kan), LifeSensors USA. 
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the SUMO tag provided the three-dimensional recognition site for SUMO protease to 
remove the fusion partner. 
pSUMO expression vector and the digested Bsa I-hGH-BamH I fragment were 
ligated as the following: 
1 Ox T4 Ligation Buffer (NEB, USA) 1 |il 
T4 DNA Ligase (NEB, USA) 2 i^l 
pSUMO expression Vector 0.5 |al 
Bsa I-hGH-BamH I digestion fragment 6.5 |al 
Ten reaction mixture was incubated overnight at room temperature. Five |il of 
ligation product was transformed into DH5a E.coli cells by heat shock method. 
Transformed cells were spread onto LBK agar plate and incubated at 37°C for 16-18 
hours. The expression vector was purified by miniprep. PGR using Bsa I forward and 
BamH I reverse primers was performed to confirm the hGH had been inserted and the 
positive clones were sequenced (TechDragon, Hong Kong) to identify the correct 
hGH sequence. 
2.4.2 Expression of SUMO-hGH fusion protein - small scale 
2.4.2.1 Expression of SUMO-hGH fusion protein by E.coli BL21 
The expression vector, pSUMO-hGH, was transformed into competent BL21 
cells by heat shock method. Transformed cells were spread onto LBK agar plate and 
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were incubated at 37°C for 16-18 hours. A single colony was picked and inoculated 
into 5 ml of LBK medium. Cells were grown at 37°C with shaking at 250 rpm 
overnight. One percent (v/v) overnight culture was inoculated into 5 ml fresh LBK 
medium and incubated at 37°C with shaking for about 2-3 hours until the OD600 
reached 0.6-0.8. The culture was then cooled down to 20°C for induction. IPTG was 
added to a final concentration at 0.1 mM to induce the fusion protein expression. The 
bacterial culture was incubated at 20°C with shaking overnight. Cells were harvested 
by centrifugation at 3000 rpm for 15 minutes. The cell pellet was resuspended in 1 ml 
sonication buffer (50 mM Tris-HCl, pH 8.0). 
2.4.2.2 Soluble fusion protein extraction 
Cell membrane was disrupted by sonication. The cell pellet was resuspended in 
sonication buffer and was kept on ice. It was sonicated by cycles of 30 seconds 
sonication followed by 30 seconds cooling until the solution became translucent. The 
disrupted cell suspension was centrifuged at 14000 rpm for 30 minutes. The 
supernatant was collected as the soluble fraction while the pellet was resuspended in 
t* 
1 ml of modified solubilization buffer and designated as the inclusion bodies fraction. 
« 
2.4.3 General protein analysis 
2.4.3.1 Protein separation by sodium dodecylsulphate polyacrylamide gel 
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electrophoresis (SDS-PAGE) 
SDS-PAGE was performed as Laemmli (1970). Fifteen percent resolving gel and 
stacking gel were prepared as the followings: 
15 % Resolving Gel (for 10 ml): 
ddH20 2.3 ml 
Acrylamide/Bis-acrylamide, 30 % solution 5 ml 
Resolving gel buffer 2.5 ml 
10 % SDS solution 0.1 ml 
10% APS solution 0.1 ml 
TEMED 0.004 ml 
Stacking Gels (for 4 ml) 
ddHiO 2.7 ml 
Acrylamide/Bis-acrylamide, 30 % solution 0.67 ml 
Stacking gel buffer 0.5 ml 
10 % SDS solution 0.04 ml 
10 % APS solution 0.04 ml 
TEMED 0.004 ml 
Resolving and stacking gels were casted in the Mini-PROTEAN®II 
electrophoresis cell (Bio-Rad, USA). Protein samples were mixed with one sixth 
volume of 6x sample loading buffer and boiled at 100°C for 5 minutes. The samples 
were loaded onto the gel and ran at 35 mA/gel. 
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2.4.3.2 Coomassie Brilliant Blue R-250 staining 
Mini-gels were stained in Coomassie Brilliant Blue staining solution at room 
temperature overnight with gentle shaking. Destaining of the background was 
achieved by soaking the gels in destaining solution at room temperature with shaking 
until the background was removed. Gels were rinsed with water and dried. 
2.5 Results 
2.5.1 Molecular cloning of hGH gene into expression vector 
The hGH gene constructed in the synthetic plasmid pJ2:G01458 was based on 
the amino acid sequence of hGH with optimization in the codon usage for E.coli in 
order to maximize protein expression. The hGH gene fragment was PGR amplified 
with the incorporation of a Bsa I and BamH I restriction site in the 5' and 3' flanking 
the sequence. The expected size of the PGR product was 611 bp which matched the 
profile of the gel (Fig 2.2). This PGR product was sub-cloned into pGEM®-T Easy 
cloning vector and sequenced to confirm the hGH gene was amplified correctly. The 
hGH gene was then cleaved from the pGEM®-T Easy vector by double restriction 
digestion. pSUMO expression vector was selected for the fusion protein construction. 
The ACCT overhang end of pSUMO vector was ligated with the AGGT overhang 
generated by Bsa I digestion while the GATC end was complementary to the CTAG 
generated by BamH I digestion. PGR was performed to confirm the incorporation of 
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the hGH gene. A DNA fragment with a size of approximately 600 bp was found and 
it is probably the hGH gene amplified from the pSUMO vector (Fig 2.6). Positive 
clones were sequenced and transformed in BL21 for expression study. The schematic 
diagrams of the pSUMO-hGH expression vector and fusion protein are shown in Fig 
2.7. 
2.5.2 Expression of SUMO-hGH 
The expression vector pSUMO-hGH was transformed into competent BL21 host 
and induced to express the SUMO-hGH fusion protein. As indicated in Fig 2.8, an 
intense protein band with a molecular weight of about 34 kDa was found in the 
insoluble fraction when induction by IPTG was carried out at 37°C for 3 hours. This 
protein matched the expected size of SUMO-hGH fusion protein, i.e. 34.3 kDa. 
Compared with the 37°C induction, 20°C induction overnight resulted in the switch of 
the fusion protein expression to soluble form instead of in inclusion bodies. As we 
desire to express the fusion protein in soluble form to prevent refolding problems, 
*  
20°C was selected to induce the fusion protein. 
2.5.3 Modification of the expression conditions 
Besides induction temperature, IPTG concentration and culture time were tried 
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Figure 2.6 Gel electrophoresis showing the PCR amplified hGH gene from 
pSUMO-hGH. Lane 1: GeneRulerTM D N A ladder (Amersham Pharmacia Biotech); 
Lane 2: hGH gene PCR fragment. Electrophoresis was performed using 1 % (w/v) 
agarose gel. 
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A- T7 promoter SUMO sequence hGH gene 
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Figure 2.7 Schematic diagram of the expression vector of the SUMO-hGH fusion 
protein. A) Expression vector pSUMO with hGH gene insert, entire molecule length 
is 6176 bp. B) A hexa-histidine tag and a SUMO were fused to hGH at the N-terminal. 
The expected molecular weight of SUMO-hGH is about 34.3 kDa. C) After SUMO 
protease digestion, a 12.2 kDa fusion tag was separated from the mature hGH. The 
molecular weight of the mature hGH is 22.1 kDa. 
48 
A. B. 
1 2 3 1 2 3 
107 kDa一 ^ ^ 107 kDa一 
81 kDa一 - 81 kDa— W M 
^S^kDa— ^ _ 48.7 kDa— ^ 
33.8 k D a « """34.�kDa ^^ ^ ^ ^^一 A P H ^ ^ ^ H — 3 4 . 3 kDa 
27 k D a * — ' ^ f ^ 27 kDa一 W m 
- ^ ^ 
20 .7 kDa—li ‘-二 
^ ^ 20.7 k D a — 
Figure 2.8 SDS-PAGE analysis on the expression of SUMO-hGH fusion protein in E. 
coli. A) Induction at 37°C for 3 hours, Lane 1: Pre-stained SDS-PAGE standard (Low 
range) (Bio-Rad, USA); Lane 2: Insoluble fraction of the bacterial cell lysate 
(inclusion bodies); Lane 3: Soluble fraction of the bacterial cell lysate (supernatant). 
B) Induction at 20°C overnight, Lane 1: Pre-stained SDS-PAGE standard; Lane 2: 
«4 
Insoluble fraction of the bacterial cell lysate (inclusion bodies); Lane 3: Soluble 
fraction of the bacterial cell lysate (supernatant). 
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to optimize the protein expression level in soluble form. As shown in Fig 2.9, the 
expression level of SUMO-hGH in soluble form was found to be quite consistent 
from 1 mM to 0.1 mM IPTG induction concentration. Only 0.05 mM IPTG 
concentration resulted in a significant decrease in the expression level of fusion 
protein. Because of this observation, 0.1 mM IPTG concentration was chosen to 
induce the fusion protein. A time-course analysis of the level of fusion protein 
expression is shown in Fig 2.10，cell cultures were harvested at 2 hours, 21 hours and 
24 hours after induction with 0.1 mM IPTG. After 2 hours of IPTG induction, fusion 
protein began to express and the expression level became maximum after 21 hours 
and remained at the same level at 24 hours. 
2.6 Discussion 
E. coli BL21 cells were used to express hGH as a fusion protein with a 
hexa-histidine tail and a SUMO tag. The deficiency of Ion and ompT proteases in this 
host gave a better expression of intact recombinant proteins instead of degraded 
fragments. We have used the fusion protein approach with the subsequent cleavage by 
enzyme to release the mature protein, such as what Franchi and Shin have reported 
(47, 50), as a means to overcome the presence of a formylmethionine at the 
N-terminal of a directly expressed hGH in E.coli (51). 
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Figure 2.9 SDS-PAGE analysis on the expression of SUMO-hGH fusion protein at 
20°C overnight with different concentration of IPTG Lane 1: Pre-stained SDS-PAGE 
standard; Lane 2，4，6, 8 and 10: Insoluble fraction of the bacterial cell lysate 
(inclusion bodies); Lane 3，5, 7, 9 and 11: Soluble fraction of the bacterial cell lysate 
(supernatant). 
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Figure 2.10 Time-course analysis on the expression of SUMO-hGH fusion protein at 
20°C overnight with 0.1 mM IPTG. Bacterial culture was harvested at different time 
points after induction. Lane 1: Pre-stained SDS-PAGE standard; Lane 2, 4, 6 and 8: 
Soluble fraction of the bacterial cell lysate (supernatant); Lane 3, 5, 7 and 9: Insoluble 
fraction of the bacterial cell lysate (inclusion bodies). 
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2.6.1 Expression vector 
pSUMO was chosen as the expression vector for our study. It provided several 
advantages in the GH expression and downstream processing (52). First, the 
hexa-histidine at the N-terminal simplified the purification process as we can use the 
highly specific IMAC to remove it from its contaminants. Second, the SUMO fusion 
enhanced the solubility of the fusion protein which avoided improper folding caused 
by the refolding of inclusion bodies. Third, the SUMO protease would only recognize 
the three-dimensional structure of SUMO which prevented the problem in cleaving of 
internal cleavage sequence of recombinant protein. In sum, this expression system is 
well suited for the expression of mature recombinant proteins. 
2.6.2 Protein expression 
Although the expression of hGH as inclusion bodies gave a high yield at 37°C, 
the most critical problem was the need to correctly refold the protein after 
solubilization. By modifying the expression conditions, soluble fusion protein with 
4« 
the expected molecular weight was obtained in our study. Induction temperature, 
IPTG concentration and culturing time had been studied. We found that lower 
induction temperature and using lower concentration of IPTG can increase the 
expression of soluble form. This observation agrees with previous reports (53, 54) 
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that reducing the expression rate by lowering the growth rate and inducer 
concentration would minimize the aggregation of fusion protein resulting in the 
increase of solubility. The optimized expression condition of SUMO-hGH in shake 
flask scale was incubation at 37°C for 3 hours, cooled down to 20°C and induced with 
0.1 mM IPTG overnight. 
2.7 Conclusion 
In this study, a SUMO-hGH fusion expression vector was successfully 
constructed. Soluble fusion protein was expressed under the optimized expression 
condition. The purification and downstream processing of the fusion protein to the 
mature hGH will be described in the following chapter. 
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Chapter 3 SUMO-hGH purification and downstream processing 
3.1 Introduction 
In the previous chapter, we have described the successful expression of soluble 
SUMO-hGH fusion protein in BL21 cells. As the fusion protein contains a 
hexa-histidine tag (His-tag) at the N-terminal, IMAC was used to purify the fusion 
protein as well as the mature rhGH. The flow diagram of the purification scheme is 
summarized in Fig 3.1. It involved six steps from cell lysis to the isolation of the 
mature rhGH as final product. After 24 hour induction, cells were harvested and 
homogenized by sonication. The cell lysate supernatant was collected after 
centrifugation and applied onto Ni^^-resin for the His-tagged SUMO-hGH absorption. 
SUMO-hGH was then eluted with imidazole buffer. The His-tag and SUMO fusion 
portion was cleaved by SUMO protease to generate a mature rhGH. The digestion 
mixture was applied onto Ni^^-resin again to remove the fusion partner and 
undigested fusion protein. Mature rhGH was collected in the flow through fraction 
and further purified by gel filtration chromatography. 
3.2 Immobilized-metal affinity chromatography (IMAC) 
The sequence of a His-tag at the N-terminal of the fusion protein facilitated the 
purification by IMAC. Binding of the His-tag to Ni^'"-resin is not conformational 
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Figure 3.1 Flow diagram of the purification and downstream processing of the 
SUMO-hGH fusion protein to the mature rhGH. It involved two rounds of 
immobilized metal affinity chromatography (IMAC) to purify the fusion protein and 
the mature rhGH. 
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dependent, it is the charge-charge interaction between the divalent ions immobilized 
on the solid support (55). The imidazole ring in the histidine residue interacts with the 
nickel ions and the His-tagged proteins are captured by the Ni^^-resin (Fig 3.2). The 
histidines in His-tag have a pKa at about 6.0 so it will be protonated in acidic 
environment like pH 4.5-5.3. By lowering the pH, His-tagged protein can be eluted 
out from the Ni^"^-resin. His-tagged protein can be also eluted by increasing imidazole 
concentration to 100-250 mM. Imidazole competes the binding to the nickel ions that 
displaced the His-tagged proteins bound onto the column. 
Both acidic environment and high imidazole concentration can be used for 
His-tagged protein elution. Step-wise imidazole gradient was chosen for the elution of 
fusion protein as it is a gentle method compare to acidic pH. The fusion protein was 
eluted out by competition of binding site in a mild condition which avoided the 
damage to the protein sometimes caused by low pH. 
3.3 SUMO protease 
«4 
After the preliminary purification of SUMO-hGH, the His-SUMO portion is 
cleaved by SUMO protease to generate a mature rhGH. Several SUMO proteases 
have been found in human, from SENPl to 7 (sentrin-specific protease) (56). They 
recognize the three-dimensional SUMO structure and cleave after the conserved 'GG' 
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Figure 3.2 A) Schematic diagram showing the interaction between the His-tag and 
the matrix through the divalent metal ion Ni^^. B) Histidine residue. C) Imidazole. 
This figure was modified from the handbook for high-level expression and 
purification of 6xHis-tagged proteins, Qiagen (Germany). 
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region to release SUMO from the target protein. The N-terminal domain of the 
protease is found to regulate the substrate specificity as well as cellular localization 
while the conserved C-terminal is found to be the catalytic domain for the substrate 
cleavage (57). In our study, the catalytic domain of human SENPl (SENPIC) was 
used for the release of the SUMO portion from the fusion protein. Four different 
constructs of SENPIC had been studied for the efficiency and convenience in the 
cleavage of the fusion protein. 
3.4 Materials 
3.4.1 Reagents for IMAC purification of SUMO-hGH fusion protein 
3.4.1.1 Start buffer 
It was 50 mM Tris-HCl with the pH adjusted to 8.0 with 1 M NaOH or 1 M HCl. 
3.4.1.2 Washing buffer 
It was prepared by mixing 50 mM Tris-HCl, 300 mM NaCl and 20 mM 
imidazole (USB, USA) with the pH adjusted to 8.0 with 1 M NaOH or 1 M HCl. 
44 
3.4.1.3 Elution buffer 1 
It was prepared by mixing 50 mM Tris-HCl, 300 mM NaCl and 150 mM 
4 
imidazole with the pH adjusted to 8.0 with 1 M NaOH or 1 M HCl. 
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3.4.1.4 Elution buffer 2 
It was prepared by mixing 50 mM Tris-HCl, 300 mM NaCl and 250 mM 
imidazole with the pH adjusted to 8.0 with 1 M NaOH or 1 M HCl. 
3.4.2 Reagents for IMAC purification of mature rhGH 
3.4.2.1 Start buffer 
It was 50 mM Tris-HCl with the pH adjusted to 8.0 with 1 M NaOH or 1 M HCl. 
3.4.2.2 Diluting buffer 
It was prepared by mixing 50 mM Tris-HCl and 300 mM NaCl with the pH 
adjusted to 8.0. 
3.4.2.3 Elution buffer 
It was prepared by mixing 50 mM Tris-HCl, 300 mM NaCl and 250 mM 
imidazole with the pH adjusted to 8.0. 
3.4.3 Reagents for Western blotting 
3.4.3.1 Bjerrum and Schafer-Nielsen transfer buffer 
It was prepared by dissolving 5.82 g Tris and 2.93 g glycine in a minimal 
< 
volume of d d H � � . Three point seventy five milliliter 10 % (w/v) SDS solution and 
200 ml methanol were then added. The final volume of this buffer was made up to 1 L 
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with ddUjO and adjusted the pH to 9.0-9.4. 
3.4.3.2 Phosphate buffered saline (PBS) 
It was prepared by dissolving 8 g NaCl, 0.2 g KCl，2.68 g Na2HP047H20 and 
0.24 g KH2PO4 in a final volume of 1 L ddHaO and the pH was adjusted to 7.4. 
3.4.3.3 Wash buffer 
It was PBS containing 0.1 % (v/v) Tween 20 (Sigma-Aldrich, USA). 
3.4.3.4 Blocking solution 
It was prepared by dissolving 5 % (w/v) non-fat dried milk powder in wash 
buffer. 
3.4.3.5 Alkaline phosphatase (AP) substrate buffer 
It was prepared by mixing 0.1 M Tris base, 0.1 M NaCl and 5 mM MgCb with 
pH adjusted to 9.5 with 1 M HCl. 
3.4.3.6 Nitro blue tetrazolium (NBT) solution 
It was prepared by dissolving 10 mg NBT (Sigma-Aldrich, USA) in each ml of 
ddH20. It was aliquoted in 1 ml each and stored in tinfoil wrapped container at -20°C. 
3.4.3.7 5-Bromo-4-chloro-3-indoIyl phosphate (BCIP) solution 
It was prepared by dissolving 50 mg BCIP (Sigma-Aldrich, USA) in each ml of 
< 
ddHiO. It was aliquoted in 200 \x\ each and stored in tinfoil wrapped container at 
-20�C. 
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3.4.3.8 Alkaline phosphatase (AP) substrate solution 
It was freshly prepared by mixing 200 |il NBT solution and 25 |il BCIP solution 
in 10 ml AP substrate buffer. Ten ml of AP substrate was used for each 8 cm x 5 cm 
PVDF membrane. 
3.4.4 Gel filtration running buffer 
It was prepared by mixing 50 mM sodium phosphate and 150 mM NaCl with pH 
adjusted to 7.2. It was filtered through a 0.22 \xm pore-size membrane and degassed. 
3.5 Methods 
3.5.1 Purification of SUMO-hGH fusion protein by Ni^^-Nitrilotriacetic acid 
(Ni2+-NTA) affinity chromatography (IMAC) 
Ni2+-NTA agarose was purchased from Qiagen, Germany. It was already charged 
with nickel ion in the agarose matrix and supplied in 20 % ethanol. Gel was washed 
with 3 bed-volumes of ddHsO and 1 bed-volume of start buffer to remove residue 
ethanol. One ml of Ni^^-NTA gel was mixed with 4 ml cell lysate supernatant in a 15 
ml Falcon tube. The gel mixture was incubated at 4°C for 1 hour with end-over-end 
rotation. The slurry was then packed into an Econo-Column (Bio-Rad，USA). Flow 
through was collected and the column was washed with 10 bed-volumes of wash 
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buffer. The final few drops of wash buffer were collected as wash sample for 
determining any protein impurity present. SUMO-hGH fusion protein was eluted by 3 
bed-volumes of elution buffer 1 and 2 bed-volumes of elution buffer 2. Eluted 
samples were assayed by SDS-PAGE and later digested by SUMO protease. Fractions 
collected were stored at 4°C. 
The Ni2+-NTA agarose column was regenerated by washing with ddHiO for 30 
minutes and followed by 0.5 M NaOH for another 30 minutes. Five bed-volumes of 
ddHiO was added to wash out the residue NaOH. Gel was resuspended in 20 % 
ethanol and stored at 4°C. The column was reused several times until the colour of gel 
changed from light blue to brownish-grey. Gel regeneration would be performed as 
described in the instruction manual to chelate nickel ion onto the agarose matrix. 
3.5.2 Cleavage of His-SUMO fusion partner to generate mature rhGH 
The purified SUMO-hGH fusion protein was dialyzed against 2 L of dialysis 
buffer (50 mM Tris and 300 mM NaCl, pH 8.0) at 4 � C overnight. SENPIC was used 
t* 
for the cleavage of SUMO fusion partner to generate mature rhGH. 
SENPIC was added at a ratio of 1 p,g protease per 100 |ig of fusion protein. The 
digestion mixture was incubated at 4°C overnight in 50 mM Tris, 300 mM NaCl and 2 
mM DTT at pH 8.0. Digestion mixture was analyzed by SDS-PAGE. Mature rhGH 
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was purified from the digestion mixture by a round of IMAC. 
3.5.3 Purification of mature rhGH by round of Ni^ '"-NTA affinity 
chromatography (IMAC) 
The digestion mixture was applied onto Ni^^-NTA again to remove digested 
fusion partner and undigested fusion protein. As the mature rhGH does not have a 
His-tag, it was expected to be collected in the flow through fraction. Gel was 
equilibrated with start buffer as described in 3.5.1. The gel mixture was incubated at 
4°C for 1 hour with end-over-end rotation. The slurry was packed into a column and 
the mature rhGH was collected in the flow through. Residual amount of unbound 
proteins were collected by washing the column with 4 bed-volumes of diluting buffer 
without imidazole. His-tagged proteins trapped inside the column were eluted with 4 
bed-volumes of elution buffer. Fractions were stored at 4°C and analysed by 
SDS-PAGE. 
** 
3.5.4 Purification of rhGH by size exclusion chromatography - gel filtration 
chromatography 
Gel filtration chromatography using a Superdex 75 10/300 G column (GE 
Healthcare Life Sciences, Sweden) was used to further purify the mature rhGH 
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collected in the flow through of the round of IMAC. A fast protein liquid 
chromatography (FPLC) system (Pharmacia Biotech, Sweden) was used to control 
the flow of buffer and to monitor the elution progress. Sample was first centrifUged at 
13000 rpm for 10 minutes at 4°C to remove insoluble particle. The column in storage 
mode was washed with 2 bed-volumes of filtered ddHiO at a flow rate of 0.5 ml/min 
to remove ethanol. Then it was equilibrated with gel filtration buffer and 1 ml rhGH 
sample was applied. Elution was carried out at a flow rate of 0.5 ml/min. Fractions 
were collected at the protein sample peak region. 
3.5.5 General protein analysis 
3.5.5.1 Protein content determination by Bradford protein assay 
Bradford protein assay based on Bradford M. M. (58) was used for protein 
concentration determination. Bradford reagent was purchased from Bio-Rad (USA). 
Bovine Serum Albumin (BSA) was used as standard for protein determination while 
bovine gamma-globulin was used as standard for immunoglobulin measurement. The 
working range of the assay for BSA is 0.1 mg/ml to 0.8 mg/ml while for 
gamma-globulin is 0.2 mg/ml to 1.5 mg/ml. Dye reagent was prepared by dilution 
with 4 volume of ddE^O. Two point five ml diluted dye was mixed with 50 |il sample 
in a disposable cuvette (Sarstedt, Germany). It was incubated at room temperature for 
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15 minutes. Absorbance was measured at 595 nm by a spectrophotometer. Sample 
protein concentration was calculated from the standard curve. 
3.5.5.2 Protein transfer by using Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad, 
USA) 
After SDS-PAGE, proteins were transferred from mini-gel to 0.2 jim pore size 
PVDF membrane (Bio-Rad, USA) using a semi-dry transfer cell. A piece of PVDF 
membrane with the size of mini-gel was activated in methanol first and was 
equilibrated in the Bjerrum and Schafer-Nielsen transfer buffer for 15 minutes. Six 
filter papers with the size of PVDF membrane were also soaked in the transfer buffer. 
Before transferring, resolving gel was equilibrated in transfer buffer for 15 minutes. 
The transfer cell was setup as described in the instruction manual. Proteins were 
transferred from the gel to PVDF membrane at 15 V for 45 minutes. PVDF 
membrane containing protein sample could be used for western blotting or for 
N-terminal amino acid sequencing. 
3.5.5.3 Western blotting 
After protein transfer, PVDF membrane was blocked with 10 ml blocking buffer 
at room temperature for 30 minutes to saturate the residue binding sites on the 
membrane. First antibody (mouse monoclonal antibody or rabbit polyclonal 
anti-serum) was added at 2500 fold dilution to probe the antigen on the membrane at 
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room temperature for 1 hour with gentle shaking or at 4 � C overnight. Membrane was 
washed three times with wash buffer (5 minutes each). Ten ml blocking buffer was 
then added with 2500 fold diluted detection antibody. Blotting-grade affinity purified 
goat-anti-mouse/rabbit IgG (H+L) alkaline phosphatase conjugate (Bio-Rad, USA) 
was used as secondary antibody to probe the mouse monoclonal antibody or rabbit 
anti-serum. After 1 hour incubation at temperature, it was washed three times with 
wash buffer again. Ten ml AP substrate solution was added for colour development at 
room temperature for 15 minutes in the dark. The reaction was stopped by rinsing the 
membrane under water for 2 minutes and the blot was then dried. 
3.6 Results 
3.6.1 Purification of SUMO-hGH fusion protein by Ni^^-NTA affinity 
chromatography (IMAC) 
The supernatant of induced BL21 cell lysate prepared as described in 2.4.2.1 was 
mixed with Ni^^-NTA for affinity binding. As shown in Fig 3.3, SUMO-hGH fusion 
protein was purified by IMAC in a trial elution condition. Absorbed proteins were 
eluted out by 250 mM imidazole buffer. A highly pure SUMO-hGH was found in the 
< 
eluted fraction with a size of approximately 34.3 kDa (Lane 5). Comparing the flow 
through and the cell lysate (Lane 2 and 3)，the flow through contained much less 
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Figure 3.3 SDS-PAGE analysis of the purification of SUMO-hGH from the induced 
cell lysate by IMAC under trial condition. Lane 1: Pre-stained SDS-PAGE standard 
(Low range) (Bio-Rad, USA); Lane 2: Soluble fraction of cell lysate (supernatant); 
Lane 3: Flow through fraction; Lane 4: Wash fraction; Lane 5: Eluted fraction by 250 
mM imidazole buffer. ^ 
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fusion protein while other proteins remained in the same level. As no proteins 
remained in the wash fraction (Lane 4), 10 bed-volumes of washing were sufficient to 
remove unabsorbed material. 
In order to optimize the elution step, an imidazole step-gradient elution was used. 
Fusion protein was eluted by a range of imidazole from 50 mM to 250 mM. Protein 
contents in the elution fractions were measured by the Bradford assay described in 
3.5.5.1. The elution profile is shown in Fig 3.4. Fusion protein can be eluted at low 
imidazole level even at 50 mM. 100 mM imidazole eluted most of the His-tagged 
protein from the column, A step-gradient elution was performed based on the finding 
in the elution profile. It consisted of 3 bed-volumes of 100 mM imidazole elution 
buffer to elute most of the fusion protein at a relatively low imidazole level and 2 
bed-volumes of 250 mM imidazole elution buffer to elute all the attached protein 
from the column. As shown in Fig 3.5, over 8 0 � / � o f SUMO-hGH was eluted out by 
100 mM imidazole (Lane 5-7). It lowered the amount of imidazole used for elution. 
3.6.2 Cleavage of His-SUMO fusion partner to generate mature rhGH 
The pooled fusion protein was dialysed against 2 L of 50 mM Tris and 300 mM 
NaCl buffer to remove imidazole. SENPIC provided by Dr. Shannon W. N. Au was 
used to cleave the fusion partner away from the hGH. As indicated in Fig 3.6，mature 
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Figure 3.4 IMAC purification of SUMO-hGH by an imidazole gradient from 50 mM 
to 250 mM. Five bed-volumes of each concentration were used to elute the protein. 
Protein concentration was determined by Bradford protein assay. 
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Figure 3.5 SDS-PAGE analysis of the IMAC purification of SUMO-hGH by 
step-gradient imidazole elution. Lane 1: Kaleidoscope polypeptide standards 
(Bio-Rad, USA); Lane 2: Soluble fraction of cell lysate (supernatant); Lane 3: Flow 
through fraction; Lane 4: Wash fraction; Lane 5, 6 and 7: Elution fractions by 100 
mM imidazole buffer; Lane 8 and 9: Elution fractions by 250 mM imidazole buffer. 
71 
1 2 3 
107 kDa 一 . 
81 kDa 一 “ 
48.7 kDa 
— 34.3 kDa 
33.8 kDa 一 -^^mmmmmmm 
27 kDa 
- — 2 2 . 1 kDa 
… • n — 20 kDa 
20:7 kDa 
Figure 3.6 SDS-PAGE analysis of the digestion of SUMO-hGH protein by SENPIC. 
Lane 1: Pre-stained SDS-PAGE standard (Low range); Lane 2: SUMO-hGH fusion 
i* 
protein (before digestion); Lane 3: Digestion mixture, it contained undigested fusion 
protein (34.3 kDa), mature rhGH (22.1 kDa) and SUMO fusion tag (about 20 kDa). 
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rhGH was obtained after digestion with an expected size of 22.1 kDa (Lane 3). Uncut 
fusion protein (34.3 kDa) and SUMO fusion tag (about 20 kDa) were also observed in 
the digestion mixture. Although the expected size of SUMO fusion tag should be 12.2 
kDa, we found it appeared in SDS-PAGE gel as double bands at 20 kDa. This was 
consistent with the protein digestion result in SUMO pro® Expression Systems 
manual, LifeSensors (USA). 
In order to confirm the identity of the bands in the digestion mixture, western 
blot was performed using the medium of hybridoma 33C5 which was raised against 
rhGH (characterization in Chapter 6). As shown in Fig 3.7, the band with a size of 
34.3 kDa in both Lane 2 and 3 could be recognized by the monoclonal antibody (mAb) 
present in the medium. The band at 22.1 kDa in digestion mixture could also be 
recognized by the mAb. It suggests that these bands have structure similar to rhGH. 
3.6.3 Digestion efficiency of different constructs of SENPIC 
Four different constructs of SENPIC were tested for their efficiency in the 
digestion of SUMO-hGH. These four constructs were based on SENPIC with the 
addition of different fusion partner as shown in Table 3.1. In this study, we want to 
determine if a His-tag containing SENP1C could be used for digestion of the fusion 
protein and at the same time co-removed by IMAC in the round of purification 
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Figure 3.7 Western blot analysis of the digestion of SUMO-hGH protein by SENPIC. 
Lane 1: Pre-stained SDS-PAGE standard (Low range); Lane 2: SUMO-hGH fusion 
protein (before digestion); Lane 3: Digestion mixture. Five fold diluted medium of 
«« 
hybridoma 33C5 raised against rhGH was used as first antibody. 
I 
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SENP 1C The catalytic domain of human sentrin-specific protease 1. * 
GST-SENP1C GST tagged at the N-terminal of SENPIC.‘ 
His-SENP 1C His-tag fused at the N-terminal of SENP 1 C / 
His-MBP-SENPIC His-tag followed by mannose-binding protein fused at the N-terminal of 
SENPIC. # 
本 a 
Kindly provided by Prof. Shannon W. N. Au; Kindly provided by Prof. K. B. Wong. 
Table 3.1 The four different SENPIC constructs. 
when the cleaved hGH is eluted in the wash-though fraction. 
The GST-SENPIC is a fusion protease expressed in E.coli (59). After digestion 
with PreScission protease to remove the GST fusion tag, unfused SENPIC could be 
obtained and purified. His-tagged SENPIC is the preferred form of SUMO protease 
in our study because the protease could also be removed from the flow through 
fraction in the 2"'' round of IMAC. Unfortunately, the solubility of His-tag fused 
SENPIC was low and a mannose-binding protein was added to increase the solubility 
of this fusion construct. 
The efficiency in the cleavage of the four different types of SUMO proteases 
«4 
was investigated by digestion of our hGH SUMO fusion. Since the molecular weight 
of the four constructs are different, a molar ratio of 1 (protease) to 100 (SUMO-hGH) 
was used. As shown in Fig 3.8，all of these fusion constructs could cleave the fusion 
protein. Digestion activities were compared by measuring the band density at 
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Figure 3.8 SDS-PAGE analysis of the digestion efficiency of SUMO-hGH by the 
four different SENPIC constructs. Lane 1: Pre-stained SDS-PAGE standard (Low 
range); Lane 2: SUMO-hGH fusion protein (before digestion); Lane 3: His-SENPIC 
digestion mixture; Lane -4: His-MBP-SENP 1C digestion mixture; Lane 5: 
GST-SENPIC digestion mixture; Lane 6: SENPIC digestion mixture. 
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34.3 kDa which reflects the amount of SUMO-hGH left. Band intensity in Lane 
2 served as the 100 % control. 
SUMO-hGH used (%) 
SENPIC 53.36 
GST-SENPIC 57.40 
His-SENP IC 12.13 
His-MBP-SENPIC 46.89 
Table 3.2 Enzymes activity calculated by substrate used percentage. 
As indicated in Table 3.2，the digestion effectiveness of GST-SENPIC, SENPIC 
and His-MBP-SENPIC were about 50 %. Only His-SENPIC showed a lower 
efficiency (12 % fusion protein cleaved). Based on these results, His-MBP-SENPIC 
was chosen for our process because it has a reasonable digestion efficiency and at the 
same time is able to be co-removed in the purification step in the isolation of the 
matured hGH; hence saving one step in our process. 
«4 
3.6.4 Purification of mature rhGH by round of Ni^^-NTA affinity 
chromatography (IMAC) 
Mature rhGH without the His-tag fusion should not be able to bind onto 
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Ni2+-NTA agarose while the SUMO fusion tag, the His-MBP-SENPIC used for 
digestion and undigested His-SUMO-hGH should bind on the IMAC column. Elution 
result of such an experiment is shown in Fig 3.9. Highly pure rhGH was found in the 
flow through fraction (Lane 4). SUMO-hGH, rhGH and SUMO-tag were observed in 
the elution fraction (Lane 6). As shown in Lane 5, only a trace amount of rhGH was 
additionally washed out from the column by the diluting buffer containing no 
imidazole. In total, some free rhGH was lost in the elution fraction indicating that 
there might be some non-specific interaction between the rhGH and Ni^'^-resin. 
3.6.5 Purification of rhGH by size exclusion chromatography - gel filtration 
chromatography 
The flow through fraction collected in the round of IMAC was further 
purified by gel filtration chromatography. One milliliter of rhGH sample was loaded 
onto the column, the amount of protein eluted out was monitored by ODiso- The 
elution profile is shown in Fig 3.10 A. The peak material collected was analyzed by 
44 
SDS-PAGE as shown in Fig 3.10 B. Peak 1 eluted at 15 minutes was the void volume, 
while peak 2 eluted at about 26 minutes was the purified rhGH. From the Coomassie 
Blue stained gel, peak 2 was highly pure and contained only a single protein band at 
22.1 kDa. 
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Figure 3.9 SDS-PAGE analysis of the purification of rhGH by the round of IMAC. 
Lane 1: Pre-stained SDS-PAGE standard (Low range); Lane 2: SUMO-hGH fusion 
protein (before digestion); Lane 3: Digestion mixture; Lane 4: Flow through fraction 
(rhGH); Lane 5: Wash fraction with diluting buffer; Lane 6: Elution fraction. 
** 
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Figure 3.10 A) Elution profile of gel filtration purification of rhGH from the flow 
through fraction of the round IMAC, flow rate at 0.5 ml/min. Peak 1 was the void 
volume; Peak 2 was rhGH. B) Coomassie Blue stained gel showing the peak collected. 
Lane 1: Pre-stained SDS-PAGE standard, Low range; Lane 2: Peak 2 (rhGH). 
80 
3.7 Discussion 
SUMO-hGH fusion protein was purified from cell lysate by IMAC. Pooled 
fusion protein was dialyzed overnight at 4®C to remove imidazole which would 
interfere with the binding in the round of IMAC. The digestion mixture was 
prepared and incubated overnight at 4°C. The 2"'' round of IMAC was performed to 
remove His-tagged protein away from the mature rhGH. The flow through fraction 
containing rhGH was further purified by gel filtration chromatography to a highly 
pure rhGH final product. 
3.7.1 Purification of SUMO-hGH fusion protein by Ni^^-NTA affinity 
chromatography (IMAC) 
SUMO-hGH was successfully purified by IMAC from the supernatant of cell 
lysate. An optimized step-gradient elution was established, and a highly pure fusion 
protein was purified. As shown in Fig 3.5, over 80 % of the fusion protein absorbed 
by Ni2+-NTA agarose was eluted out by 100 mM imidazole buffer. From Coomassie 
Blue stained gel, the eluted fusion protein by IMAC was already 90 % pure. By 
comparing the fusion protein amount in the flow through fraction with the cell lysate 
supernatant, IMAC was very efficient in capturing the His-tagged fusion protein. 
Pooled fusion protein was dialyzed to remove imidazole because the imidazole 
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present in the buffer would interfere with the 2"(丨 round of purification by IMAC. 
3.7.2 Cleavage of His-SUMO fusion partner to generate mature rhGH 
SENPIC was used to cleave the fusion partner away from hGH. As indicated in 
Fig 3.6, SUMO-hGH could be digested to mature rhGH and SUMO fusion tag. The 
identity of rhGH was confirmed by western blot using a monoclonal antibody, 33C5, 
raised against rhGH. 
His-MBP-SENP 1C was chosen for our process development because it can 
digest the SUMO-hGH fusion as effectively as the unfused SENPIC. The advantage 
of this enzyme is that it carries a His-tag so it could be co-removed from rhGH in the 
round of IMAC. As the size of SENPIC is about 27 kDa, it would be difficult to 
separate it from rhGH (22.1 kDa) by gel filtration chromatography if it was not 
removed beforehand. 
3.7.3 Purification of mature rhGH by 2"'' round of Ni^^-NTA affinity 
1* 
chromatography (IMAC) 
Unfused free rhGH was expected to be collected in the flow through fraction in 
this step as it does not carry a His-tag. As indicated in Fig 3.9, rhGH was collected in 
the flow through fraction. Undigested SUMO-hGH, His-MBP-SENP IC and 
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SUMO-tag were eluted out from the column by imidazole buffer. Some rhGH were 
also eluted in this fraction. As a total of 4 bed-volumes of diluting buffer were used to 
wash the column and yet some rhGH still found in the elution fraction indicated that 
there was a non-specific association between tag free rhGH and the Np^-resin. To 
confirm the non-specific binding of rhGH is not an artifact due to our process, a 
commercial purchased preparation of rhGH (Scitropin, SciGen) was applied onto the 
Ni2+-NTA column. A similar observation was found that some rhGH was absorbed 
and could only be eluted by imidazole. Such association may be explained by the 
Zn2+ binding site presence on the surface of hGH (60). This cation-binding pocket is 
located on the surface of helices 1 and 4 which is formed by His'^, His^^ and Glii'^ "^ 
as Fig. 3.11 shown. In physiological pH (or start buffer with pH 8.0), these three 
residues carry negative charges forming a binding pocket for the divalent ions. Brian 
and James's study showed that Zn^^ ion is essential for the binding of hGH to the 
extracellular domain of the human prolactin receptor (60). We believe that in our 
purification this cation-binding site interact with the immobilized Ni^ "^  ions resulting 
in the non-specific binding even the His-tag group was removed from the rhGH. 
More elution conditions will be tried in the following chapter to see if we can 
minimize the lost of rhGH due to non-specific binding. 
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Figure 3.11 Location of the Zn^^ binding site in human growth hormone. The binding 
pocket is formed by His'^ His^', and Glu'^^ This figure was adapted from Brian C. 
f* 
Cunningham and James A. Wells (60) 
< 
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3.7.4 Purification of rhGH by size exclusion chromatography - gel filtration 
chromatography 
The final purification step in our process is by size exclusion chromatography. 
As hGH is a heterogeneous hormone, it may be present as monomeric, dimeric or 
even oligmeric forms (18). We have determined the molecular isoform of hGH by the 
elution profile from gel filtration chromatography and SDS-PAGE analysis. A single 
protein peak in the elution profile and the expect molecular weight of mature hGH 
indicated hGH is present as monomeric form after the whole process. 
3.8 Conclusion 
Highly pure and monomeric rhGH was successfully prepared from SUMO-hGH 
fusion protein by the process described in this chapter. The methods involved were 
easy to scale-up. Since some of rhGH were lost in the purification steps, more 
optimizations are needed to increase the yield of the final product. The fermentation 
expression of SUMO-hGH fusion protein will be described in the following chapter. 
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Chapter 4 Fermentation expression of SUMO-hGH and scale-up of 
downstream process 
4.1 Introduction 
A soluble SUMO-hGH fusion protein was successfully expressed in E.coli BL21 
and the procedure for the purification and isolation of the fusion protein to rhGH was 
established. In this chapter, we will describe the scale-up production of the hormone 
by a 2 L pilot fermentor and the optimization of its isolation in this scale. 
Since SUMO-hGH was expressed as an intracellular protein in E.coli, cell 
density is a critical parameter to optimize for production yield. Therefore high cell 
density cultivation is the focus of this study. Fixed volume fed-batch fermentation 
was chosen to achieve high cell density. Compared with batch fermentation, fed-batch 
fermentation can reach a higher biomass yield in a smaller culture volume. This is 
achieved by real-time control of the growth rate by controlling the addition of 
limiting substrate (61). The most important advantage of fed-batch over batch 
fermentation is that the level of carbon source (glucose) in the culture medium is 
always maintained at nearly complete consumption. This prevents the carbon 
catabolic repression caused by excess glucose present in the medium as glucose will 
suppress gene expression of the Lac operon resulting in lower expression of the 
fusion protein (62). A fixed volume fed-batch fermentation scheme was developed for 
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the production of SUMO-hGH fusion protein in LB medium in the present study. A 
simple glucose feeding strategy controlled by cross indexing with pH and dissolved 
oxygen was used. 
4.2 Bioreactor system for E.coli host cultivation 
A 2 L bench-top small laboratory fermenter KLF (Bioengineering AG, 
Switzerland) was used in this study (Fig 4.1). It was hooked up to a computer and 
controlled by software. pH, dissolved oxygen and temperature probes were used to 
provide real-time monitoring of these parameters and feeding rate was fine-tuned 
according to these parameters to control growth rate. 
_ 
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Figure 4.1 A 2 L bench-top small laboratory fermenter KLF (Bioengineering AG, 
Switzerland) used for the cultivation of E.coli BL21 cells. 
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4.3 Mechanical cell disruption for cell 
After cultivation, cells were harvested by centrifugation. The cell pellet was 
suspended in 50 mM Tris buffer at pH 8.0 (12.5 ml buffer per OD600) and 
mechanically disrupted using glass beads in a Dyno®-mill (Fig 4.2). The glass bead 
slurry was chilled to 20°C in order to prevent protein denaturation by heat generated 
during grinding. The cell suspension was passed through the grinder 3 times to ensure 
complete breakage of the cell membrane. Compared with sonication, Dyno®-mill can 
handle a larger cell suspension volume up to 1 to 2 L. 
wm 
Figure 4.2 Dyno®-mill cell grinder type KDL (Willy A. Bachofen, UK) - A cell 
disruption machine used for handling cells harvested from fermentation culture. 
4.4 rhGH binding assay 
The functional activity of purified rhGH from fermentation was assessed by 
Dual-Liiciferase® Reporter Assay System (Promega, USA). This assay is based on the 
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binding of hGH onto its receptor. When rhGH binds onto growth hormone receptor 
(GHR) and activates it, GHR will activate the signal transduction pathway that 
triggers the expression of a transfected luciferase gene. Receptor binding activity can 
then be compared quantitatively by the luminescence measurement. 
4.5 Materials 
4.5.1 Reagents for bacterial culture by fermenter 
4.5.1.1 LB based complex fermentation medium 
It was prepared by dissolving 50 g LB broth (which contained 20 g sodium 
chloride, 20 g tryptone and 10 g yeast extract. Sigma-Aldrich, USA), 5.8 g sodium 
phosphate dibasic (Na2HP04, Sigma-Aldrich), 6.0 g potassium phosphate monobasic 
(KH2PO4, Sigma-Aldrich), 3.0 g ammonium sulphate ((NH4)2S04) and 0.1 ml 
antifoam A (Sigma-Aldrich) in final volume of 1.9 L d d H � � . It was sterilized by in 
situ autoclaving for 20 minutes at 121'^ C in the fermenter. 
4.5.1.2 M9 based defined fermentation medium 
It was adopted from Rasoul Khalilzadeh et al. (63). It was prepared by 
dissolving 25.6 g sodium phosphate dibasic (Na2HP04.7H20), 6.0 g potassium 
phosphate monobasic (KH2PO4), 1 g sodium chloride, 2 g ammonium chloride 
(NH4CI) and 0.1 ml antifoam A in final volume of 1.4 L ddH^O. It was sterilized by in 
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situ autoclaving for 20 minutes at 121°C in the fermenter. 
Twenty g glucose and 1 g magnesium sulfate heptahydrate (MgSCVTHiO) were 
dissolved in 500 ml ddH^O. It was sterilized separately for 20 minutes at 121°C. 
Fermentation PTM trace salt solution for Pichia pastoris (Invitrogen, USA) was 
supplemented into defined medium to provide essential trace element for growth. It 
contained 24 mM cupric sulphate, 0.534 mM sodium iodide, 17.8 mM manganese 
sulphate, 0.827 mM sodium molybdate, 0.323 mM boric acid, 2.1 mM cobalt chloride, 
0.147 M zinc chloride, 0.234 M ferrous sulphate, 1.64 mM Biotin and 0.188 M 
sulphuric acid. 2.81 g/L CaCl2"2H20 was added so it contained all the metal ions as 
described by Rasoul Khalilzadeh et al. (63). This solution was sterilized by filtration 
in a 0.22 |im filter. 
Two ml of trace element solution and 500 ml glucose solution were added into 
1.4 L defined medium and mixed in the fermenter before seed culture inoculation. 
4.5.1.3 Glucose supplement feed 
It was prepared by dissolving 50 g glucose and 5 g magnesium sulfate «  
heptahydrate in final volume of 400 ml ddH^O. It was sterilized by autoclaving for 20 
minutes at 121°C. 
4.5.1.4 Base Feed 
It was prepared by mixing 27 ml ammonia (35 %, about 14.8 M) and 173 ml 
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pre-sterilized ddHaO in a fume cupboard. 
4.5.2 Reagents for HEK293 Hi cultivation 
4.5.2.1 DMEM/F12 medium 
DMEM/F12 medium was purchased from Gibco, USA. It was supplied in liquid 
form in a package size of 500 ml per bottle. It contained 365 mg/L L-glutamine, 
3574.5 mg/L HEPES and 55 mg/L pyruvate at pH 7.4. It was stored at 4°C. 
4.5.2.2 Fetal bovine serum (FBS), certified grade 
FBS was purchased from Gibco, USA. It was supplied in a package size of 500 
ml per bottle and kept in -20"C. Serum was heat-inactivated at 56°C for 30 minutes 
before used. Heat-inactivated serum was ready to use and aliquoted into 50 ml each in 
50 ml Falcon centrifuge tube and was stored at -20°C. 
4.5.2.3 Antibiotic (lOOx) 
It was purchased from Gibco, USA in a package size of 100 ml per bottle. It 
contained 10000 units of-penicillin G and 10000 |j.g streptomycin sulphate in 0.85 % 
saline. It was aliquoted in 5 ml each and was stored at -20°C. 
4.5.2.4 Complete DMEM/F12 medium 
It was DMEM/F12 medium supplemented with 1 % (v/v) antibiotic and 10 % 
(v/v) heat-inactivated fetal bovine serum. 
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4.5.3 Reagents for Dual-Luciferase® Reporter Assay System 
4.5.3.1 Lipofectamine reagent 
Lipofectamine was purchased from Invitrogen, USA. It was used to transfecl 
plasmids pRL/CMV (internal control) and spi/luc (experimental vector) into HEK293 
Hi cells. It was supplied as a 3:1 (w/w) liposome formulation of polycationic lipid 
2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl]-N,N-dimethyl-l-propanaminium 
trifluoroacetate (DOSPA) and neutral lipid dioleoyl phosphatidylethanolamine 
(DOPE) in filtered water. It was mixed gently before use and stored at 4°C. 
4.5.3.2 Passive Lysis Buffer 
Passive lysis buffer was purchased from the Dual-Luciferase® Reporter Assay 
System (Promega, USA). It was supplied as 5x concentrated solution. Working stock 
solution was prepared by diluting 1 volume of 5x concentrated solution with 4 
volume of ddH^O. 5x passive lysis buffer was stored at -20°C. 
4.5.3.3 Luciferase Assay Reagent II 
It was prepared by mixing lyophilized Luciferase Assay Substrate (Promega, 
USA) in 10 ml of Luciferase Assay Buffer II (Promega). Luciferase Assay Reagent II 
was stored at -20°C for one month or at -70°C for one year. 
4.5.3.4 Stop & Glo® Reagent 
Stop & Glo® Substrate (Promega) was purchased and supplied in 5Ox 
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concentrated solution. Stop & Glo® Reagent was freshly prepared by mixing 1 
volume of 50x Stop & Glo® substrate with 49 volumes of Stop & Glo® Buffer 
(Promega) in a siliconized polypropylene tube. 
4.5.4 Reagents for silver stain of SDS-PAGE mini-gel 
4.5.4.1 Fixative enhancer solution 
Silver stain plus kit was purchased from Bio-Rad (USA). Fixative enhancer 
solution was prepared according to the manual by mixing 10 % (v/v) fixative 
enhancer concentrate, 50 % (v/v) methanol and 10 % (v/v) glacial acetic acid in 
ddH20. 
4.5.4.2 Staining substrate solution 
Substrate solution I was prepared by freshly mixing 1 ml of each of silver 
complex solution, reduction moderator solution, and image development reagent in 
final volume of 10 ml with ddH20. Substrate solution II was prepared by freshly 
dissolving 4 % (w/v) development accelerator powder in 10 ml of ddHsO. Silver stain 
staining substrate solution was prepared by mixing these two solutions. 
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4.6 Methods 
4.6.1 Bioreactor system and fixed volume fed-batch fermentation 
4.6.1.1 Seed culture inoculum 
A single colony from the pSUMO-hGH plasmid transformed BL21 LBK agar 
plate was picked and inoculated into a 20 ml LBK medium shake flask aseptically as 
described in Chapter 2 section 2.4.2. The seed culture was incubated overnight at 
JTC with shaking at 250 rpm. When the culture reached an ODeoo of 2-3, it was used 
as the inoculum for the fermentation. 
4.6.1.2 Fermenter set-up 
The fixed volume fed-batch fermentation was carried out in a 2 L bench-top 
laboratory fermenter KLF (Bioengineeriiig AG, Switzerland). Before use, the 
fermenter was sterilized by autoclaving 2 L of ddHiO in situ. LB based complex 
fermentation medium or M9 based defined fermentation medium were loaded into the 
fermenter. The pH probe was calibrated by pH standard between 4 and 7. It together 
with the dissolved oxygen (DO) probe were then installed. The medium and 
fermenter were sterilized in situ at 121"C for 20 minutes. After sterilization, the 
fermenter was cooled down to 37°C. Base feed was hook up to a tubing pump and 
connected to the fermenter. Twenty milliliter of filtered (0.22 |im) kanamycin solution 
(5 mg/ml) was added into the fermenter aseptically. pO? was calibrated at 100 % 
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under the following conditions: temperature at 3TC; stirrer speed at 400 rpm; pH at 
12, air flow maximum. 
4.6.1.2 Inoculation of fermenter 
Twenty ml of the seed culture inoculum was inoculated into the fermenter. 
Fermentation was started and the culture time, fermentation parameters were recorded. 
A medium sample was collected as 0 hour. 
4.6.1.3 Cell growth analysis 
Cell growth was monitored by OD6oo- The spectrophotometer was blanked with 
ddH20 at OD600, medium samples collected at different time points were measured 
and recorded. Glucose concentration was measured by glucose test paper to prevent 
overfeed of glucose. After measurement, medium samples were stored at -20°C. 
4.6.1.4 Glucose feeding strategy 
Glucose feeding was separated into three phases. Fed-batch fermentation started 
with a batch phase in the first 3-4 hours. When cells have consumed all the limiting 
substrate (carbon source),— a rapid increase in pH would be observed. After the 
depletion of the limiting substrate, glucose feeding was initiated. Feeding was 
controlled by a combination of pH-stat and dissolved oxygen. In the first phase of 
glucose feeding, pH-stat was used. Glucose supplement feed was hook up to a pump 
controlled by the computer for acid addition. When the pH of the fermentation broth 
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rose above the set-point 7.2，the acid pump will be triggered to add glucose into the 
medium. Besides providing carbon source, glucose could act as an acid since glucose 
metabolism will eventually produce acidic metabolites like acetic acid and lactic acid 
to neutralize the pH. After IPTG induction, glucose feeding would change to the 
second phase in which glucose is added continuously. The flow rate of glucose feed 
was controlled by the dissolved oxygen feedback. Flow rate was manually adjusted in 
order to keep the dissolved oxygen maintained at below 30 %. 
4.6.1.5 IPTG induction of SUMO-hGH 
After 24 hours cultivation at 37°C, the fermenter was cooled down to 20°C for 
IPTG induction. Culture medium sample was collected before induction, 200 \i\ of 1 
M IPTG stock solution was added aseptically. Induced cells were cultured for another 
24 hours. 
4.6.1.6 Fermentation harvest 
After induction for 24 hours, the fermentation was stopped and the culture end 
time and fermentation parameters were recorded. Glucose supplement feed and base 
feed used were calculated. Cells were harvested by centrifugation at 4000 rpm for 20 
minutes at 4°C. 
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4.6.2 Large scale mechanically disruption of cell membrane 
Cell pellet obtained after centrifugation (from fermentation broth with ODeoo at 
40) was resuspended in 500 ml 50 mM Tris buffer, pH 8.0. The cell suspension was 
then loaded into the Dyno®-mill for the mechanical cell membrane disruption. 
Autoclaved glass beads with a diameter of 0.1-0.2 mm were first loaded into the 
grinding chamber. The grinding chamber was chilled at 20°C to prevent heat 
denatiiration. The flow rate of cell suspension was adjusted to 30 ml/min. For the 
complete breakage, cell suspension was passed through the grinding chamber at least 
3 times. Tris buffer was used to wash the grinding chamber and to elute out proteins 
trapped in the beads slurry until there was no protein remain (detected by Bradford 
assay). Cell lysate was centrifiiged at 14000 rpm for 30 minutes at 4°C. The soluble 
cell lysate was collected and stored at 4°C. 
4.6.3 Downstream processing of SUMO-hGH 
The steps of downstream processing were same as Chapter 3 described. 
4.6.4 Culture of HEK293 Hi cells 
HEK293 Hi cell-line was kindly provided by Prof. Christopher H.K. Cheng. It 
was human embryonal kidney cells with high expression level of human growth 
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hormone receptor (GHR). Cells were grown in complete DMEM/F12 medium in 75 
cm^ culture flasks at 37°C with 5 % CO2 supplement. The cells were maintained in 
log phase (0.5-1 x 10^  cell/ml) by subculturing in a ratio of 1:2 to 1:4 every 2 to 3 
days. Briefly, culture medium was removed and cell layer was rinsed with 
trypsin-EDTA (0.05 % Trypsin, 0.53 mM EDTA.4Na; Gibco) to remove all the serum 
left. Two milliliter of trypsin-EDTA solution was added and observed under 
microscope until the cell layer was dispersed. Ten milliliter of complete medium was 
added to resuspend the cells. Cell suspension was centrifuged, appropriate aliquots of 
cells was added to a new culture flask. 
4.6.5 Dual-Luciferase® Reporter Assay System 
4.6.5.1 Transfection of luciferase vectors 
The experimental vector spi/luc and internal control vector pRL/CMV were 
kindly provided by Prof. Christopher H.K. Cheng. The spi/luc reporter vector was 
driven by a STATS-binding site which is activated by the GHR signaling pathway 
resulting in a luciferase gene expression (64). rhGH induced GHR activity was 
measured by the amount of luciferase activity generated. Co-transfection of spi/luc 
and pRL/CMV vectors was performed as described in the instruction manual of 
LipofectamineTM reagent (Invitrogen). 
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Briefly, 1 x 10^  HEK293 Hi cells were seeded in each well of poly-D-lysine 
(Sigma-Aldrich, USA) coated 24-well plate one day before transfection with 500 |il 
complete DMEM/F12 medium that without antibiotics supplement. Each transfection 
sample was prepared as following: a) Fifty ng pRL/CMV and 500 ng spi/luc DNA 
vectors were diluted in 25 \i\ serum free DMEM/F12 medium and mixed gently, b) 
One microliter lipofectamine was diluted in 25 |il serum free DMEM/F12 medium 
and mixed gently, c) Diluted DNA vectors and diluted lipofectamine were mixed 
gently and incubated at room temperature for 30 minutes to allow the lipofectamine 
encapsulate the vectors, d) One hundred and fifty microliter of serum free 
DMEM/F12 medium was added into the complex and mixed gently. Each transfection 
sample was prepared for each well of HKE293 Hi cells. Growth medium was 
removed from 24-well plate and washed twice with pre-warmed DMEM/F12 medium 
free of serum and antibiotics. Two hundreds microliter of transfection sample solution 
was added to each well and mixed gently by rocking the plate. Cells were incubated 
with transfection solution at 37°C in 5 % CO2 incubator for 5 hours. After incubation, 
transfection solution was removed from each well and washed with pre-warmed 
complete DMEM/F12 medium once. HEK293 Hi cells were co-transfected with two 
vectors and were ready for luciferase assay. 
4.6.5.2 rhGH binding assay 
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Shake flask and fermentation produced rhGH were used for the binding assay. A 
commercial preparation of rhGH, Scitropin (SciGen, Singapore), was used as a 
positive control. One milliliter medium containing 100, 250 and 500 ng/ml rhGH was 
added to the transfected cells and incubated at 37°C in 5 % CO2 incubator overnight. 
4.6.5.3 Preparation of cell lysate using passive lysis buffer 
Growth medium was removed from 24-well plate and the wells were gently 
washed with 1 ml sterilized PBS. PBS was completely removed and 100 |il of Ix 
passive lysis buffer was dispensed into each culture well to cover the cell layer. The 
plate was gently rocked and placed at room temperature for 15 minutes. Cell lysate 
was transferred to a new 1.5 ml micro-centrifuge tube prior to luciferase assay. 
4.6.5.4 Dual-Luciferase® Assay 
Luciferase Assay Reagent II (LAR II), Stop & Glo® Reagent and cell lysate 
samples were warmed to room temperature before luciferase assay. Luciferase assay 
was performed as described in the instruction manual (Promega). Briefly, 100 [•ii of 
LAR II was perdispensed into each of siliconized polypropylene tube. Twenty ^il of 
cell lysate was transferred into the LAR II tube and mixed by pipetting. Tubes were 
placed in the luminometer for the measurement of firefly luciferase activity. 
Luminometer was adjusted to 2 second premeasurement delay and followed by a 10 
second measurement period for each assay. Sample tube was removed from 
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luminometer, 100 |j.l of Stop & Glo® Reagent was added and mixed by vortex. Renilla 
luciferase activity was then measured by the luminometer. Experimental data 
collected were normalized by subtraction of the reading in negative control in which 
no rhGH was added. 
4.6.6 Silver staining of SDS-PAGE mini-gels 
Silver stain was performed as described in the instruction manual of silver stain 
plus kit. Briefly, 20 ml of silver stain fixative enhancer solution was used to soak each 
piece of mini-gel (8 cm x 5 cm). The gel was fixed by fixative enhancer solution for 
20 minutes at room temperature with gentle shaking. Fixed gel was rinsed twice with 
40 ml ddHbO for 20 minutes with shaking. Staining substrate solution was added to 
stain the gel at room temperature for about 20 minutes. Stained gel was fixed by 20 
ml 5 % (v/v) glacial acetic acid for 20 minutes and rinsed by ddH20 before air drying. 
4.7 Results 
t* 
4.7.1 Fed-batch fermentation of E. coli BL21 
Transformed E. coli BL21 was cultured in a 2 L fermenter for a total of 48 hours 
to express the SUMO-hGH fusion protein. The growth curve of E.coli cultured in LB 
medium is shown in Fig 4.3. Foam formation was suppressed by manually adding 
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E. coli BL21 growth curve in LB medium 
. B a 化 j h , p H - ^ l a t taiadirva p h a s c ' O O l<?vol Tcodinj] pha'S^i 
丨 phase 丨 ‘ ‘ 
5 0 j UUUUUUJUW.UL.X. LL.jmr:L™trnn, if ,r •„ r u««nr«arrrm.ir™r.im. rnrr, ,.、._..,. 一…._”_.,一一 .•. .amulu. .. --..WW—^™一'~ " ™ “ i 
45 - — - — . ^ ^ ^ _ “ 1 
—40 …“ - “ / - - - — 1 
§ 35 . — . 7 . I 
Q 30 ... __ 1 — i 
j I 
w - — — ‘ “ —一.…"i 
CT3 9 0 _ _ _ — _ 
E 二 - ] 
1 0 — — ！ 
0 — ^ -.......— i 
0 4 8 12 16 20 24 28 32 36 40 44 48 
Culturing time (hour) 
Figure 4.3 The growth of E coli BL21 cells in LB medium during high cell density 
cultivation. The feeding in the first 24 hours cultivation was controlled by pH-stat 
while the late 24 hours was manually adjusted by keeping the dissolved oxygen at 
below 30 %. 
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antifoam A. Twenty milliliter of filtered kanamycin solution (5 mg/ml) was added 
into the fermenter aseptically for each 24 hours. After the depletion of carbon source 
(at 4 hours) in the initial LB medium, pH-stat feeding was initiated. The feeding flow 
rate was controlled by the rise of pH which was due to the metabolic shift to the 
utilization of complex nitrogen source (amino acid) in the tricarboxylic acid (TCA) 
cycle. Deamination of amino acid and reutilization of excreted acids resulted in a pH 
rise that triggered the glucose feeding. After 24 hours of culture, the OD600 of the 
fermentation broth reached a level of about 22.5. Cultiiring temperature was then set 
to 20°C for IPTG induction. Several induction temperatures have been tried and 
20-22°C IPTG induction gave the highest expression yield of the soluble fusion 
protein. During this period, the dissolved oxygen level was maintained at below 30 %. 
In the second phase of glucose feeding, the principle of feeding is based on the fact 
that when substrate level was limiting respiration rate will reduce and less oxygen is 
consumed. The rise in dissolved oxygen indicates that glucose was depleted and to 
maintain the DO level, feeding flow rate was increased. At the end of the 48 hours, 
t* 
the OD600 of the fermentation culture reached about 46. 
A time-course analysis of SUMO-hGH expression level is shown in Fig 4.4. 
Cells were harvested at 7, 24, 33 and 48 hours and a shake flask culture was included 
as a control. After 24 hours of cultivation at 37"C, the fermentation culture was 
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Figure 4.4 A) SDS-PAGE analysis on the expression of SUMO-hGH in different 
time points of fermentation by induction at 28°C. Lane 1: Pre-stained SDS-PAGE 
standard; Lane 2, 4, 6 and 8: Cell lysate supernatant at time 7，24, 33 and 48 hours 
while Lane 3,5,7 and 9 are the inclusion bodies respectively. B) SDS-PAGE analysis 
on the expression of SUMO-hGH in different time points of fermentation by 
induction at 20 Lane 11: SDS-PAGE standard; Lane 1, 3, 5 and 7: Cell lysate 
supernatant at time 7, 24, 33 and 48 hours while Lane 2, 4, 6 and 8 are inclusion 
« 
bodies respectively. Lane 9 and 10: Cell lysate supernatant and inclusion bodies of 
shake flask culture. After 24 hours cultivated, fermentation culture was induced by 
0.1 mM IPTG. Samples loaded in the gel were normalized with same ODeoo. 
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induced with 0.1 mM IPTG. To study the effect of induction temperature on the 
solubility of SUMO-hGH expressed, two induction temperatures, 28°C and 20°C, 
have been tried. For 28"C induction (Fig 4.4 A), about 60 % of soluble protein in the 
cell lysate was found to be SUMO-hGH at 9 hours after IPTG addition (Lane 6) and 
the expression level was already maximized and remained unchanged until the end of 
fermentation (Lane 8). Although a slower expression rate of SUMO-hGH was 
observed in 20。C induction (Fig 4.4 B), the level of soluble SUMO-hGH in the cell 
lysate was increased from 50 % (9 hours after induction, Lane 5) to 80 % until the 
end of fermentation (Lane 7). Roughly 50 % of SUMO-hGH was lost as inclusion 
bodies in the 28°C induction while less than 10 % was lost in the 20°C induction. 
Induction temperature gives a similar effect on the solubility of protein expression in 
both fermentation and shake flask, the lower the induction temperature the higher the 
solubility of SUMO-hGH expressed. The yield of SUMO-hGH from fermentation is 
much higher than the result from the shake flask culture. In this study, we have shown 
that high cell density cultivation and high expression level of soluble SUMO-hGH 
fusion protein could be achieved in our fed-batch strategy with low induction 
temperature. 
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4.7.2 Comparison on disruption methods and the purification of SUMO-hGH 
from cell lysate 
Three disruption methods have been studied in order to compare the efficiency 
in the breakage of cell membrane. Due to the difference in the maximum culture 
volume capacity, different volumes of fermentation culture were used. For sonication, 
5 ml of fermentation culture was used and the final volume for disruption was 
adjusted to 13 ml (same dilution factor as Dyno®-mill). For B e a d B e a t e i . T M (a 
bench-top cell grinding machine with stainless-steel chamber designed for handling 
culture volume at about 50-175 ml), 50 ml culture was used and adjusted to 130 ml. 
For Dyno®-mill, 1000 ml culture was grinded as 2600 ml cell lysate. Thirteen 
milliliter of cell lysate supernatants were mixed with 2 ml of Ni^^-NTA agarose for 
His-tagged protein binding. Step-gradient elution as described in Chapter 3 section 
3.6.1 was performed, and the elution profile is shown in Fig 4.5. The band intensity at 
34.3 kDa of Lane 2 of in each gel was compared. Both sonication and Dyno®-mill 
gave similar intensities suggesting that these two methods have similar efficiency in 
cell disruption. The result from the B e a d B e a t e r T M was less efficient. Bradford protein 
assay was performed to determine the amount of fusion protein purified by IMAC. 
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Figure 4.5 SDS-PAGE analysis of the comparison on different disruption methods. A) 
Sonication, B) BeadBeater™, C) Dyno®-mill. Lane 1: Pre-stained SDS-PAGE 
standard; Lane 2: Cell lysate supernatant; Lane 3: Flow through, Lane 4: Wash 
fraction; Lane 5, 6，7, 8 and 9: Elution fraction 1, 2, 3, 4 and 5 respectively. 
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The estimated amount of SUMO-hGH purified by IMAC from 1 L of culture 
was calculated according to the following equation: 
(SUMO-hGH purified by IMAC / Volume of cell lysate supernatant used) x Total 
volume of cell lysate after disruption x (1 L fermentation culture / Volume of cell 
culture used of disruption) 
For sonication: (4.45 mg /13 ml) x 13 ml x (1000 ml / 5 ml) = 890 mg/L 
For BeadBeater™: (2.14 mg / 13 ml) x 130 ml x (1000 ml / 50 ml) = 428 mg/L 
For Dyno®-mill: (4.59 mg /13 ml) x 2600 ml x (1000 ml / 1000 ml) = 918 mg/L 
According to the above results, Dyno®-mill was very effective in handling the 
fermentation culture as it yielded 100 % cell breakage in a large volume compared 
with sonication. Three passages of cells through the grinding chamber appeared to be 
enough and this grinding condition was used for further studies. 
From the parallel shake flask culture, 15.10 mg fusion protein was purified from 
100 ml culture by IMAC (151 mg/L). High cell density fermentation boosted the 
«4 
yield of SUMO-hGH by about 5 fold compared to shake flask. 
4.7.3 Optimization of His-MBP-SENPIC digestion condition 
In this section, we study the use of digestion buffer and pH for the enzymatic 
cleavage of SUMO-hGH to release mature rhGH. As shown in Fig 4.6，the use of 
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Figure 4.6 SDS-PAGE analysis of the digestion of SUMO-hGH at different 
conditions. A) PBS digestion buffer. Lane 1: Pre-stained SDS-PAGE standard; Lane 2, 
3, 4 and 5: Digestion mixture in pH 8.0 at time 0, 2.15, 5 hours and overnight; Lane 6, 
7, 8 and 9: Digestion mixture in pH 7.3 at time 0，2.15, 5 and overnight respectively. 
B) 50 mM Tris and 300 mM NaCl buffer. Lane 1: SDS-PAGE standard; Lane 2, 3, 4 
and 5: Digestion mixture in pH 8.0 at time 0, 2.15, 5 and overnight; Lane 6, 7，8 and 9: 
Digestion mixture in pH 7.3 at time 0, 2.15, 5 and overnight; Lane 10, 11, 12 and 13: 
Digestion mixture in 250 mM imidazole (pH 7.3) at time 0，2.15, 5 and overnight 
respectively. 
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PBS and Tris buffer did not produce significant difference in the yield of digestion. 
pH was found to be more important and digestion at pH 8.0 overnight in both buffers 
gave better results than pH 7.3. Moreover, at pH 7.3 there was some precipitate 
formed after dialysis. Therefore, Tris buffer at pi-I 8.0 was chosen for the dialysis as it 
provides a better digestion environment and this pH was essential for the binding of 
the His-tagged SUMO in the round IMAC when the matured rhGH was purified. 
Although the presence of 250 mM imidazole in the digestion mixture did not affect 
the digestion efficiency, SUMO-hGH was dialyzed with 50 mM Tris, 300 mM NaCl 
(pH 8.0) overnight before digestion as the imidazole might interfere with the 
round of IMAC. 
4.7.4 Optimization of rhGH purification in 2'"' round of IMAC 
As shown in Chapter 3, some of rhGH was lost in the elution fraction during the 
round of IMAC. Mature rhGH found in the elution indicated that there was some 
association between tag. free rhGH and the IMAC matrix. In order to study this 
unexpected association, addition of detergent and increasing the elution temperature 
were tried. As shown in Fig 4.7，30 mg of SUMO-hGH digestion mixture was 
separated into three portions for testing the elution condition. Pre-chilled gel slurry 
and buffer at 4°C was the original elution condition. As suspected, rhGH may have 
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Figure 4.7 SDS-PAGE analysis of the elution profile of mature rhGH under different 
elution conditions. A) Pre-chilled condition, B) Pre-warmed condition, C) Addition of 
1 % Tween 20. Lane 1: Pre-stained SDS-PAGE standard; Lane 2: Digestion mixture; 
Lane 3: Flow through fraction (rhGH); Lane 4: Wash fraction 1 with 2 bed-volumes 
of diluting buffer; Lane 5: Wash fraction 2 with 2 bed-volumes of diluting buffer; 
Lane 6: Elution fraction 1 with 2 bed-volumes of elution buffer; Lane 7: Elution 
fraction 2 with 2 bed-volumes of elution buffer. 
I l l 
some weak non-specific interaction with the IMAC matrix, we tried increasing the 
temperature and the addition of detergent (1 % Tween 20) to minimize such 
non-specific interaction. However, some rhGH were still trapped inside the gel and 
could only be eluted with the elution buffer as shown in Lane 6 of Fig 4.7 B and C. 
Brian and James's studies showed that hGH contains a cation-binding pocket on 
its surface (60) making it potentially amenable to bind with the Ni^ "^  ions immobilized 
on the matrix. A low level of imidazole (20 mM) was added into the digestion mixture 
to evaluate i f this could reduce the non-specific absorption; unfortunately, the result is 
still negative. 
4.7.5 Characterization of mature rhGH 
4.7.5.1 FPLC gel filtration chromatography elution profile 
The gel filtration elution profiles of rhGH isolated from our fermentation 
experiment and a commercial preparation of rhGH (Scitropin) are shown in Fig 4.8 A 
and B. rhGH was eluted at about 27-28 minutes in both samples, this retention time is 
the eluting time of a protein with a molecular weight roughly about 20 kDa. As 
indicated in the Coomassie Blue stained gel (Fig 4.8 C), a highly pure rhGH was 
collected in peak 1 having identical electrophoretic property as the commercial one. 
By virtue of its elution time in FPLC, our rhGH is probably in a monomeric form. 
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Figure 4.8 A) Elution profile of gel filtration purification of rhGH from the 2"'' round 
of IMAC. B) Elution profile of commercial preparation of rhGH (Scitropin). C) 
SDS-PAGE analysis of the purified rhGH by gel filtration from our fermentation 
experiment. Lane 1: Pre-stained SDS-PAGE standard, Low range; Lane 2: 
Commercial rhGH (Scitropin); Lane 3: rhGH from the round of IMAC; Lane 4: 
rhGH from gel filtration (Fig 4.8 A Peak 1). 
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Silver staining of the gel was performed to reveal whether impurity still exists 
after gel filtration. As shown in Fig 4.9 A, protein bands at 80 and 40 kDa were 
successfully removed by gel filtration chromatography. A single band was observed in 
the rhGH final product. 
Western blot was preformed to confirm the identity of the GH by using mAb 
33C5 raised against rhGH. As shown in Fig 4.9 B, both Scitropin and our rhGH final 
product reacted positively with the monoclonal antibody, indicating that they share 
the same immunoreactive characteristic. 
4.7.5.2 N-terminal sequencing of rhGH 
Purified rhGH was transferred to PVDF membrane as described in Chapter 3 
section 3.5.5.2. rhGH was sequenced by the Molecular Biology-Proteomics Facility 
of the University of Oklahoma Health Sciences Center and the result is presented in 
Table 4.1. 
Cycle number 
1 2 3 4 5 
hGH sequence Phe Pro Thr He Pro 
rhGH final product Phe Pro Thr lie Pro 
Table 4.1 N-terminal sequencing of rhGH. 
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Figure 4.9 A) SDS-PAGE gel with silver staining of rhGH purified by gel filtration. 
Lane 1: Pre-stained SDS-PAGE standard, Low range; Lane 2: rhGH purified by the 
2nd round of IMAC; Lane 3: rhGH purified by gel filtration. B) Western blot of the 
purified rhGH by gel filtration. Lane 1: Pre-stained SDS-PAGE standard, Low range; 
t* 
Lane 2: Scitropin; Lane 3: rhGH purified by gel filtration. 
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As indicated, the five amino acid residues at the N-terminal were completely 
identical to hGH. This confirms that His-MBP-SENPIC cleaved at the expected 
cleavage site in the SUMO-hGH fusion protein. 
⑩ 
4.7.5.3 GH receptor binding assay - Dual-Luciferase Assay 
The functional activity of rhGH was assessed by Dual-Luciferase® Reporter 
Assay. Spi/luc and pRL/CMV (strong promoter CMV provides low-level and 
constitutive expression of Renilla liiciferase as internal control) were co-transfected 
into HEK293 Hi cells. Luciferase activities of firefly luciferase and Renilla luciferase 
were measured. Luciferase activity was normalized by dividing the activity of firefly 
luciferase over Renilla luciferase to eliminate error raised by the difference in 
transfection efficiency. Fold of luciferase activity induction by various concentration 
of rhGH was plotted and presented in Fig 4.10. The commercial preparation of rhGH, 
Scitropin, was included as a positive control. Both rhGH from fermentation or shake 
flask exerted similar activities as the positive control suggesting that our rhGH final 
product is bioactive and that it can bind to GHR and trigger the dimerization of GHR 
initiating the gene activation pathway. 
4.8 Discussion 
A fixed volume fed-batch fermentation scheme was developed for the production 
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Figure 4.10 Spi promoter activity stimulated by various rhGH preparations in 
co-transfected HEK293 hi cells. 100, 250 and 500 ng/ml rhGH was added to HEK293 
Hi cells for overnight incubation. Luciferase activity was measured and normalized 
by dividing the activity of firefly luciferase over Renilla luciferase. The commercial 
preparation of rhGH was used as a positive control. The concentration of commercial 
preparation of rhGH was calculated from the labelled amount in the package while 
the concentration of our preparations was measured by Bradford protein assay. 
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of SUMO-hGH fusion protein in LB medium. High cell density of transformed E.coli 
BL21 cells were cultivated by a glucose feeding strategy using pH-stat and the 
dissolved oxygen level. The SUMO-hGH production yield increased 5 fold compared 
with shake flask expression. Highly pure and bioactive monomeric rhGH was 
obtained as the final product after going though a 6 step isolationypurification process. 
4.8.1 Fed-batch fermentation of E. coli BL21 
Fermentation cultivation can be separated into three types, batch fermentation, 
fed-batch fermentation and continuous fermentation. Batch fermentation is simple, 
just like shake flask cultivation. All the nutrients for cell growth are prepared at the 
time before inoculation of the seed culture. Cells grow at the maximum specific 
growth rate when all nutrients are in excess. However, the cell density in batch 
fermentation is much lower compared with fed-batch fermentation. It is because cell 
growth will be limited when one of the nutrients is depleted. Carbon source is usually 
the limiting substrate in batch fermentation. Continuous fermentation avoids the 
problem of nutrient depletion in batch mode by feeding the cells with fresh medium 
containing all the nutrients. During feeding, same amount of fermentation culture is 
removed from the fermenter. Although cells continuously grow in the fermenter, cell 
density in the fermenter is fairly steady as in the batch mode (65). In order to achieve 
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high cell density cultivation, fed-batch fermentation is used as our production scheme. 
By controlling the feeding rate, the growth rate of the cells can be regulated to 
maintain at a relatively slow growth rate. Slow growth rate of microbes always gets a 
high cell density and high product yield since there is less accumulation of 
by-products and toxic metabolites like acetate (66). Substrate feeding rate is adjusted 
to slightly below the consumption rate thus ensuring the level of carbon source 
(glucose) in the culture medium is always maintained at low level. This is important 
as high glucose level wil l cause carbon catabolic repression that suppresses the 
expression of SUMO-hGH protein. 
Once limiting substrate in the initial medium was depleted, glucose feeding 
began. The feeding was controlled by combining pH and dissolved oxygen level 
feedback. In the first 24 hours of cultivation at 37°C, pH-stat feeding was deployed. 
pH-stat provided a more accuracy feeding control than dissolved oxygen level 
because once carbon source was depleted the culture pH would rise. As LB medium 
contained complex nutrients, high respiration rate through amino acid catabolism 
could be maintained at low dissolved oxygen level even carbon source was depleted. 
At the second 24 hours cultivated at 20°C, the dissolved oxygen level control was 
used. It is because low cultivation temperature would result in less responsive change 
in culture pH as the metabolic rate is deceased. Such lagging response in the pH-stat 
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feeding may result in the over feeding of glucose that led to carbon catabolic 
repression. Therefore, the combination of the two feeding methods provided the 
advantages of both pH-stat and dissolved oxygen feedback control. 
4.8.2 Downstream processing of fermentation culture and characterization of 
rhGH 
As mentioned in section 4.7.2, three disruption methods were compared. 
Dyno®-mill was chosen for the disruption of fermented cells due to its large capacity 
and similar efficiency as sonication. SUMO-hGH was purified from the cell lysate 
supernatant by IMAC. 
SUMO-hGH was first dialyzed with 50 mM Tris and 300 mM NaCl buffer at pH 
8.0 overnight before enzyme digestion. After overnight digestion at 4°C, rhGH was 
purified by a round of IMAC. During the purification of mature rhGH, we 
observed a non-specific association of rhGH to the IMAC matrix as described in 
Chapter 3. In order to try to minimize the lost of rhGH caused by such association, 
the addition of detergent and increasing elution temperature had been tried but still 
could not reduce the lost of rhGH in the elution fraction. As a cation-binding site is 
located on the surface of hGH, the non-specific association is probably due to the 
binding of immobilized Ni^ "^  ions onto the divalent ion binding pocket of the rhGH. 
• 120 
To confirm the cause of non-specific interaction, other brands of IMAC matrix may 
be used to see i f the non-specific association is due to the cation-binding pocket or the 
interaction with NTA agarose matrix. 
rhGH was further purified by gel filtration. The purity of the rhGH final product 
was assessed by silver staining. Only a single band of rhGH was obtained. The 
identity of rhGH was further confirmed by western blot and N-terminal sequencing. 
The biological potency of rhGH was found to be the same as the commercial rhGH 
by Dual-Luciferase® Assay. The GHR activity at 100, 250 and 500 ng/ml rhGH was 
not significantly different from one another. Presumably, the response was already at 
its maximum at the lowest dose treatment, i.e., 100 ng/ml. In order to give a more 
realistic comparison, lower concentrations of the GH should have been used. 
According to the literature, a bell-shaped dose response curve should have been 
observed. The biphasic response can be explained by the initial step of signal 
transduction pathway; viz, GH receptors dimerization. The binding of hGH to GHR is 
sequential, forming a hGH-GHR complex through site 1 first and then dimerize the 
second GHR through site 2. However, higher hGH concentration wil l eventually 
decreases the number of unoccupied GHR for dimerization resulting in the reduction 
of GH activity. This biphasic GH activity have been demonstrated by Hondo et al. 
experiment in the effects of GH in rat adipocytes and human IM-9 lymphocytes (67). 
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4.8.3 M9 based defined medium fermentation study 
Medium composition may affect the SUMO-hGH expression and the growth of 
the host cells. Defined medium was used to express SUMO-hGH in a shake flask to 
see if better results could be obtained. A 1 % seed inoculum was grown at 37°C for 2 
hours and cooled down to 25°C for IPTG induction overnight. The ODeoo of overnight 
culture reached 1.87 which is similar to the LB medium (1.85). The expression profile 
of SUMO-hGH in the two different media is shown in Fig 4.11. Although cultivation 
by two different media gave a similar cell density, the expression level of 
SUMO-hGH fusion protein was different. LB expression of SUMO-hGH was about 
two fold higher than defined medium when the band intensity at 34.3 kDa in Lane 3 
and 5 were compared. The ratio of soluble and insoluble protein was similar in the 
two expression media. 
Defined medium was then used to cultivate BL21 cells in a fermenter with the 
same feeding strategy as described before. The growth behavior of the BL21 cells 
was similar to LB cultivation and the OD600 at 48 hours reached 46.76. Cells were 
harvested and processed as previously described. The SUMO-hGH elution profile by 
IMAC is shown in Fig 4.12 A. Purified SUMO-hGH was then dialyzed with Tris 
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Figure 4.11 SDS-PAGE gel analysis of SUMO-hGH expression in two different 
media. Lane 1: Pre-stained SDS-PAGE standard, Low range; Lane 2 and 3: Inclusion 
bodies and supernatant of cell lysate cultivated with defined medium; Lane 4 and 5: 
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Figure 4.12 A) SDS-PAGE gel analysis of the SUMO-hGH purified by IMAC from 
defined medium fermentation. Lane 1: Pre-stained SDS-PAGE standard; Lane 2: Cell 
lysate supernatant; Lane 3: Flow through; Lane 4: Wash fraction; Lane 5, 6, 7, 8 and 9: 
Elution fraction 1, 2, 3, 4 and 5 respectively. B) The digestion profiles of 
SUMO-hGH expressed from different media. Lane 1: SDS-PAGE standard; Lane 2: 
LB medium shake flask (SF) expressed; Lane 3: Defined medium SF expressed; Lane 
4: Defined medium fermentation expressed. Same concentration of digestion mixture 
was loaded into the gel. 
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buffer overnight. Digestion profiles using His-MBP-SENPIC to cleave LB and 
defined medium expressed SUMO-hGH are shown in Fig 4.12 B. It was surprising to 
find that fermentation in defined medium produced a SUMO-hGH less susceptible to 
protease digestion. In contrast, both shake flask produced SUMO-hGH from either 
LB or defined medium could be digested by the protease. As Fig 4.12 B shows, the 
size of SUMO-hGH was identical in these three expression conditions. However, only 
the SUMO-hGH expressed in defined medium in fermentation was unable to cleave. 
A co-digestion experiment by mixing the shake flask and fermentation samples have 
been carried out to see i f this result is due to the presence of some inhibitors of 
SENPIC activity in the fermentation sample. The result indicated that SENPIC 
activity was not affected in the co-digestion mixture. As His-MBP-SENP IC 
recognizes the three-dimensional structure of SUMO tag, we suspected that high cell 
density cultivation in a "thin" medium (compared with LB, defined medium only 
contained essential metal ions, carbon and nitrogen sources) may result in a misfolded 
protein due to the deficiericy of chaperone proteins and co-factors for a proper protein 
folding. 
To determine the folding of SUMO-hGH expressed in different expression 
conditions, circular dichroism (CD) spectra of the different preparations were 
determined. The CD spectra in the wavelength range of 190-260 nm were measured 
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with a Jasco J-810 Spectrometer (Tokyo, Japan). SUMO-hGHs were dialyzed in 10 
mM phosphate buffer, pH 7.4. The data collected was normalized with a buffer blank. 
As shown in Fig 4.13, the CD spectra have two negative peaks at 210 and 222 nm 
indicating that helical structures are present in all of the samples. There is a nearly 
100 % overlapping at the negative peak at 222 nm while some deviations were 
observed in the fermentation expressed SUMO-hGH at the negative peak at 210 nm. 
A K2D2 algorithm was used to compare the estimated percentage of a-helix and 
p-strand in these three preparations of SUMO-hGH (84). As table 4.2 shows, the 
predicted secondary structure of fermentation expressed fusion protein was slightly 
different from the shake flask expression. As SUMO tag contained a-helix and 
p-sheets, such deviations may be caused by the misfolding of SUMO-tag. This may 
account for the difference in digestion efficiency as their folding appears to be 
slightly different in the CD spectrum. 
LB shake flask Defined medium shake flask Defined medium fermentation 
expressed expressed expressed 
Predicted a-helix %: 87.76 87.76 87.59 
Predicted p-strand %: 0.47 0.47 0.48 
Table 4.2 K2D2 algorithm analysis on the three preparations of SUMO-hGH 
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Figure 4.13 CD spectra of purified SUMO-hGH from different preparations. The 
wavelength range of 190-260 nm was measured with Jasco J-810 Spectrometer 
(Tokyo, Japan). The proteins were dialyzed in 10 mM phosphate buffer pH 7.4. 
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Semi-defined medium by addition of yeast extract can be tried to solve this 
problem. As defined medium was too minimal and may be lacking some of the 
vitamins and chaperone proteins, when cells were grown under such pressure (higher 
growth rate compare with shake flask) misfolding of protein may become a serious 
issue. In support of this, shake flask expressed SUMO-hGH can be digested but 
fermentation expressed one cannot. 
4.8.4 rhGH production yield estimation 
The production yield of rhGH by the fermentation cultivation was calculated and 
the yield is shown step by step. 
Fermentation parameters: 
Medium used: LB medium 
Culturing time: 48 hours 
OD600 Final: 44.40 
Culture temperature: 37°C for 24 hours and 20°C for another 24 hours 
Glucose supplement used: 400 ml 
Base supplement used: 270 ml 
Final culture volume: 2.5 L 
Cell lysate supernatant volume: 2.8 L 
After 48 hours cultivation in fermenter, cells were harvested from 2.5 L 
fermentation broth and cell membrane was disrupted by Dyno®-milL 2.8 L cell lysate 
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supernatant was collected after the centrifugation. 260 ml of supernatant was then 
mixed with 40 ml of Ni2+-NTA agarose for IMAC to purify SUMO-hGH. 
ist round of IMAC purification (SUMO-hGH): 
Cell lysate supernatant used: 260 ml 
n P - N T A gel used: 40 ml 
Volume of each elution fractions: 40 ml 
Elution 1 (lOOmM imidazole) protein amount: 62.50 mg 
Elution 2 (lOOmM imidazole) protein amount: 75.80 mg 
Elution 3 (lOOmM imidazole) protein amount: 8.25 mg 
Elution 4 (250mM imidazole) protein amount: 21.05 mg 
Elution 5 (250mM imidazole) protein amount: 3.60 mg 
SUMO-hGHfusion protein purified: 
From 1 L fermentation broth: (171.20 mg/0.26 L) x (2.8 L / 2.5 L) 
=737.48 mg/L 
Purified SUMO-hGH was dialyzed with 50 mM Tris and 300 mM NaCl buffer 
(pH 8.0) overnight. Digestion mixture was prepared with 8.43 mg of SUMO-hGH for 
overnight digestion at 4°C. rhGH was then purified in the flow through fraction of the 
2nd round of IMAC. 
2nd round of IMAC purification (rhGH): 
SUMO-hGH used for digestion: 8.43mg 
Ni-NTA gel used: 3 ml 
Flow through protein amount: 1.63 mg 
Dilution fraction 1 protein amount: 0.44 mg 
Dilution fraction 2 protein amount: 0.03 mg 
Conversion rate from SUMO-hGH to 2.10 mg / 8.43 mg x 100 % 
mature rhGH: = 24.91 % 
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The conversion rate from SUMO-hGH to purified rhGH in the round of 
IMAC was 24.91 %. The purification yield of gel flirtation was also studied. 0.137 
mg rhGH sample was loaded into the Siiperdex 75 column. 
Gel filtration purification: 
rhGH sample used: 0.137 mg 
Peak 1 protein amount: 0.063 mg 
Purification yield: 0.063 mg /0.137 mg x 100 % 
=45.99% 
The purification yield of gel flirtation was found to be 45.99 %. Highly pure 
rhGH was obtained after the downstream processing. 
The final product yield is calculated as follows: 
(SUMO-hGH purified per L of fermentation culture) x (rhGH conversion rate from 
SUMO-hGH) X (Purification efficiency of gel flirtation) 
737.48 mg/L x 24.91 % x 45.99 % = 84.49 mg/L 
The estimated yield of rhGH final product is 84.49 mg per L of fermentation 
culture. 
4.8.5 Comparison of our fermentation expression system to the published data 
In our fermentation expression system, the yield of rhGH after purifications is 
84.49 mg per liter of fermentation culture. Compared with published data (Table 4.3), 
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our yield is much lower. This is not surprising as the GH was expressed in the 
inclusion body form. As the expressed rhGH was aggregated into insoluble form, 
bacteria can tolerate the accumulation of rhGH in the inclusion bodies. Moreover, 
inclusion bodies are resistance to proteolytic degradation. However, solubilization 
and refolding may lead to a low recovery of active hormone. 
^ 
Host strain Medium Temp. Feeding mode Induction Soluble or Purified rhGH Reference 
-- ^ (oC) mode insoluble protein conc. (g/L) 
MC1061 Complex 30 Stepwise Constitutive Inclusion 2.000* Jensen E. B., 
(HKSII) bodies et al. (85) 
A6、5 Complex 30-42- pH-stat Heat Inclusion 2.000 Fatemeh 
(LB) 37 bodies Tabandeh, et 
al. (86) 
Complex 30-42- Exponential Heat Inclusion 2.700 Fatemeh 
(LB) 37 bodies Tabandeh, et 
al. (86) 
Complex 37-20 pH-stat + DO IPTG Soluble fusion 0.085 This project 
(LB) feedback protein 
* hGH was expressed with met-ala-glu N-terminal extension. 
Table 4.3 Comparison of rhGH production in E. coli fermentation with other works. 
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4.9 Conclusion 
Highly pure and bioactive monomeric rhGH have been successfully prepared by 
high cell density fermentation and our downstream processing. The novel SUMO 
fusion constructs simplified the purification of fusion protein by immobilized metal 
affinity chromatography. Ninety percent pure SUMO-hGH was obtained by a 
round of IMAC. After protease digestion, mature rhGH was purified in the flow 
through fraction by a round of IMAC. Further purification was done by gel 
filtration chromatography. 
Human growth hormone was used as a template for the development of a 
downstream processing strategy for His-SUMO-tag proteins. Generic purification 
methods have been established. Theoretically this fermentation expression framework 
can express any other protein products by substitution of the hGH sequence in the 
pSUMO vector. Since SUMO protease recognizes the three-dimensional structure of 
SUMO tag, this expression system avoids the problem of recombinant protein cleaved 
by internal cleavage sequences present within the protein. Soluble fusion protein was 
expressed in high cell density fermentation which avoided complications arising from 
the solubilization and refolding of inclusion bodies. Our success in rhGH production 
4 
suggests that this production scheme may be adapted to other proteins like human 
epidermal growth factor and interferon-y. 
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Chapter 5 His-MBP-SENPIC expression and purification 
5.1 Introduction 
In the previous chapter, we have described the fermentation expression and the 
downstream processing of SUMO-hGH fusion protein to mature rhGH. Under this 
framework, His-MBP-SENP 1C was chosen among the four constructs of protease for 
the digestion of SUMO-hGH. 
I f His-tag free SENPIC is used for cleavage of the fusion protein, it will be 
collected in the flow through fraction together with rhGH in the round of IMAC. 
Since the size of SENPIC is similar to hGH (27 vs. 22 kDa), it is difficult to separate 
them by gel filtration. Although the enzyme activity of His-MBP-SENP 1C is only 87 
% of its native form (referred from Table 3.2), this construct is still preferred because 
the presence of a His-tag tail at the N-terminal will simplify the purification of both 
the protease itself as well as its separation from cleaved rhGH. 
In this chapter, the expression and the purification of His-MBP-SENP 1C will be 
described. E.coli BL21 was also used as the host cell for expression of the soluble 
recombinant protease. IMAC was used to isolate the protease from cell lysate. A 
semi-purified His-MBP-SENPIC was used for the digestion of SUMO-hGH. 
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5.2 Materials 
5.2.1 Reagents for bacterial culture 
5.2.1.1 Ampicillin solution 
The stock solution (100 mg/ml) was prepared by dissolving 100 mg ampicillin 
sodium salt (Sigma-Aldrich, USA) into each ml of ddH20. It was sterilized by 
filtration through a 0.22 jim pore size membrane filter (Millipore, USA) and stored in 
aliquots of 1 ml at -20°C. The working concentration was 100 |ig/ml. 
5.2.1.2 LB ampicillin (LBA) medium 
LB A was LB medium supplemented with ampicillin at 100 |ig/ml. 
5.2.1.3 LBA agar plates 
LBA agar was prepared by addition of ampicillin at 100 fig/ml to the 60°C LB 
agar solution after autoclaving. Twenty ml agar medium were allowed to set at room 
temperature and stored at 4°C. Agar plates were dried in 3TC incubator for 2 hours 
before use. 
5.2.1.4 LB based fermentation medium 
It was prepared by dissolving 50 g LB broth (which contained 20 g sodium 
chloride, 20 g tryptone and 10 g yeast extract. Sigma-Aldrich), 5.8 g sodium 
phosphate dibasic (Na2HP04, Sigma-Aldrich), 6.0 g potassium phosphate monobasic 
(KH2PO4, Sigma-Aldrich), 3,0 g ammonium sulphate ((NH4)2S04) and 0.1 ml 
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antifoam A (Sigma-Aldrich) in final volume of 1.9 L ddH2〇. It was sterilized by in 
situ autoclaving for 20 minutes at 121°C in the fermenter. 
5.2.2 Reagents for immobilized metal affinity chromatography (IMAC) 
purification of His-MBP-SENPIC 
5.2.2.1 Nickel binding buffer 
It was prepared by mixing 20 mM Tris, 500 mM NaCl, 5 mM p-mercaptoethanol 
and 1 mM PMSF with the pH adjusted to 8.5 with 1 M NaOH. 
5.2.2.2 Washing buffer 
It was prepared by mixing 20 mM Tris, 500 mM NaCl, 10 mM imidazole, 5 mM 
p-mercaptoethanol and 1 mM PMSF with the pH adjusted to 8.5. 
5.2.2.3 Elution buffer 1 
It was prepared by mixing 20 mM Tris, 500 mM NaCl, 100 mM imidazole, 5 
mM p-mercaptoethanol and 1 mM PMSF with the pH adjusted to 8.5. 
5.2.2.4 Elution buffer 2 
It was prepared by mixing 20 mM Tris, 500 mM NaCl, 300 mM imidazole, 5 
mM (3-mercaptoethanol and 1 mM PMSF with the pH adjusted to 8.5. 
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5.3 Methods 
5.3.1 Expression of His-MBP-SENPIC 
5.3.1.1 Shake flask expression of His-MBP-SENPIC 
The expression vector for His-MBP-SENPIC was kindly provided by Prof. K.B. 
Wong. It was transformed into competent BL21 cells by the heat shock method. 
Transformed cells were spread onto LBA agar plate and were incubated at 37°C for 
16-18 hours. A single colony was picked and inoculated into 5 ml of LBA medium. 
Cells were grown at 37°C with shaking at 250 rpm overnight. A 1 % (v/v) overnight 
culture was inoculated into 200 ml fresh LBA medium and incubated at 37°C with 
shaking for about 2-3 hours until the 0 D _ reached 0.6-0.8. The culture was then 
cooled down to 16°C for induction. IPTG was added to a final concentration of 0.2 
mM to induce protease expression. The bacterial culture was incubated at 16°C with 
shaking overnight. Cells were harvested by centrifugation at 4000 rpm for 15 minutes. 
The cell pellet was resuspended in 20 ml pre-chilled nickel binding buffer. 
5.3.1.2 Fermentation expression of His-MBP-SENPIC 
Trial expression of His-MBP-SENPIC was carried out in a 2 L bench-top small 
laboratory fermenter KLF (Bioengineering AG, Switzerland). The seed culture flask 
was incubated in 20 ml LBA medium overnight at 37。C with shaking at 250 rpm. A 
seed culture of ODeoo at 2-3 was used as the inoculum for fermentation. 
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Calibrated pH and dissolved oxygen probe were sterilized with LB medium in 
the fermenter at 121。C for 20 minutes. After the sterilization of the medium, the 
fermenter was cooled down to 37°C and base feed (2 M Ammonia solution) was 
hooked up to the base pump. Two ml of 0.22 |im filtered ampicillin solution (100 
mg/ml) was added into the fermenter aseptically. p02 was calibrated as 100 % using 
the following conditions: temperature at 37°C; stirrer speed at 400 rpm; pH at 7.2, 
airflow maximum. 
Fixed volume fed-batch fermentation was chosen for His-MBP-SENPIC 
expression. It contained 3 hours batch phase cultivation and 21 hours pH-stat feeding. 
After 3 hours of cultivation at 37"C, the fermenter was cooled down to 16°C for IPTG 
induction. Ten ml culture medium was collected before induction. Four hundreds |il 
of 1 M IPTG stock solution was added aseptically. Induced cells were cultured in 
total period of 24 hours. 
After induction for 21 hours, the fermentation was stopped and the culture end 
time and the fermentation parameters were recorded. The amount of glucose and base 
feed used were calculated. Cells were harvested by centrifugation at 4000 rpm for 20 
minutes at 4°C. The cell pellet was resuspended in 200 ml pre-chilled nickel binding 
buffer. 
5.3.1.3 His-MBP-SENPIC extraction 
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The cell suspension was sonicated by cycles of 30 seconds sonication followed 
by 30 seconds cooling until the solution became translucent. In order to maintain the 
cell disruption efficiency, cell suspension was aliquoted into 40 ml each for sonication 
cycles. Cell lysate was centrifuged at 14000 rpm for 30 minutes. His-MBP-SENPIC 
was collected in the supernatant and purified by IMAC. 
5.3.2 Semi-purification of His-MBP-SENPIC by Ni^^-NTA affinity 
chromatography (IMAC) 
His-MBP-SENPIC was expressed as a soluble protein. It was semi-purified 
from cell lysate by IMAC. Ni^'^-NTA agarose was purchased from Qiagen. Agarose 
was washed with 3 bed-volumes of ddHiO and 1 bed-volume of nickel binding buffer. 
Five ml ofNi^^-NTA gel was mixed with 20 ml cell lysate supernatant. Gel slurry was 
incubated at 4°C for 1 hour with end-over-end rotation. The mixture slurry was then 
packed into an Econo-Column. The flow through was collected and the column was 
washed with 10 bed-volumes of pre-chilled washing buffer. The final few drops of 
wash buffer were collected as wash sample. His-MBP-SENPIC was eluted by 4 
bed-volumes of elution buffer 1 and 4 bed-volumes of elution buffer 2, Elution 
samples (2 bed-volumes each) were assayed by SDS-PAGE. Enzyme activity was 
studied by SUMO-hGH digestion. Elution fractions collected were stored at -80°C. 
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5.4 Results 
5.4.1 Expression of His-MBP-SENPIC 
Shake flask expression of His-MBP-SENPIC and purification protocols were 
kindly provided by Prof. K.B. Wong. The molecular weight of His-MBP-SENPIC is 
about 70 kDa. As indicated in Fig 5.1, the elution profiles of shake flask expression 
and fermentation expression are compared. His-MBP-SENP 1C could be purified 
from the cell lysate by IMAC from both shake flask and fermentation culture. The 
purity of the protease from shake flask appears to be higher than that from 
fermentation. As the cell density of fermentation (OD600 = 13) was about 7 fold 
higher than the shake flask culture (OD 600 = 1.824), the presence of more 
non-specific protein binding was expected. Over 90 % of His-MBP-SENP 1C was 
eluted out by 100 mM imidazole buffer. The amount of His-MBP-SENPIC in the 
eluted fractions was estimated by assay of total protein content (measured by 
Bradford protein assay) multiplied by the band intensity at 70 kDa over the total 
bands intensities. The elution fractions were aliquoted into 1 ml and stored at -80°C. 
5.4.2 Digestion activity of His-MBP-SENPIC expressed 
The digestion activity of both shake flask and fermentation expressed protease 
was studied by SDS-PAGE analysis. SUMO-hGH (34.3 kDa) was used as the 
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Figure 5.1 SDS-PAGE analysis of the semi-piirification of His-MBP-SENPIC from 
the cell lysate by IMAC. A) Shake flask expression. B) Fermentation expression. 
Lane 1: Pre-stained SDS-PAGE standard (Low range); Lane 2: Soluble fraction of 
cell lysate (supernatant); Lane 3: Flow through fraction; Lane 4: Wash fraction; Lane 
5 and 6: Elution fraction 1 and 2 by eluting with 100 mM imidazole buffer; Lane 7 
and 8: Elution fraction 3 and 4 by eluting with 300 mM imidazole buffer 
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substrate for digestion as described in Chapter 3 section 3.5.2. The digestion profiles 
are shown in Fig 5.2. Both preparations of His-MBP-SENP 1C were able to cleave the 
SUMO-hGH to mature rhGH with a similar activity. The digestion profile of shake 
flask expressed protease is shown in Lane 3 while that from fermentation is shown in 
Lane 4. 
5.5 Discussion 
5.5.1 Expression and purification of His-MBP-SENPIC 
111 order to meet the demand of protease in the downstream processing of 
SUMO-hGH, we studied the fermentation expression of the protease in this chapter. 
As the recombinant protease is expressed intracellularly, high cell density 
fermentation was selected as a strategy to increase its production yield. A fixed 
volume fed-batch fermentation was selected to produce the protease. After 24 hours 
of cultivation, the OD600 of fermentation culture reached 13 which is about 7 fold 
higher than shake flask. The soluble protease could be obtained in high cell density 
cultivation and it can be purified by IMAC. The digestion profiles showed that both 
shake flaSk and fermentation expressed protease gave similar digestion efficiency. 
The addition of His-tag to the SENP1C construct provides several advantages 
over the original protease. First, His-tag simplifies the preliminary purification of the 
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Figure 5.2 SDS-PAGE analysis of the digestion activity of semi-purified 
His-MBP-SENPIC on SUMO-hGH fusion protein. Lane 1: Pre-stained SDS-PAGE 
standard (Low range); Lane 2: SUMO-hGH purified by IMAC; Lane 3: Digestion 
mixture using protease from shake flask; Lane 4: Digestion mixture using protease 
from fermentation. 
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protease by using IMAC. A single step of purification scheme could minimize loss. 
Second, the His-tag protease can be conveniently removed during the round of 
IMAC for the removal of rhGH from its fusion protein or partner. Although only a 50 
o/o purity protease was used, most of it and its associated impurity could be absorbed 
by Ni2+-NTA in the round of purification for rhGH. Therefore, there is no need to 
purify the protease further and based on our observation that using a semi-pure 
preparation of protease for digestion, the purity of the final rhGH was not affected. 
5.5.2 His-MBP-SENPIC production yield estimation 
The production yield of semi-purified His-MBP-SENPIC by fermentation was 
calculated and the yield is shown below. 
Fermentation parameters: 
Medium used: LB medium 
Culturing time: 24 hours 
OD600 Final 13.00 
Culture temperature: 37°C for 3 hours and 16°C for 21 hours 
Glucose supplement used: 150 ml 
Base supplement used: 30 ml 
Final culture volume: 2 L 
Cell lysate supernatant volume: 200 ml nickel binding buffer 
I 
After a 24 hour cultivation, cells were harvested from 2 L fermentation broth and 
resuspended in 200 ml nickel binding buffer. Cells membrane was disrupted by 
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sonication. To ensure the complete breakage of cell membrane, sonication cycles was 
performed by using five aliqiiots of 40 ml cell suspension. The cell lysate was 
clarified by centrifugation and the supernatant was then mixed with 20 ml of 
Ni2+-NTA agarose to isolate the His-MBP-SENPIC. 
IMAC purification (His-MBP-SENPIC): 
Cell lysate supernatant used: 200 ml 
Ni2+-NTA gel used: 20 ml 
Volume of each elution fractions: 40 ml 
Elution 1 (lOOmM imidazole) protein amount: 126.34 mg 
Elution 2 (lOOmM imidazole) protein amount: 21.04 mg 
Elution 3 (300mM imidazole) protein amount: 9.64 mg 
Elution 4 (300mM imidazole) protein amount: 3.00 mg 
Semi-purified protease amount per L offermentation culture (assume 50% purity) 
(160.02 mg) / 2L X 50 % = 40.01 mg/L 
According to SDS-PAGE gel profile, only 50 % pure His-MBP-SENPIC was 
obtained by IMAC and factoring this in, the yield of semi-purified protease was 40.01 
mg per L of fermentation culture. For the shake flask, the estimated yield of 
semi-purified protease was 17.29 mg/L. 
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Chapter 6 Production and characterization of monoclonal 
antibodies against rhGH 
6.1 Introduction 
In the previous chapters, we have described the production of recombinant hGH 
in E. coli. The second part of this project is to develop a sandwich enzyme linked 
immunosorbent assay (ELISA) for the measurement of rhGH. 
For the development of sandwich ELISA, production of murine monoclonal 
antibodies (mAbs) against rhGH is the first step. Kohler and Milstein first 
demonstrated the antibody secreting B-Iymphocyte can be immortalized by fusion 
with plasmacytoma (68). Hybridoma is a hybrid cell derived from the fusion of 
myeloma cell and B-cell and inherits the genetic material from both parents, i.e., the 
unlimited growth ability and antibody secretion capability. MAbs refer to those 
antibodies secreted by a clone of hybridoma cells which in turn is derived from a 
single B-lymphocyte. Unlike polyclonal antibodies purified from the anti-serum of 
immunized animals, mAb binds to a single epitope of a given antigen. Moreover, the 
immortal nature of hybridoma provides an unlimited source of antibodies despite the 
\ 
life span of the animal. 
In this chapter, we will describe the production and characterization of mAbs 
against rhGH. Briefly, mAbs were produced by conventional polyethylene glycol 
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(PEG) fusion method. Hybridomas were screened by ELISA and limiting dilution was 
used to enrich the positive clones. MAbs from the positive clones were mass 
produced in vivo in ascites fluid. The isotype, avidity and specificity of the mAbs 
were also studied. 
6.2 Materials 
6.2.1 Reagents for Sp2/0-Agl4 cultivation 
6.2.1.1 Dulbecco's Modified Eagle's Medium (DMEM) 
DMEM medium was purchased from Gibco, USA. It was supplied in liquid form 
in a package size of 500 ml per bottle. It contained 4,500 mg/L D-glucose, 4 mM 
L-glutamine, and 110 mg/L sodium pyruvate at pH 7.4. It was stored at 4°C. 
Plain DMEM medium was DMEM medium with only 1 % (v/v) antibiotics 
supplement. It was used in washing cells and PEG fusion. 
6.2.1.2 Fetal bovine serum (FBS), certified grade 
FBS was purchased from Gibco in a package size of 500 ml per bottle and kept 
in -20°C. Serum was heat-inactivated at 56°C for 30 minutes before used. 
Heat-inactivated serum was ready to use and aliquoted into 50 ml each in 50 ml 
Falcon centrifuge tube and stored at -20°C. 
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6.2.1.3 Antibiotic (lOOx) 
It contained 10000 units of penicillin G and 10000 |ig streptomycin sulphate in 
100 ml 0.85 % saline (Gibco, USA). It was aliquoted in 5 ml each and stored at 
-20°C. 
6.2.1.4 Complete DMEM medium 
It was DMEM medium supplemented with 1 % (v/v) antibiotics and 10 % (v/v) 
heat-inactivated fetal bovine serum. 
6.2.2 Reagents for PEG fusion 
6.2.2.1 8-Azaguanine 
Lyophilized powder of 8-azaguanine was purchased from Sigma-Aldrich, USA. 
5Ox concentrated 8-azaguanine solution was prepared by reconstituting the contents 
of vial with 10 ml sterile DMEM medium. Each vial of powder was dissolved in 500 
ml medium and the working concentration was 130 pM. Complete DMEM medium 
contained 8-azaguanine was used to ensure the sensitivity of the myeloma cells 
toward HAT medium. Only cells deficient in hypoxanthine guanine phosphoribosyl 
transferase can grow in 8-azaguanine medium (69). 
6.2.2.2 50 % Polyethylene glycol (PEG) 1500 
It was purchased from Roche Applied Science, Germany. 50 % PEG 1500 (w/v) 
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was supplied in 75 mM HEPES, pH 8.0. It was sterile-filtered and ready for use. It 
was stored at 4°C. 
6.2.2.3 Hypoxanthine-aminopterin-thymidine (HAT) medium 
5Ox concentrated HAT supplement solution was purchased from Gibco, USA. Ix 
HAT supplement contained 0.1 mM sodium hypoxanthine, 0.4 | jM aminopterin and 
16 |iM thymidine. Ix or 2x HAT medium was prepared by mixing 1 or 2 volume of 
5Ox concentrated HAT solution in 49 or 48 volume of complete DMEM medium 
before use. 5Ox concentrated HAT supplement solution was stored in -20°C. 
6.2.2.4 Hypoxanthine-thymidine (HT) medium 
lOOx concentrated HT supplement solution was purchased from Gibco, USA. Ix 
HT supplement contained 0.1 mM sodium hypoxanthine and 16 |iM thymidine. It was 
used as a rescue medium that provide purines and pyrimidines to overcome the effects 
of residual intracellular aminopterin. Ix HT medium was prepared by mixing 1 
volume of lOOx concentrated HT solution in 99 volume of complete DMEM medium. 
lOOx concentrated HT supplement solution was stored in 4°C. 
6.2.2.5 GlutaMAXTM-l 
5Ox concentrated GlutaMAXTM-i supplement solution was purchased from 
Gibco, USA. It contained 200 mM dipeptide L-Alanyl-L-Glutamine in 0.85 % NaCl. 
Ix GlutaMAX™-! was supplemented in hybridoma culturing medium for a better 
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growth of newly fused hybridomas which were highly dependent on glutamine. 
GlutaMAX™-! supplement solution was stored at -20°C. 
6.2.2.6 Recombinant murine interleukin 6 (rmIL-6) 
It was purchased from Roche Applied Science, Germany. rmIL-6 is a growth 
factor of murine B-lymphocytes and was added to hybridoma culturing medium to 
stimulate the growth of newly fused hybridomas. It was added to complete DMEM 
medium at a final concentration of 100 U/ml. 
6.2.3 Reagents for enzyme linked immunosorbent assay (ELISA) 
6.2.3.1 ELISA coupling buffer 
It was prepared by dissolving 1.6 g Na2C03 and 2.9 g NaHCOs in 1 L ddHiO. 
This buffer was adjusted to pH 9.6 and stored at 4°C. 
6.2.3.2 PBST 
It was PBS containing 0.05 % Tween 20. 
6.2.3.3 PBSTM 
It was-PBST containing 0.1 % (w/v) non-fat dried milk powder. 
6.2.3.4 Blocking buffer 
It was prepared by dissolving 1 % (w/v) bovine serum albumin (BSA) in PBS. 
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6.2.3.5 Horseradish peroxidase (HRP) substrate buffer 
It was 100 mM tri-sodium citrate solution with pH adjusted to 4.1 with 1 M HCl. 
6.2.3.6 2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS) 
50x ABTS stock solution was prepared by dissolving 0.499 g of 
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt (Sigma-
Aldrich) in 20 ml of HRP substrate buffer. It was stored in aliquots of 1 ml at -20°C. 
6.2.3.7 HRP substrate 
It was freshly prepared by mixing 200 5Ox ABTS solution and 140 |j.l 3 % 
(v/v) H2O2 in total 10 ml of HRP substrate buffer. Ten ml HRP substrate was enough 
for one 96-well microtiter plate. 
6.2.4 Reagents for mAbs purification by HiTrapTM Protein G HP Column (GE 
Healthcare Bio-Sciences AB，Sweden) 
6.2.4.1 Elution buffer 
It was 100 mM glycine-HCl solution with pH adjusted to 2.7 by 1 M HCl. It was 
filtered with 0.22 |im pore-size membrane and stored at 
6.2.4.2 Neutralizing buffer 
It was I M Tris-HCl solution with pH adjusted to 9.0 by 1 M NaCl. It was filtered 




Protein sample (rhGH) was diluted in ELISA coupling buffer at a concentration 
of 1 |ig/ml (100 ng/well) and 100 jil/well sample was coated onto 96-well MaxiSorp 
polystyrene plate (Nalge Nunc international, Demark) at overnight. The coated 
plate was flicker-dried and washed with 200 |il PBSTM three times. It was then 
blocked with 200 \x\ blocking buffer at room temperature for 2 hours to saturate the 
residual binding sites in the well. Blocked plate was flicker-dried and washed with 
200 |j.l PBST three times. One hundred |il/well first antibody (or antibody containing 
samples) to be assayed was added and the plate was incubated at 37°C for 1 hour. The 
plate was then flicker-dried and washed with 200 fil PBSTM five times. One hundred 
|il/well of 2000 fold diluted EIA-grade affinity purified goat anti-mouse IgG (H+L) 
HRP conjugate (Bio-Rad, USA) second antibody in blocking buffer was added to the 
plate and was incubated at 3TC for 1 hour (depending on the first antibody, goat 
anti-rabbit IgG (H+L) HRP conjugate (Bio-Rad) may be used). Plate was flicker-dried 
and washed with PBSTM three time and then twice with PBST at 200 |il/well. One 
hundred p_l/well of freshly prepared HRP substrate was added and incubated at 37°C 
for 20 minutes for colour development. Optical density at 405 nm was measured by a 
microplate reader (liQuant™ Microplate reader, BIO TEK Instruments Inc., USA). 
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6.3.2 Immunization 
Inbred BALB/c mice were bred in the Animal House of The Chinese University 
of Hong Kong. Female BALB/c mice at the age of 6-8 weeks old were used in our 
experiment. Immunization scheme was slightly modified from Baumgarten et fl/.(70). 
Pre-immunize serum was collected from the tail vein of each mouse as a negative 
control. Equal volume of 50 jig of rhGH (Scitropin, SciGen) in PBS and complete 
Freund's adjuvant (CFA) were mixed in two syringes connected with double-hub 
emulsification connector. One hundred and fifty microliter emulsified rhGH, 
containing 50 }xg of rhGH, was subcutaneously injected into each mouse on day 1. 
After 21 days, mice were boosted subcutaneously with 150 |il emulsion of rhGH and 
incomplete Freund's adjuvant (IFA). Second and third boosters were done on day 42 
and 63 respectively with the same procedure as the first booster. Serum was collected 
3 days after the third booster and the antibody titer was determined by ELISA. Fusion 
was performed when the serum titer was higher than 100000 (serum titer was defined 
as the dilution factor of serum giving the OD405 value at half of the maximum in 
ELISA against rhGH). Mouse with the highest titer was selected for fusion on the 
following week. Final booster in IFA was given subcutaneously 3 days before the 
PEG fusion. 
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6.3.3 Culturing of myeloma fusion partner cells 
Sp2/0-Agl4 myeloma cell-line (ATCC, USA) was used as the fusion partner for 
PEG fusion. It was formed by fusing BALB/c spleen cells (from mouse immunized 
with sheep red blood cell) with the P3X63Ag8 myeloma (71). It is resistant to 
8-azaguanine and is HAT sensitive. Unlike other myeloma cells like NS-1, it does not 
secrete immunoglobulin by its own. 
Sp2/0-Agl4 was cultured in complete DMEM medium in 75 cm^ culture flask at 
37°C with 5 % CO2. Cells were maintained in log-phase (0.5-5 x lO'^  cell/ml) by 
subculturing every 2-4 days. Two weeks before PEG fusion, cells were cultured in 
complete DMEM medium contained Ix 8-azagiianine. 
6.3.4 Isolation of splenocyte 
Three days after the final booster, mouse was killed by cervical dislocation and 
the spleen was isolated under aseptic condition. Spleen was washed with 10 ml 
complete DMEM medium and was placed on a sterilized metal sieve over a Petri dish 
containing 10 ml complete DMEM medium. Spleen was dispersed by using a 
sterilized plunger of 5 ml syringe gently push and rub over the sieve. Large tissue 
aggregates were discarded and cell suspension was centrifuged at 1500 rpm for 5 
minutes at room temperature. The supernatant was discarded and cell pellet was 
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washed with 10 ml complete DMEM medium. After centrifugation, cell pellet was 
resuspended in 10 ml complete medium and the viable cells were counted with 
haemacytometer. 
6.3.5 PEG fusion 
Sp2/0-Agl4 cells were harvested from three 75 cm^ culture flasks and the viable 
cells were counted. Splenocytes from the immunized mouse and myeloma cells were 
mixed in a ratio of 5:1, from our previous experiences this ratio always generates 
most number of stable hybridoma clones. Cell mixture was centrifuged at 1500 rpm 
for 5 minutes at room temperature and the supernatant was discarded. Cell pellet was 
resuspended and washed twice with 30 ml plain DMEM medium supplemented with 
antibiotics. After washing, cell pellet was loosened by gently tapping the centrifuge 
tube and incubated in water bath at 37°C. One ml of pre-warmed 50 % PEG 1500 was 
added dropwise over a 1 minute period with gently shaking. The fusion mixture was 
gently stirred with a pipette tip for 1 minute. One ml pre-warmed plain DMEM was 
added drop by drop with continuously stirring over a period of 1 minute. Three ml 
plain DMEM medium was added over 3 minutes with stirring. Fusion mixture was 
finally diluted with 10 ml plain DMEM medium over a 5 minute period. Fused cells 
were incubated at 37°C for 5 minutes so that they could become stabilized. Fusion 
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mixture was centrifuged at 1200 rpm for 5 minutes at room temperature and the 
supernatant was discarded. Cells pellet was gently loosened and resuspended in 
complete DMEM medium with GlutaMAX'^^-I and rmIL-6 supplement at a final 
concentration of 5 x 10^  cells/ml. One hundred {.il/well fused cells (0.5 x 10^  
cells/well) were seeded onto 96-well plates and incubated at 37°C with 5 % CO2 for 5 
hours. One hundred jil/well of 2x HAT medium was then added to the 96-well plates 
to select the fused cells. Five days after the cell fusion, 100 [il of Ix HAT medium 
was exchanged with the medium from each well. After a twelve day selection with 
HAT medium, 100 |il of Ix HT medium was exchanged with HAT medium in each 
well. On day to 1 1 0 0 fil medium was removed from each well to screen for 
positive hybridoma clones by ELISA. Second round of screening was preformed on 
day 20th to 22nd after cell fusion to identify any slow growing hybridoma clones. 
96-well plates were observed microscopically and the number of cell colonies was 
recorded. 
6.3.6 Limiting dilution 
Hybridoma clones showing positive reaction in two rounds of ELISA screening 
were enriched by limiting dilution. Splenocytes from non-immunized BALB/c mice 
were isolated and seeded with hybridoma cells as feeder cells. One hundred |_L1 of cells 
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from the positive well was removed by pipetting the medium up and down and mixed 
with 400 111 of complete DMEM medium. Viable hybridoma cells were counted and 
diluted by feeder cell suspension (5 x 10^  cells/ml) to a final concentration of 100 
cells/ml, 50 cells/ml and 1 cell/ml. One hundred }j.l/well cell mixture was distributed 
into 96-well plates (100 of complete medium with GlutaMAX'^'^-I and rmIL-6 
supplement was pre-dispensed) at a concentration of 10 hybridoma cells/well, 5 
hybridoma cells/well and 1 hybridoma cell/well. ELISA screening was performed on 
twelve days after the limiting dilution. Positive clones with single observable colony 
was further enriched by limiting dilution at 1 hybridoma cell/well and 0.5 hybridoma 
cell/well until all the colonies obtained were positive. Enriched cell clones were 
expanded in complete DMEM medium and frozen in liquid nitrogen for storage. 
6.3.7 Cryopreservation of hybridoma cell lines 
Enriched hybridoma cells were expanded in 75 cm^ culture flasks and subcloned 
with complete DMEM medium one to two days before frozen. Viable hybridoma cells 
were counted and cell suspension was centrifuged at 1500 rpm for 5 minutes at room 
temperature. The supernatant was discarded and the cells were resuspended in 10 % 
(v/v) DMSO in complete DMEM medium at 1 x 10^  cells/ml. Cells suspension was 
aliquoted in 1 ml each of Cyrotubes^"^ (Nalge Nunc international, Demark). 
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Cyrotubes were wrapped with paper towel and froze at -20°C for 3 hours. Frozen 
tubes were transferred to -80°C overnight and stored in liquid nitrogen for storage. 
6.3.8 Mass production of monoclonal antibodies 
MAbs were mass produced by in vivo method. Female BALB/c mice were used 
as the host and were primed with 0.5 ml pristane (Sigma- Aldrich) intraperitoneally 
14 days before hybridoma inoculation. Enriched hybridoma cells were grown in 
complete DMEM medium and the cells were split 1:1 (v/v) with fresh complete 
medium on the day before inoculation. On the day of inoculation, hybridoma cells 
were harvested and washed with sterilized PBS three times. Viable cells were counted 
and cells were resuspended in PBS at a final concentration of 2 x 10^  cells/ml. 0.5 ml 
per dose of cell suspension was injected intraperitoneally to each of primed mouse. 
Ascites were collected from two to three weeks after inoculation in those mice with a 
swelling in the abdominal region. Ascites were incubated at room temperature for 1 
hour to clot blood. Ascites were then centrifuged at 4000 rpm for 10 minutes at room 
temperature. Supernatants were pooled and stored at -20°C. 
6.3.9 Purification of IgG mAbs from ascites 
Collected ascites were first isotyped to determine the subtype of 
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immunoglobulin. IgG mAbs were purified by HiTrapTM Protein G HP Column (GE 
Healthcare Bio-Sciences AB, Sweden). Al l the solutions were filtered through 0.45 
|im pore-size membrane and chilled at Frozen ascites were thawed and 
centrifuged at 14000 rpm for 30 minutes at 4°C to remove fine particles. The 
supernatants were pooled and diluted four fold with PBS. Diluted ascites samples 
were filtered with 0.45 jim filters and kept on ice. Five ml HiTrap™ Protein G HP 
Column in storage mode was washed with 3 bed-volumes of ddHiO and 3 
bed-volumes of PBS. Diluted ascites samples were pumped into the column and the 
flow through was reloaded into the column until the whole batch passed through the 
column three times. The column was washed with 5 bed-volumes of PBS to wash out 
unbound proteins. One hundred and fifty |.il neutralizing buffer (1 M Tris at pH 9) was 
pre-dispensed in 15 ml centrifuge tubes for collection of elution fractions. MAbs 
trapped in the column was eluted with elution buffer (100 mM glycine-HCl at pH 2.7) 
at 1 bed-volume per fraction. MAbs were immediately neutralized by neutralizing 
buffer to prevent the damage to IgG caused by acidic pH. Neutralized mAbs were 
stored at 4°"C. For storage, mAbs were diluted with 50 % glycerol and stored at -20°C. 
MAbs purified was assayed by SDS-PAGE and used for immunoassay of rhGH. 
After elution, the column was washed with 3 bed-volumes of PBS and 3 
bed-volumes of ddH〗。. Column was finally washed with 3 bed-volumes of 20 % 
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ethanol and stored at 4°C. 
6.3.10 MAbs isotyping 
MAbs were isotyped by Mouse Typer Sub-isotyping kit (Bio-Rad, USA). It was 
based on ELISA using a set of specific rabbit anti-sera to determine the isotype of 
mouse immunoglobulin. One hundred microliter of mAbs containing sample was 
applied to a 96-well plate coated with 100 ng/well rhGH for binding at 37°C for 30 
minutes. Plate was flicker-dried and washed with PBST three times. One hundred 
microliter of a panel of 8 ultra pure rabbit anti-mouse subclass specific antisera 
against mouse IgGi, IgGia, IgGib, IgGs, IgM, IgA, K light chain and X light chain was 
added to 96-well plate and incubated at 3TC for 30 minutes. After washing with 
PBST three times, EIA-grade affinity purified goat anti-rabbit IgG (H+L) HRP 
conjugate (Bio-Rad, USA) was added and incubated at 3TC for 30 minutes. HRP 
substrate was finally added for colour development and OD405 was measured by plate 
reader. 
6.3.11 Determination of kinetic parameters of mAbs 
I 
Biacore® 3000 (GE Healthcare Biacore AB, Sweden) was used to study the 
antigen-antibody interaction by surface plasmon resonance analysis. Experiments 
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were performed by using Biacore® 3000 with control software version 4.1 and sensor 
chip CMS (carboxymethylated dextran surface, GE Healthcare Biacore AB, Sweden). 
Assays were carried out at 25®C, 0.22 |im filtered and degassed HBS buffer (10 mM 
HEPES with 0.15 M NaCl, 3 mM EDTA, pH 7.4) was used as the running buffer. 
6.3.11.1 Immobilization of rhGH on senor chip CMS 
rhGH was immobilized by amine coupling, amine groups in rhGH were 
chemically attached to the activated surface esters in the second flow cell, 
activated-deactivated surface without ligand was used as reference surface in the first 
flow cell. pH-scouting was performed prior to immobilization with the Biacore® 3000 
instrument handbook suggested conditions. rhGH was diluted in 10 mM sodium 
acetate buffer to 10 }ig/ml from a range of pH in 5.5, 5, 4.5 and 4 to determine the 
optimal pH for the absorption of rhGH to the senor chip, CMS. The pH 4.5 sodium 
acetate buffer showed maximum binding of the rhGH to CMS chip and this pH was 
chosen for immobilization. Senor chip surface was first washed with 1 M 
ethanolamine-HCl (Amine coupling kit, GE Healthcare Biacore AB) and the surface 
was activated with l-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 
N-hydroxysuccinimide (NHS) (Amine coupling kit). Ten |ig/ml rhGH in 10 mM 
sodium acetate buffer at pH 4.5 was injected to achieve an immobilization level of 
1000 RU. 1 M ethanolamine-HCl was then added to inactivate the residual active 
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groups on the chip surface. 
6.3.11.2 Regeneration scouting 
Regeneration scouting was performed as described in the Biacore® 3000 
instrument handbook. 10 mM glycine solution at pH 3, 2.5, 2 and 1.5 (Regeneration 
scouting kit, GE Healthcare Biacore AB) were injected onto the analyte (mAbs) 
bound surface to determine which pH could completely regenerate the baseline level 
RU. From the regeneration scouting results, 0.5 minute injection of glycine solution 
(pH 1.5) at 20 |il/min flow rate allowed complete regeneration of the chip surface 
back to the baseline level. 
6.3.11.3 Kinetic parameters of antigen-antibodies interaction 
Binding kinetics of mAbs purified from ascites toward immobilized rhGH was 
determined by kinetic analysis at various concentrations. A range of mAbs 
concentrations (1.92 [iM to 6.40 nM) was employed and six different concentrations 
of analytes were analyzed. Analytes were injected for 3 minutes at 30 |il/min flow rate 
and dissociated for 15 minutes in running buffer without dissociating agent. Data 
collected were subtracted from reference surface (flow cell 1). The association rate 
constant (ka), dissociation rate constant (kd) and dissociation equilibrium constant (KD) 
were calculated by using BIAevaluation Software 4.1 (GE Healthcare Biacore AB). 
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6.4 Results 
6.4.1 Production of murine anti-rhGH monoclonal antibodies 
6.4.1.1 Immunization 
Five female BALB/c mice of 6-8 weeks were used for immunization as 
described in section 6.3.2. Three days after the third booster injection, anti-sera were 
collected and ELISA screening was performed using the anti-sera as first antibody. As 
Fig 6.1 shows, all anti-sera titer of the immunized mice were higher than 100000. It 
indicates that our immunization scheme was successful. Fusion was performed using 
mouse whose has the highest titer. A final booster was given subcutaneously 3 days 
before PEG fusion. Other mice were continuously boosted every 21 days until use. 
6.4.1.2 PEG fusion 
The spleen is the largest lymph organ. The white pulps of the spleen are rich in 
mature antibody secreting B-lymphocytes. Antibody secreting B-cells were isolated 
from the spleen of immunized mouse according to standard procedures. 
B-lymphocytes were fused with log phase growing fusion partner cells, Sp2/0-Agl4, 
in a ratio of 5:1. Two rounds of PEG fusions were performed and 2 stable anti-rhGH 
antibody secreting hybridoma clones were generated. The hybridoma clones obtained 
are shown in Fig 6.2. Each of the two PEG fusion generated a stable hybridoma clone 
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Figure 6.1 ELISA curve of immunized mice anti-sera collected after booster 
injection against rhGH. 100 ng/well rhGH was coated. 
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Figure 6.2 Hybridoma clone generated from PEG fusion. A) Hybridoma clone 
obtained 9 days after PEG fusion in HAT selective medium. B) Negative control. 
Unfused Sp2/0-Agl4 cultured 9 days in HAT medium. All of the myeloma cells dead 
in the selective medium. 
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and they were named 23D3 and 33C5. Table 6.1 summarizes the data on the 
successful fusion in these two experiments. 
PEG fusion Trial 1 Trial 2 
Number of spleen used: 1 1 
Number of splenocytes: 1.05 x 10^  1.80 x 10^  
Number of Sp2/0-Agl4: 2.10 x 10^  3.60 x lO? 
Cell fusion ratio: 5:1 5:1 
Clones of stable anti-rhGH antibody secreting hybridoma: 1 1 
Table 6.1 Summary of two successful PEG fusions. 
6.4.1.3 Limiting dilution 
After fusion, the anti-rhGH antibody secreting hybridoma cells are normally 
found in a mixed population of cells in 96-well plates. Within the positive well, there 
might be hybridoma cells secreting antibodies against other antigens but not rhGH or 
even non-Secreting hybridomas. In order to separate anti-rhGH antibody secreting 
hybridoma cells from others cell types, limiting dilution was performed. In the first 
round of limiting dilution a higher cell number was seeded in a concentration of 10 
cells/well, 5 cells/well and 1 cell/well. Because the viability of newly formed 
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hybridoma is low, seeding at 5 to 10 cells per well can prevent the loss of antibody 
secreting hybridoma. Positive wells in ELISA with a single observable colony under 
microscope were chosen for the second round of limiting dilution. Hybridoma cells 
were seeded at 1 cell/well and 0.5 cell/well. I f a well contains only one hybridoma 
cell, an identical clone will grow up and secrete an identical antibody (mAb). The 
enrichment data of hybridoma clone 23D3 is summarized in Table 6.2. After two 
rounds of limiting dilution, all the wells containing cells were positive indicating a 
mAb secreting hybridoma clone was successfully isolated. 
Rounds of limiting dilution Number of viable Number of anti-rhGH Ab Percentage of 
hybridoma clones secreting hybridoma clones positive clone (%) 
1 38 14 37 
2 116 116 100 
Table 6.2 Enrichment of hybridoma clone 23D3 by limiting dilution. 
6.4.1.4 Mass production of mAbs 
MAbs were mass produced by in vivo method. Antibody secreting hybridoma 
cells were inoculated into ten pristane primed female BALB/c mice. Pristane can 
severely depress the normal immunological function of mouse that allows hybridoma 
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cells to grow inside the host. Ascites were collected when swelling at the abdominal 
region was observed from two to three weeks after inoculation (Fig 6.3). About 25 ml 
of ascites were collected from the inoculated mice. Collected ascites were first 
isotyped to determine the subtype of immunoglobulin. Both clones 23D3 and 33C5 
were found to be IgGi and mAbs were purified by Hi-Trap™ Protein G HP column. 
6.4.1.5 Purification of mAbs by Hi-TrapTM Protein G HP column 
Clarified ascites were diluted four folds with PBS and applied to Hi-Trap™ 
Protein G HP column (GE Healthcare Bio-Sciences AB, Sweden). The whole batch of 
ascites was passed through the column three times for the absorption of mAbs to 
protein G. Protein G is a cell surface protein of Group G streptococci that binds to the 
Fc region of IgG. MAbs were eluted out by 0.1 M glycine at pH 2.7 and immediately 
neutralized by 1 M Tris at pH 9.0. Elution fractions were analyzed by SDS-PAGE. As 
Fig 6.4 A and B show, mAbs from the ascites were effectively purified by the column. 
Most of the antibodies were absorbed in the flow through fractions. The purified 
mAbs have, a 50 kDa heavy and 27 kDa light chain. 
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Figure 6.3 MAbs production by in vivo method. A) Pristane primed mouse before 
hybridoma cells inoculation. B) Ascites formed after 14 days of inoculation. Ascites 
were collected and the mAbs were purified by Hi-TrapTM Protein G HP column. 
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Figure 6.4 SDS-PAGE analysis of the purified mAbs by Hi-Trap^M Protein G HP 
column. A) MAbs from hybridoma clone 23D3. B) MAbs from hybridoma clone 
33C5. Lane 1: Pre-stained SDS-PAGE standard; Lane 2: Ascites; Lane 3: Flow 
through fraction; Lane 4: Wash fraction; Lane 5: Elution fraction containing purified 
mAbs. 
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6.4.2 Characterization of anti-rhGH mAbs 
6.4.2.1 MAbs isotyping 
Diluted ascites were first isotyped before the purification of the mAbs. An 
ELISA based isotyping assay was preformed using a Mouse Typer Sub-isotyping 
panel (Bio-Rad, USA). The results are shown in Table 6.3. The OD405 value of 
anti-IgGi and anti-K light chain from both ascites samples of 23D3 and 33C5 were 
larger than 1 while the others were below 0.2. This indicates that clones 23D3 and 
33C5 secrete a single type of antibody belonging to the IgGi with a K light chain 
class. 
O D 4 0 5 value 
M A b s IgG, IgGsa IgG’� IgG：, IgM IgA K light chain X light chain 
23D3 3.780 0.059 0.101 0.070 0.133 0.155 3.361 0.132 
33C5 2.854 0.042 0.008 0.015 0.002 0.015 2.894 0.083 
Table 6.3 Isotyping of mAbs 23D3 and 33C5. O D 4 0 5 values were subtracted by 
background reading which no ascites sample was added. 
6.4.2.2 Reactivity of mAbs against rhGH 
The reactivity of mAbs purified from ascites was studied by ELISA. One 
hundred ng/well rhGH was coated onto 96-well plate, 10 fold serial diluted mAbs in 
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blocking buffer from 288000 ng/ml to 0.0288 ng/ml (mAb 33C5) or 215000 ng/ml to 
0.0215 ng/ml (mAb 23D3) were used as first antibody. Goat anti-mouse HRP 
conjugate was added as secondary antibody. The results are as plotted in Fig 6.5 and 
6.6. The titer of mAb 23D3 against rhGH was about 17.5 ng/ml while that of mAb 
33C5 was 166.0 ng/ml. Based on these titers, the sensitivity of mAb 23D3 was about 
10 fold higher than mAb 33C5. 
6.4.2.3 Cross reactivity of mAbs against SUMO-hGH 
The specificity of mAbs was studied by western blot. Induced E. coli cell lysate 
was used as a sample for the study of cross reactivity of the mAbs against 
SUMO-hGH. After SDS-PAGE separation, protein contents in mini gel were 
transferred to membrane for western blotting. One p,g/ml mAbs were used as the first 
antibody since this dilution is the least concentration of antibodies giving the 
maximum OD405 value in the ELISA titer curve. As Fig 6.7 shows, SUMO-hGH 
fusion protein can be recognized by the two mAbs as a band at 34.3 kDa. From Fig 
6-7 B andX, two protein bands at about 30 and 27 kDa could also be stained by the 
mAbs. As these sizes are smaller than the intact SUMO-hGH, we suspect that these 
bands were degraded fragments of SUMO-hGH inside the host cell. Besides the 
native antigen rhGH, the two mAbs raised by us are able to interact with the 
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Figure 6.5 ELISA curve of mAb 23D3 against rhGH. The titer was found as 17.5 
ng/ml (Titer was defined as the concentration of antibodies giving the O D 4 0 5 value at 
half of the maximum in ELISA). 
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Figure 6.6 ELISA curve of mAb 33C5 against rhGH. The titer was found as 166.0 
ng/ml. 
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Figure 6.7 Cross reactivity studies of mAbs against SUMO-hGH. A) Coomassie Blue 
stained SDS-PAGE gel. B) Western blot using mAb 23D3 as first antibody. C) 
Western blot using mAb 33C5 as first antibody. Lane 1: Pre-stained SDS-PAGE 
standard, low range; Lane 2: Induced E. coli cell lysate. 
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SUMO-hGH fusion protein. 
6.4.2.4 Kinetic parameters of rhGH and mAbs interaction 
Kinetic studies of the antigen-antibody interaction were analyzed by surface 
plasmon resonance using a Biacore® 3000 machine (GE Healthcare Biacore AB, 
Sweden). The optimized immobilization condition of rhGH on senor chip CMS was 
determined by pH scouting. As Fig 6.8 A shows, the binding of rhGH to the chip 
surface was maximum at pH 4.5. rhGH was immobilized on the CMS chip by 
standard EDC/NHS protocol. After immobilization, regeneration scouting was 
performed to determine the regeneration condition. As shown in Fig 6.8 B, only the 
0.5 minute injection of glycine solution (pH 1.5) at 20 |j.l/min flow rate could 
regenerate the chip surface back to the baseline level. The ka, kd and K d of the mAbs 
were measured by the kinetic analysis wizard - concentration series protocol. Data 
collected were subtracted from reference surface (flow cell 1) and repeated twice. 
Sensorgrams of the time course interaction between mAbs and rhGH immobilized are 
shown in Fig 6.9 A and B. Various kinetic parameters were calculated by using the 
BIAevaliiation Software 4.1 (GE Healthcare Biacore AB). The binding of mAbs to 
t 
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Figure 6.8 A) Sensorgram of pH scouting. Determination of the optimized 
immobilization condition for rhGH onto the sensor chip CMS. B) Sensorgram of 
regeneration scouting. Determination of the optimized regeneration condition for the 
sensor chip back to the baseline level. 
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The Langmuir binding model is briefly described: (A is the analyte and B is the 
ligand immobilized on the chip) 
hi 
A + B O A B 
ko 
ka and kd are the forward and reverse rate constants for the antigen and antibody 
binding; K a I s calculated by ka/kd； K d is calculated by kd/ka. 
k “ l / M s ) kd ( l /s) Rmax (RU) K a ( 1 / M ) K d ( M ) 
Mab 23D3 6.59x10^ 2.02xl0_3 267 3.27 x10^ 3.06x10-8 
Mab 33C5 4.24x10^ 2.51x10-^ 39 1.68 x10^ 5.94x10-8 
Table 6.4 Biacore kinetic and equilibrium analysis for antigen-antibody interaction. 
The kinetic results are shown in Table 6.4. The K d of mAbs 23D3 and 33C5 
were 30.6 nM and 59.4 nM, respectively. In general, antigen-antibody interaction 
would yield a K d ranging from 10"^  M to 10"" M (72. 73). The K d of our mAbs is 
within the normal range of an antigen-antibody interaction. The larger K d means a 
weaker binding affinity, hence mAb 23D3 has a higher binding affinity to rhGH than 
t 
mAb 33C5. The kinetic values obtained by Biacore analysis is consistent with those 




m.i «iA& , Injeiion 
<00 -r eJld 
.1' 
？SO -
mAb / \ 
300. Mjfiam \ 
J 
.200- I . \ 
i 彻：//K^S^ 
? / Efx3 Of 
I / cissociaiion 
. z 一 —..•.•--.....-
-so H 1 1 1 » ‘ ‘ ‘ 




PI) iVLAO . injecion 




/ I End cf / V dissociation 
奶“ / ^ , _ - —I - , . i 
I — / i 
u start / 、： 
- 1 0 -
-20 4 1 1 1 1 1 1 
0 ？00 咖 600 600 1000 1：?00 
Time s 
Figure 6.9" A) Time courses analysis of the association and dissociation for mAb 
23D3 binding to the immobilized rhGH. From the bottom upwards, the mAb 
concentrations were 0, 0.7167, 2.15, 7.167, 21.5, 71.67 and 215 |ig/ml, respectively. 
B) Time courses analysis of the association and dissociation for mAb 33C5. From the 
bottom, the mAb concentrations were 0, 0.96, 2.88, 9.6, 28.8, 96 and 288 |ig/ml. 
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6.5 Discussion 
Two murine anti-rhGH monoclonal antibodies have been produced by 
conventional PEG fusion method. From the immunization of mice to the second 
round of limitation dilution, a total of five to six months were required to generate a 
stable antibody secreting hybridoma clone. Over 70 % of the wells in a 96-well plate 
were found to contain hybridomas after PEG fusion. However, only one stable 
antibody secreting hybridoma clone was generated in each fusion. The yield of the 
positive clone obtained is relatively low compared with published papers related on 
mAb production against hGH. The range of positive clones generated from those 
reports was 5 to 8 clones per fusion (74, 75). In our study, we generated a reasonable 
numbers of stable hybridomas after PEG fusion, but only one of them is positive. This 
result suggests that the fusion procedure and reagents used are acceptable in cell 
fusion. The low yield of anti-rhGH antibody secreting clone is probably due to the 
low number of activated B-lymphocyte against rhGH isolated from the spleen. Using 
more immunized spleen per fusion could probably improve the yield of positive clone. 
Besides, more boosters given to the mice should increase the numbers of activated 
B-lymphocyte as a stronger immune response can be stimulated by repeated 
immunization and the final booster can be given as intravenous injection for a quicker 
absorption. 
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6.5.1 Mass production of mAbs 
MAbs were produced by in vivo method. Ascites were collected from inoculated 
mice. About 25 ml of ascites were collected from a total ten mice for each hybridoma 
clones. Highly pure mAbs was eluted from Hi-Trap™ Protein G HP column and the 
yield of purified mAb 23D3 was 66.4 mg (2.656 mg/ml in ascites) and mAb 33C5 
was 57.6 mg (2.304 mg/ml in ascites). The purified mAbs from ascites fluid is found 
to be within the reported range of 1 to 28 mg/ml (76). Compared with in vitro 
production method using culture shake, the yield of in vivo production is about 20 
fold higher than in the culture medium; 1 to 100 |ig/ml (77). Besides the low yield, 
the quality of purified mAbs could also be affected by the in vitro production. Unless 
the hybridomas can adapt to a serum free medium, mAbs purified from culture 
medium wil l suffer from a high degree of contamination with bovine serum 
immunoglobulin. 
6.5.2 Future works on mAbs 
The cross reactivity of the mAbs against growth hormones, prolactins and 
placental lactogens from different species should be studied. As GHs from different 
species share a high degree of homology, it is worthwhile to find out the cross 
reactivity between them. Since there is about a 20 % of amino acid identity and 50 % 
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amino acid homology between mammalians' GH (13), there is a high chance of 
epitope similarity. 
The binding site of mAbs on rhGH could be determined by epitope mapping. 
Sets of short (10-15 amino acids) overlapping polypeptide fragments of rhGH can be 
constructed and they can be coated onto 96-well plate to assay the interaction 
between them and the mAbs. By probing the wells containing mAbs with secondary 
antibody, the binding site can be identified from the peptide sequence coated. Linear 
epitope based on the primary sequence of the protein antigen can be determined by 
this method (78). For conformational epitopes which resemble the native structure of 
the antigen, more complicated chemically linked peptides on scaffold support or 
truncated protein could be used for structural mapping. 
The effects of mAbs on the biological activity of hGH should also be explored. 
In vitro study can be performed by co-incubation of mAbs with rhGH in the 
luciferase assay. Antibodies bound onto the GH may inhibit the actions of hormone 
due to the blockage of the binding between GH and GH receptors (79). Such 
neutralization effect of GH may be utilized as a therapeutic agent for patients with 
hyper-secretion of GH. 
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6.6 Conclusion 
By conventional PEG fusion technique, two mAbs against rhGH were produced 
as the required reagent for setting up a sandwich ELISA for hGH. Both mAbs are 
IgGi subtype with K light chain. The titer of mAb 23D3 was 17.5 ng/ml and mAb 
33C5 was 166.0 ng/ml while the K d of mAb 23D3 and 33C5 were 30.6 nM and 59.4 
nM, respectively. MAb 23D3 gave a stronger binding to rhGH than mAb 33C5. As 
both of them can cross react with the fusion form rhGH (SUMO-hGH), they are 
suitable to work as capturing antibody in a sandwich ELISA for the measurement of 
rhGH as well as SUMO-hGH fusion. 
< 
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Chapter 7 Development of sandwich ELISA for rhGH 
7.1 Introduction 
We have described the production and characterization of mAbs against rhGH in 
the previous chapter. The establishment of a sandwich ELISA for the measurement of 
rhGH will be described in this chapter. 
The level of rhGH and SUMO-hGH fusion protein expressed in our study are 
estimated by the total protein content (by Bradford protein assay) multiplied by the 
purity of the protein preparation (the band intensity of rhGH or fusion protein over 
the total intensity in the SDS-PAGE gel). Quantitative determination of protein 
content from Coomassie Brilliant Blue R-250 stained SDS-PAGE gel requires clear 
separation of the bands. The presence of stainable groups in the protein is also critical 
as it affects the intensity of the band (80). Combining the deviation from Coomassie 
Brilliant Blue G-250 staining between BSA standard and rhGH, the determined the 
protein amount by this method is not accurate. High-performance liquid 
chromatography (HPLC) is preferred as a more sensitive analytic method to 
determine the quantity of protein by the peak area. However, HPLC requires a 
semi-purified sample instead of crude lysate hence increasing sample preparation 
4 
time. Sandwich ELISA is preferred as an immunoassay for the determination of rhGH 
concentration as well as to monitor the level of SUMO-hGH in the crude cell lysate 
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during the course of fermentation. 
Two mAbs against rhGH have been produced from two clones of hybridoma. 
They can be immobilized onto micro-titer plates separately as capturing antibody. 
Rabbit polyclonal anti-serum against rhGH can then be used as a second antibody to 
interact with the rhGH captured by the immobilized mAbs. Goat anti-rabbit IgG 
(H+L) HRP conjugate is then used to detect the amount of rabbit antibodies bound. A 
total of three antibodies are involved in this sandwich ELISA as illustrated in Fig 7.1. 
Detection antibody 
y Z {goat anti-rabbit IgG (H+L) HRP conjugate) 
p p / Z 
A /A\ 
：： i： 一 _ _ _ 一 - Rabbit antiserum against rhGH 
JU 
rhGH、、 />• % ! i % o 
V\ \ / / W / / Capturing antibody 
\ J J (mAb 23D3 or 33C5) 
Figure 7.1 Schematic diagram of sandwich ELISA for rhGH measurement. Three 
antibodies are involved in this assay. 
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7.2 Materials 
7.2.1 Reagents for sandwich ELISA 
It was prepared as described in Chapter 6 section 6.2.3 under the heading 
reagents for enzyme linked immunosorbent assay (ELISA). 
7.3 Methods 
7.3.1 Production of rabbit polyclonal antiserum against rhGH 
7.3.1.1 Rabbit immunization with rhGH 
New Zealand White rabbits were bred in the Animal House of The Chinese 
University of Hong Kong. Two New Zealand White rabbits at the age of one year 
were used in our experiment. Pre-bled-serum was collected from the marginal ear 
vein of each rabbit as a negative control. Equal volume of 100 jig of rhGH (Scitropin, 
SciGen) in PBS and complete Freund's adjuvant (CFA) were mixed in a two syringe 
set up to emulsified the rhGH. One ml of the mixture containing 100 jig of rhGH was 
injected intramuscularly into each rabbit on day 1. After 28 days, rabbits were 
boosted intramuscularly with 1 ml emulsion of rhGH and incomplete Freund's 
adjuvant (IFA). Boosters were given in two-week intervals with the same procedures 
as the first booster. Serum was collected two weeks after each booster. A total of four 
boosters were given to the rabbits. 
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7.3.1.2 Serum preparation 
Blood was collected from the marginal ear vein of the rabbit in a 50 ml Falcon 
centrifuge tube. Blood was clotted by placing it at room temperature for 1 hour. 
Serum was separated from the clotted red blood cell by centrifugation at 4000 rpm for 
20 minutes at 4°C. The supernatant was transferred to another centrifuge tube for 
another round of centrifugation to remove residue blood clot. Serum was stored in 
aliquots of 1 ml at -80。C. 
7.3.2 Sandwich ELISA 
Capturing antibody (mAb 23D3 or 33C5) was diluted in ELISA coupling buffer 
at an optimized concentration (100 [.il/well) and was coated onto 96-well MaxiSorp 
polystyrene plate (Nalge Nunc international, Demark) at 4°C overnight. Coated plates 
were flicker-dried and washed with 200 |il PBSTM three times. It was then blocked 
with 200 \x\ blocking buffer at room temperature for 2 hours to saturate the residue 
binding sites in the well. Blocked plates were flicker-dried and washed with 200 [i\ 
PBST three times. One hundred |il/well of samples to be assayed were added to the 
blocked plate and the plate was incubated at room temperature for 1 hour. The plate 
was then flicker-dried and washed with 200 PBSTM three times. One hundred 
Ill/well of 5000 fold diluted rabbit anti-serum in blocking buffer containing 0.05 % 
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Tween 20 was added to the plate and was incubated at 37。C for 45 minutes. The plate 
was again flicker-dried and washed with 200 |il PBSTM three times. One hundred 
l_il/well of 2000 fold diluted EIA-grade affinity purified goat anti-rabbit IgG (H+L) 
HRP conjugate (Bio-Rad, USA) in blocking buffer (0.05 % Tween 20) was added to 
the plate and was incubated at 37°C for 45 minutes. The plate was flicker-dried and 
washed with PBSTM three time and then twice with PBST at 200 ^il/well. One 
hundred |il/well of freshly prepared HRP substrate was added and incubated at 37°C 
for 20 minutes for colour development. Optical density at 405 nm was measured by a 
microplate reader. 
7.4 Results 
7.4.1 Production of rabbit antiserum against rhGH 
Two New Zealand White rabbits were immunized with rhGH. Sera were 
collected two weeks after the second (6 weeks after the first immunization), third (8 
weeks) and fourth (10 weeks) booster immunization. Serum titers against rhGH were 
measured by ELISA. The OD405 values of pre-sera collected from rabbit and 2料 
were 0.080 and 0.069 respectively. As Fig 11 shows, an increasing trend of 
anti-rhGH serum titer was observed after boosters in rabbit The end-point titer of 
rabbit 2# reached a level of 218700 dilutions after the fourth booster injection. 
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End-point titers of rabbits anti-sera against rhGH 
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Figure 7.2 End-point titers of rabbit sera against rhGH. Second bleed was collected in 
2 weeks after the second booster injection (at 6 weeks after first immunization). 
(End-point titer was defined as the dilution factor of serum giving the OD405 value at 
0.2 above the background in ELISA against rhGH). 
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Compared with rabbit 2 \ rabbit was less responsive to rhGH immunization. 
Although there was a tiny improvement in serum titer after boosters, the binding 
affinity was much weaker than rabbit 2 . Therefore, the fourth bleed of rabbit 2 , 
which gave the highest serum titer, was used in the sandwich ELISA. The ELISA titer 
curve of the fourth bleed of rabbit 2 is shown in Fig 7.3. Serum titer was about 
10000 fold dilution at the OD inflection point. 
7.4.2 Sandwich ELISA 
Sandwich ELISA was performed by using the purified mAbs and rabbit 
anti-serum. Both mAbs 23D3 and 33C5 were used as the capturing antibody. One 
hundred |il/well capturing antibody (1.6 |ig/ml) was coated onto 96-well plate and 
blocked with blocking buffer. Various concentrations of rhGH (Scitropin, SciGen) 
were added to test the detection range of the sandwich ELISA. Ten thousands fold 
diluted rabbit anti-serum (serum titer that gave an OD405 value of 2 in ELISA) was 
added to detect the rhGH captured by the mAbs. Two thousands fold diluted goat 
anti-rabbit HRP conjugate was finally added to probe the amount of rabbit antibody 
bound. After reacting with the substrates, the optical density at 405 nm is proportional 
to the amount of rhGH present in the sample. The O D 4 0 5 values plotted against the 
concentration of rhGH from the two capturing mAbs used are shown in Fig 7.4. Both 
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Figure 7.3 ELISA curve of the fourth bleed of rabbit 2# against rhGH. Serum titer 
was about 10000 fold dilution (half of the maximum). 
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Figure 7.4 The OD405 values against rhGH concentration from the two capturing 
mAbs 23D3 and 33C5 in sandwich ELISA. 10000 fold diluted rabbit anti-serum was 
added to detect the rhGH captured by immobilized mAbs. 
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mAbs showed an increase in absorbance as the amount of rhGH increased in the 
sample. A plateau phase was reached when the concentration of rhGH went up to 
about 500 ng/ml. MAb 23D3 was much more sensitive than mAb 33C5. This result is 
as expected as the binding affinity of mAb 23D3 is significantly higher than 33C5. 
Since the O D 4 0 5 value of mAb 33C5 was too low (1000 ng/ml rhGH only gave about 
0.5) this niAb is not suitable for rhGH detection. Therefore, mAb 23D3 was used as 
the capturing antibody for later studies. 
7.4.3 Optimization of sandwich ELISA 
The sensitivity and consistency of the assay were optimized by varying the 
amount of different components in the ELISA. The effect of capturing antibody 
concentrations, the rabbit anti-serum dilutions and the binding conditions were 
studied step by step to improve the performance of the sandwich ELISA. 
7.4.3.1 Capturing antibody concentrations 
Different concentrations of mAb 23D3 were coated onto 96-well plate to 
optimize ,the amount needed for rhGH detection. A range of concentrations from 2.5 
|ig/ml to 0.164 ng/ml was tested and the result is shown in Fig 7.5. Coating with 2.5 
and 1.641 |ig/ml antibodies produced measurable signals with a rhGH concentration 
ranging from 1000 to 1 ng/ml. At 10 fold lower concentration of mAb (164.1 ng/ml or 
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Effect of capturing antibody concentrations on sandwich ELISA ^500 ng/ml 
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Figure 7.5 Optimization of sandwich ELISA for rhGH detection by the amount of 
capturing antibody coated. MAb 23D3 was coated as capturing antibody. 
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below) no significant signal was obtained. The signals generated from the 2.5 and 
1.641 }ig/ml coating were nearly identical. The magnitude of the signal generated 
appears to be proportion to the amount of rhGH from concentration of 1 to 100 ng/ml. 
The signal plateaus from 100 to 1000 ng/ml. Although 1.641 |_ig/ml was determined to 
be the minimum coating concentration, 2.5 |ig/ml was chosen for later sandwich 
ELISA as excess antibodies coating can avoid the inconsistency in rhGH detection 
caused by a limiting amount of capturing antibodies in the well. 
7.4.3.2 Rabbit anti-serum dilutions 
The second factor directly affecting the signal is the amount of rabbit anti-serum 
to be used. Ten thousands fold diluted rabbit anti-serum was used in the sandwich 
ELISA trial as it was the serum titer in ELISA. To study the effect of rabbit 
anti-serum dilution, 5000 and 10000 fold dilutions were tested. As shown in Fig 7.6, 
2.5 jag/ml mAb 23D3 was coated on the plate and the two dilutions of rabbit anti-sera 
were added to detect the amount of rhGH captured by the mAb. The two dilutions of 
the anti-sera gave a response curve with a similar shape. However, the 5000 fold 
dilution gave a stronger signal. Thus, by increasing the anti-serum level, the signal to 
noise ratio of the sandwich ELISA can be improved (OD405 value increased about 70 
0/0). In the subsequent sandwich ELISA, 5000 fold diluted rabbit anti-serum was used. 
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Effect of rabbit anti-serum dilutions on sandwich ELISA 
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Figure 7.6 Effect of rabbit anti-serum dilutions on sandwich ELISA. Two point five 
fig/ml mAb 23D3 was coated as capturing antibody. 
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7.4.3.3 Binding conditions of rhGH sample 
Binding temperature and time can affect the kinetic of the antigen-antibody 
interaction. In addition, these parameters could also affect the stability of the rhGH 
during the assay. To study the effect of binding condition, three different temperatures 
with two time points were tried as shown in Fig 7.7. The binding of rliGH in 
sandwich ELISA was dependent more on incubation temperature rather than 
incubation time. At 4°C, both overnight and 1 hour incubation gave a very weak 
signal. The strongest signal was obtained by incubation at 37°C. On the other hand, 
incubation at room temperature gave an acceptable signal also. We prefer using room 
temperature as the presence of contaminating proteins in the sample, such as that in 
the bacteria lysate, may increase the degradation of rhGH. Therefore, we choose 1 
hour incubation at room temperature. 
7.4.4 Specificity of sandwich ELISA 
The specificity of the optimized sandwich ELISA was studied by challenging the 
assay using mixtures of rhGH standards in different crude samples. 10 % fetal bovine 
serum, LB medium and 10。/。E.coli cell lysate in blocking buffer were studied (Fig 
7.8). rhGH standards were diluted in crude samples from a range of 0 to 500 ng/ml. 
As indicated, the linearity of the curves was not affected by the different mixtures. 
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Figure 7.7 Effect of binding conditions on sandwich ELISA. Two point five |ig/ml 
mAb 23D3 was coated as capturing antibody. Five thousands fold diluted rabbit 
anti-serum was added to probe the rhGH. Besides rhGH sample binding, all 
antibodies were incubated at 3TC for 45 minutes. 
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Figure 7.8 Specificity study of sandwich ELISA by challenging with different crude 
mixture. rhGH standards diluted in different crude mixture were incubated at room 
temperature for 1 hour. 
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This sandwich ELISA is quite specific as 10 % fetal bovine serum containing bovine 
growth hormone which share 75 % sequence homology with hGH (14) did not 
interfere with the background reading. However, 10 % E.coli cell lysate interfered 
with the ELISA and increased the background OD405 reading from 0.01 to 0.34. This 
may due to the presence of non-specific binding proteins in the bacteria against the 
capturing antibody. As we intended to used the sandwich ELISA to monitor the 
expression of SUMO-hGH during the course of fermentation, the cross reactivity 
observed was further studied. 
7.4.5 Cross reactivity of sandwich ELISA to E.coli cell lysate 
E.coli cell lysate was prepared by inoculation of a single colony of BL21 
cell from LB plate in 5 ml LB medium containing chloramphenicol at 34 |ig/ml (pLys 
plasmid is responsible for chloramphenicol resistance) and incubated at 37°C 
overnight with shaking. Cells were harvested by centrifugation and resuspended in 1 
ml 50 mM Tris buffer (pH 8.0). Cell lysate was prepared by sonication on ice. A 
range of-E.coli cell lysate from 1 to 10000 fold dilution in blocking buffer was used 
for the study. As shown in Fig 7.9，the background reading of cell lysate dramatically 
reduced to below 0.02 when the lysate was diluted to more than 500 fold. This 
suggests that the interference may not be significant i f the E. coli cell lysate could be 
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Figure 7.9 Cross reactivity of E.coli cell lysate in optimized sandwich ELISA. Two 
point five |xg/ml mAb 23D3 was coated. Five thousands fold rabbit anti-serum was 
used. Different dilutions of E. coli cell lysate were incubated at room temperature for 
1 hour. 
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diluted to 500 fold or greater when the assay is done. 
To confirm the interference of E.coli cell lysate on the background could be 
removed, rhGH standards diluted in 1000 fold E. coli cell lysate were measured. As 
indicated in Fig 7.10, the curve of cell lysate and blocking buffer were nearly 
identical in term of shape and reading. 
7.4.6 Measurement of SUMO-hGH with sandwich ELISA 
As the background interference caused by bacteria protein could be prevented by 
dilution, the sandwich ELISA was further tested for the measurement of SUMO-hGH. 
Semi-purified SUMO-hGH was serially diluted and assayed by the sandwich ELISA. 
A standard curve of rhGH is shown in Fig 7.11. The x-axis was plotted in log scale in 
term of the amount of rhGH. As the molecular weight of SUMO-hGH (34.3 kDa) is 
larger than rhGH (22.1 kDa), the use of molar amount should be more appropriate. 
The linear range of the standard curve lies between 13.57 pmol (300 ng/ml) to 1.36 
pmol (30 ng/ml). The SUMO-hGH semi-purified preparation was diluted in a range 
of lOOO-to 128000 fold in blocking buffer. From the OD405 value, dilutions at 2000, 
4000 and 8000 fold are within the linear range of the standard curve. The amount of 
SUMO-hGH in the sample was calculated by the average amount of SUMO-hGH 
from the data points within the linear range. 
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Sandwich ELISA with optimized E.coli cell lysate background 
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Figure 7.10 Sandwich ELISA with optimized E.coli cell lysate background. Two 
point five ^ig/ml mAb 23D3 was coated. Five thousands fold rabbit anti-serum was 
used. rhGH standards diluted in 1000 fold E.coli cell lysate were incubated at room 
temperature for 1 hour. 
rhGH standard curve in sandwich ELISA 
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Figure 7.11 rhGH standard curve in sandwich ELISA. Two point five }ig/ml mAb 
23D3 was coated. Five thousands fold rabbit anti-serum was used. rhGH standards 
diluted in blocking buffer were incubated at room temperature for 1 hour. 
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The molar amount bound to antibodies is calculated by substitution of the O D 4 0 5 
value in the equation of the curve, 3； 二 0.5909 Ln(x) + 0.1102. The SUMO-hGH 
concentration in the sample was calculated by the pmol captured multiplied by the 
dilution factor and the molecular weight (34.3 kDa). 
SUMO-hGH dilution O D 4 0 5 Particles captured (pmol) SUMO-hGH concentration (ng/ml) 
2000 1.355 8.225 8.225 x 2000 x 34.3 = 564236.60 
4000 0.944 4.098 4.098 x 4000 x 34.3 = 562248.24 
8000 0.557 2.130 2.130 x 8000 x 34.3 = 584479.44 
Table 7.1 Calculation of the SUMO-hGH concentration in the sample measured by 
sandwich ELISA. 
As shown in Table 7.1，the concentration of SUMO-hGH measured by sandwich 
ELISA is about 0.570 土 0.012 mg/ml. The concentration of SUMO-hGH in this 
preparation as measured by Bradford protein assay was 0.343 mg/ml. Thus, the 
SUMO-hGH concentration measured by sandwich ELISA was about 66 % more than 
the Bradford protein assay. This difference may due to the variance in the binding of 
the Coomassie Brilliant Blue G-250 dye to BSA standard versus SUMO-hGH. 
To study the cross reactivity of SUMO-hGH in sandwich ELISA, western blots 
were preformed by using the antibodies involved to probe the cell lysate sample 
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containing SUMO-hGH. As indicated in Fig 7.12, SUMO-hGH is recognized by 
anti-His, anti-rhGH monoclonal and polyclonal antibodies. Anti-His antibody was 
used as a reference to confirm the size of SUMO-hGH by the His-tag. Both capturing 
antibody and rabbit anti-serum can recognize the SUMO fusion form of rhGH. The 
specificity of the monoclonal antibody was higher than polyclonal rabbit serum. As 
the SUMO-hGH was first captured by a highly specific mAb, the detection by the less 
specific rabbit serum should not decrease the specificity of the assay. 
7.5 Discussion 
In this study, we have established a sandwich ELISA for the measurement of 
rhGH and SUMO-hGH. It involved the production of monoclonal and polyclonal 
antibodies against rhGH. Highly specific mAbs were produced as described in the 
previous chapter. As the two mAbs were highly specific, they were coated on 96-well 
plate as capturing antibody. Rabbit anti-serum was produced and used as detection 
antibody to probe the rhGH captured by the mAbs. 
There are two reasons for us to develop the sandwich ELISA in this monoclonal 
and polyclonal antibody approach. First, the production of monoclonal antibody 
t 
secreting hybridoma is time consuming. We have only produced two antibody 
secreting cell clones, and the binding sites of the two mAbs have not been located yet. 
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Figure 7.12 SDS-PAGE and western blots analysis on the cross reactivity of 
SUMO-hGH in sandwich ELISA. A) Coomassie Blue stained gel. B) Western blot 
using 2500x anti-His mAb (Amersham biosciences, USA). C) Western blot using 
2500x mAb 23D3 (capturing antibody). D) Western blot using 2500x rabbit 
anti-serum bleed. Lane 1: Pre-stained SDS-PAGE Standards; Lane 2: Induced 
BL21 cell lysate supernatant. 
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Although mAb used as detection antibody in the sandwich ELISA may provide more 
consistent result (not affected by batch-to-batch variation of rabbit anti-serum), there 
is a risk that the capturing and detection mAbs may bind to an overlapping site. 
Capturing antibody and detection antibodies must recognize two non-overlapping 
epitopes. Polyclonal rabbit antiserum is raised against multiple epitopes, therefore its 
use in detecting rhGH prevents the problem of overlapping binding site. Second, by 
using a second antibody for signal amplification, higher sensitivity could be achieved. 
Thus, we used goat anti-rabbit IgG (H+L) HRP conjugate to probe the bound 
antibody. The combination of monoclonal and polyclonal antibodies facilitated the 
development of our sandwich ELISA and enhanced the sensitivity of the assay. 
7.5.1 Application of sandwich ELISA 
One of the applications of sandwich ELISA is the measurement of hGH level in 
human serum. The mean basal serum concentrations of hGH is 2.4 土 2.8 ng/ml in 
normal boys and 2.5 土 3.1 ng/ml in normal girls (81). However, the working range 
and detection limit of our assay does not match with the physiological level of hGH. 
Comparing with those published sandwich ELISA assay for hGH by Juliana F. Moura 
et al (82), the sensitivity of ours assay is lower. The working range of Moura's 
ELISA is at 1.95 to 31.50 ng/ml of rhGH and the detection limit is 0.12 ng/ml. 
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Although our detection limit is not as sensitive as Moura et al, the larger coverage of 
working range in our assay is suitable for the measurement of rhGH level produced 
by fermentation. Our sandwich ELISA system is quite specific to hGH as it shows no 
interference from 10 % fetal bovine serum or E.coli cell lysate with 500 fold or 
greater dilutions. 
The cross reactivity of our sandwich ELISA to SUMO-hGH was studied. 
SUMO-hGH is the precursor of rhGH in our fermentation production scheme. As Fig 
7.12 shows, both capturing and detection antibodies can recognize the SUMO fused 
form of rhGH. Sandwich ELISA was performed to measure the concentration of 
semi-purified SUMO-hGH. A calibration curve of rhGH was transformed from 
concentrations (ng/ml) to molar amount (pmol). The concentration of SUMO-hGH 
sample was calculated by the average concentration of diluted SUMO-hGH samples 
within the linear range. However, the amount of SUMO-hGH measured was 66 % 
higher than the Bradford protein assay. Such variations may be due to interference 
from non-specific components in the semi-purified sample to sandwich ELISA assay. 
The difference in the binding affinity between Coomassie Brilliant Blue G-250 dye to 
BSA versus SUMO-hGH may also accounts for this variation. A more sophisticated 
qualitative method such as HPLC should be tried to quantify the amount of 
SUMO-hGH in order to study the cause of this discrepancy. 
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7.5.2 Future works on sandwich ELISA 
For the future, a sandwich ELISA with HRP conjugation to mAb 33C5 could be 
set up i f the epitopes of our two mAbs do not overlap. Whether a sandwich ELISA 
using two mAbs for capturing and detection would be better remains to be seen. 
However, the problem of batch-to-batch variation of rabbit anti-serum could need to 
be carefully calibrated to avoid inter-assay errors. 
7.6 Conclusion 
In this study, we have developed a specific and sensitive sandwich ELISA for the 
quantification of rhGH. The assay was not affected by the presence of 10 % fetal 
bovine serum, LB medium and diluted E.coli cell lysate. The working range of this 
assay is 30 to 300 ng/ml and the detection limit is 10 ng/ml. Although the sensitivity 
of the assay is not sensitive enough to measure serum hGH level, it is still good for 
the measurement of rhGH and SUMO-hGH level during fermentation production. 
Sandwich ELISA provides an efficient method to measure the level of rhGH from cell 
lysate without going through a pre-purification step. 
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Appendix 1 
pJ2:G01458 nucleotide sequence 
1 CTTGTACAAA GTTGGCATTA TAAGAAAGCA TTGCTTATCA ATTTGTTGCA ACGAACAGGT 
61 CACTATCAGT CAAAATAAAA TCATTATTTG CCATCCAGCT GATATCCCCT ATAGGTCATA 
121 GCTGTTTCCT GGCAGCTCTG GCCCGTGTCT CAAAATCTCT GATGTTAGAT TGTACAAGAT 
181 AAAATAATAT CATCATGAAC AATAAAACTG TCTGCTTACA TAAACAGTAA TACAAGGGGT 
241 GTTATGAGCC ATATTCAACG GGAAACGTCG AGGCCGCGAT TAAATTCCAA CATGGATGCT 
301 GATTTATATG GGTATAAATG GGCTCGCGAT AATGTCGGGC AATCAGGTGC GACAATCTAT 
361 CGCTTGTATG GGAAGCCCGA TGCGCCAGAG TTGTTTCTGA AACATGGCAA AGGTAGCGTT 
421 GCCAATGATG TTACAGATGA GATGGTCAGA CTAAACTGGC TGACGGAATT TATGCCACTT 
481 CCGACCATCA AGCATTTTAT CCGTACTCCT GATGATGCAT GGTTACTCAC CACTGCGATC 
541 CCCGGAAAAA CAGCGTTCCA GGTATTAGAA GAATATCCTG ATTCAGGTGA AAATATTGTT 
601 GATGCGCTGG CAGTGTTCCT GCGCCGGTTG CACTCGATTC CTGTTTGTAA TTGTCCTTTT 
661 AACAGCGATC GCGTATTTCG CCTCGCTCAG GCGCAATCAC GAATGAATAA CGGTTTGGTT 
721 GATGCGAGTG ATTTTGATGA CGAGCGTAAT GGCTGGCCTG TTGAACAAGT CTGGAAAGAA 
781 ATGCATAAAC TTTTGCCATT CTCACCGGAT TCAGTCGTCA CTCATGGTGA TTTCTCACTT 
841 GATAACCTTA TTTTTGACGA GGGGAAATTA ATAGGTTGTA TTGATGTTGG ACGAGTCGGA 
901 ATCGCAGACC GATACCAGGA TCTTGCCATC CTATGGAACT GCCTCGGTGA GTTTTCTCCT 
961 TCATTACAGA AACGGCTTTT TCAAAAATAT GGTATTGATA ATCCTGATAT GAATAAATTG 
1021 CAGTTTCATT TGATGCTCGA TGAGTTTTTC TAATCAGAAT TGGTTAATTG GTTGTAACAC 
1081 TGGCAGAGCA TTACGCTGAC TTGACGGGAC GGCGCAAGCT CATGACCAAA ATCCCTTAAC 
1141 GTGAGTTACG CGCGCGTCGT TCCACTGAGC GTCAGACCCC GTAGAAAAGA TCAAAGGATC 
1201 TTCTTGAGAT CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA AACCACCGCT 
1261 ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA AGGTAACTGG 
1321 CTTCAGCAGA GCGCAGATAC CAAATACTGT TCTTCTAGTG TAGCCGTAGT TAGCCCACCA 
1381 CTTCAAGAAC TCTGTAGCAC CGCCTACATA CCTCGCTCTG CTAATCCTGT TACCAGTGGC 
1441 TGCTGCCAGT GGCGATAAGT CGTGTCTTAC CGGGTTGGAC TCAAGACGAT AGTTACCGGA 
1501 TAAGGCGCAG CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT TGGAGCGAAC 
1561 GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCTATGA GAAAGCGCCA CGCTTCCCGA 
1621 AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG AGCGCACGAG 
1681 GGAGCTTCCA GGGGGAAACG CCTGGTATCT TTATAGTCCT GTCGGGTTTC GCCACCTCTG 
1741 ACTTGAGCGT CGATTTTTGT GATGCTCGTC AGGGGGGCGG AGCCTATGGA AAAACGCCAG 
1801 CAACGCGGCC TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA TGTTCTTTCC 
1861 TGCGTTATCC CCTGATTCTG TGGATAACCG TATTACCGCC TTTGAGTGAG CTGATACCGC 
1921 TCGCCGCAGC CGAACGACCG AGCGCAGCGA GTCAGTGAGC GAGGAAGCGG AAGGCGAGAG 
1981 TAGGGAACTG CCAGGCATCA AACTAAGCAG AAGGCCCCTG ACGGATGGCC TTTTTGCGTT 
2041 TCTACAAACT CTTTCTGTGT TGTAAAACGA CGGCCAGTCT TAAGCTCGGG CCCCAAATAA 
2101 TGATTTTATT TTGACTGATA GTGACCTGTT CGTTGCAACA CATTGATGAG CAATGCTTTT 
2161 TTATAATGCC AACTTTGTAC AAAAAAGCAG GCT|CATAT"^T TTCCAACTAT TCCACTGTCC 
2221 CGTCTGTTCG ATAACGCAAT GCTGCGCGCG CATCGTCTGC ACCAGCTGGC GTTCGACACT 
2281 TACCAGGAGT TCGAAGAGGC ATATATCCCG AAGGAACAGA AATACAGCTT TCTGCAGAAC 
2341 CCGCAGACGT CCCTGTGCTT CTCTGAATCT ATCCCGACTC CGTCTAACCG CGAAGAAACT 
2401 CAACAGAAAT CCAACCTGGA ACTGCTGCGT ATCTCTCTGC TGCTGATCCA GAGCTGGCTG 
2461 GAACCGGTAC AGTTCCTGCG CAGCGTTTTC GCTAACTCTC TGGTATATGG CGCATCCGAT 
2521 TCTAATGTGT ACGATCTGCT GAAGGATCTG GAAGAAGGCA TTCAGACTCT GATGGGTCGT 
2581 CT(^GAAGATG GTTCTCCACG CA^'^CA^'TCTTCAAAC AGACCTACAG CAAATTCGAT 
2641 ACCAACTCTC ACAACGATGA CGCACTGCTG AAGAACTACG GTCTGCTGTA CTGCTTTCGT 
2701 AAAGACATGG ACAAGGTTGA AACGTTCCTG CGCATTGTTC AGTGCCGTTC CGTTGAAGGT 
2761 TCTTGCGGCT TCTGATAA|GA ATTC|ACCCAG CTTT 
*The letter underlined indicates the sequence of hGH (2200-2778). The letter in a box 
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